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  Cancer is a disease of modern civilization and the second leading cause of human 
deaths [1,2]. This is mainly due to the aging population and the current lifestyle [3]. 
Specifically, GLOBCAN 2008 estimated that 7.6 million people died from cancer worldwide 
in 2008 accounting for a 11% risk of dying from cancer before the 75-year of age [2,4]. 
With  these  numbers  in  mind,  the  prospect  of  curing  cancer  might  seem  daunting. 
However, specific knowledge of the molecular hallmarks of cancer has already enabled us 
to develop better tools for prevention, detection and treatment. Here, I will first provide 
a brief overview of these hallmarks of cancer, followed by the current available treatment 
and diagnostic options. This overview will hopefully help to localize the research presented 
in the further chapters of this thesis in the current trends in oncology.
Hallmarks of cancer 
  Cancer is a complex disease due to its heterogeneous origins. For example, 
almost every cell type can generate a cancer cell and all these cancers manifest themselves 
with varying symptoms. This process of tumorigenesis includes four development phases 
shared by all cancers, namely initiation, promotion, progression, and conversion [5] (Fig. 
1).
  In all these phases of development, cancer cells acquire many adaptations to 
avoid elimination by the body’s defense mechanisms and to acquire a selective advantage 
over neighboring cells [6]. Among the most characteristic cancer adaptations are self-
sufficiency  in  providing  growth  signals,  insensitivity  to  growth  inhibition,  evasion  of 
apoptosis  (programmed  cell  death),  sustained  angiogenesis  (vascularization),  tissue 
invasion and metastasis, and the potential for unlimited self-replication [5,6] (Fig. 1). 
Acquisition of selective advantages is usually the result of genome instability that enables 
cancers to stratify mutations in genes controlling the aforementioned processes [7,8]. As 
a result of these mutations, the balance between tumor suppressor genes and oncogenes 
is disturbed. 
  For  instance,  self-sufficiency  in  providing  growth  signals  and  insensitivity  to 
growth-inhibitory  signals  can  result  from  active  Harvey  rat  sarcoma  viral  oncogene 
homolog (H-Ras) or loss of the suppressor retinoblastoma protein (Rb), which induces 
uncontrolled division of cancer cells and, ultimately, cancer promotion and progression 
[5,7]. 
  Furthermore, evasion of apoptosis, during which apoptotic mechanisms become 
impaired, may be exemplified by the mutation in the tumor suppressor gene p53 [9]. The 
p53 mutation is found in more than 50% of cancers, where it contributes to resistance of 
cancer to apoptosis-inducing treatment [5]. Another example for increased pro-survival 
signaling  and  impaired  apoptosis  is  upregulation  of  the  PI3K-Akt  pathway.  A  proto-11
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-> self-su￿ciency in providing growth signals
-> insensitivity to growth inhibition
-> tissue evasion and metastasis -> avoidance of immune destruction
-> evasion of apoptosis
-> sustained angiogenesis
-> potential for unlimited self-replication
-> deregulation of cellular energetics
Fig. 1. Phases of cancer development. Tumorigenesis is initiated by multifactor mutations in cell. 
Disease is promoted if the mutation-burdened cell escapes body’s defense mechanisms, starts to 
proliferate abnormally and possesses genomic flexibility allowing further mutations and/or epigenetic 
changes. During tumor progression several adaptation, proliferation and selection cycles take place. 
This process of acquiring more invasive and resistant phenotype increases tumor survival. Finally, 
highly motile cancer cells will move from the primary tumor and hatch to distant locations in the body, 
beginning an advanced stage of the disease.12 Scope and overview of the thesis
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oncogenic  phosphatidylinositol-3-kinase  (PI3K)  is  a  key  cellular  signaling  coordinator 
of  processes  such  as  cell  growth,  proliferation,  differentiation,  motility,  survival  and 
intracellular trafficking [7,10]. Cancer cells with mutation of the PIK3CA oncogene or 
mutation/deletion of the PtdIns(3,4,5)P3 phosphatase (PTEN) tumor suppressor gene 
have hyperactive signaling downstream of PI3K, allowing cancerous transformation [11]. 
Probably the best known downstream effector from PI3K is Akt kinase [12]. In its active 
phosphorylated form, Akt kinase stimulates the aerobic glycolysis, regulates cell cycle and 
facilitates pro-survival mechanisms in cancer. Therefore, cells which develop resistance to 
apoptosis (via p53, PI3K-Akt or other pathways) will have a selective advantage compared 
to their neighbors based on their ability to survive e.g. hypoxic environment and acidosis 
[7]. Surviving hypoxia means stabilization of hypoxia inducible factor 1-alpha (HIF1α) 
and, possibly consequently, increased glucose metabolism. Increased glucose metabolism 
through increased aerobic glycolysis and decreased reliance on mitochondrial oxidative 
phosphorylation is a biochemical hallmark of cancer cells and, as mentioned below, an 
important characteristic for cancer diagnosis [13]. The propensity of the cancerous tissue 
to  have  different  energy  metabolism  than  the  non-cancerous  tissue  was  discovered 
by Otto Warburg, a Nobel Prize winner in 1931 [14]. Interestingly, increased glucose 
metabolism and decreased perfusion results in acidosis of cancer environment [7]. Due 
to these processes, cells with superior invasive behavior are selected. 
  Angiogenesis, a process of vasculature formation, is necessary to constantly 
supply a growing tumor with necessary oxygen and nutrients and to remove metabolic 
byproducts.  For  example,  in  cells  which  survive  hypoxia,  HIF1α  may  contribute  to 
formation of tumor microvasculature by increasing transcription of several angiogenic 
genes such as vascular endothelial growth factor (VEGF), platelet-derived growth factor 
(PDGF) and nitric oxide synthase (NOS) [15].
  Immortalization  of  tumor  cells  with  their  acquired  adaptations  must  be 
completed in order to allow limitless replication, circumvent senescence and continue 
the progression step. The immortalization of cancer cells can be achieved or potentiated 
by for example increased expression/activity of telomerase enzyme and decreased p53 
suppressor function [16].
  Limitations, such as space for division and access to nutrients, are bypassed 
by cancer cells able to invade adjacent tissues and metastasize to distant sites in the 
body. Dissemination of cancer cells from the primary tumor requires cessation of cell-
cell contacts and increased cell motility. These contacts can be reshaped by the activity 
of  extracellular  proteases  on  cell  contact  proteins  such  as  cadherins,  cell  adhesion 
molecules (CAMs) and integrins [5]. Cell motility is achieved by formation of various 
plasma membrane structures, such as invadopodia and pseudopodia, which require actin 
cytoskeleton remodeling by a variety of specialized proteins [17].13
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Cancer treatment 
  Surgery: In 1862, an American antiques collector and dealer, Edwin Smith, 
purchased an old scroll of papyrus detailing one of the first recorded descriptions of 
surgery performed in 3000 BC [18], (for overview see Fig. 2). This and other scrolls 
confirm early attempts at tumor identification and treatment in ancient Egypt, then still 
considered as an incurable disease. Since then, developments in surgery have made 
it the foundation of treatment methods for early diagnosed non-hematological cancers 
[19]. However, invasion of cancer into the host tissue or, in advanced carcinoma, multiple 
metastases to distant sites are limiting factors in surgical intervention.
  Radiation therapy: In 1899, Marie Curie-Skłodowska and her husband Pierre 
Curie discovered that certain elements such as radium or polonium emit harmful energy, 
termed  as  radioactivity  [20,21].  After  further  development  and  refinement,  radiation 
therapy was introduced as a cancer treatment modality in the 1920s [22]. Radiation 
Fig. 2. Development of cancer treatment modalities: A) Smith’s Surgical Papyrus (provided by 
Dr. George Thoma at the US National Library of Medicine); B) a historical timeline of cancer treatment 
and imaging method development.14 Scope and overview of the thesis
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therapy works by damaging cellular DNA, and in this way prevents cells from growing 
and dividing. Therefore, rapidly dividing cells, like cancer cells or bone marrow cells, are 
more vulnerable to radiation therapy than cells which divide more slowly. However, some 
cancers are less susceptible to this treatment and radiation can inflict irreversible damage 
to healthy tissues and organs.
  Chemotherapy:  In  the  1940s,  the  first  cancer  chemotherapy  with  nitrogen 
mustards and folic acid antagonistic drugs was performed [22-24]. Thereafter, many 
different  chemotherapeutics  were  discovered  and  introduced  into  clinical  use  (e.g. 
doxorubicin,  cisplatin,  paclitaxel  and  vincristine).  Various  chemotherapeutic  regimes 
such as dose-intense treatment, sequential therapy, adjuvant therapy and combination 
therapy were subsequently designed to increase cancer cell death and overcome cancer 
resistance. Unfortunately, chemotherapy kills all rapidly dividing cells and cells which are 
unable to successfully repair the damage and, therefore, it lacks cancer specificity.
  Hormonal therapy: In the 1970s, attention was focused on the development 
of more personalized anti-cancer therapy. The first attempt at hormonal therapy was 
a treatment of hormone receptor-positive cancer cells with tamoxifen [25]. The main 
cancers treated with hormonal therapy today are prostate and breast cancer [26,27].
  Targeted therapy: The first available targeted therapy dates from the late 
1990s [28]. Targeted therapy is based on targeting a specific deregulated protein in 
cancer cells. Targeted therapy is still a very active area of research which includes e.g. 
monoclonal antibody therapy (e.g. rituximab and trastuzumab/Herceptin, FDA approval in 
1997 and 1998, respectively), small-molecule therapy (e.g. imatinib/Glivec, FDA approval 
in 2001), immunotherapy (e.g. autologous immune enhancement therapy used in Japan 
since 1990, or human leukocyte interferon-α, FDA approval in 2009), anti-angiogenic 
therapy (bevacizumab/Avastin, first FDA approval in 2004), vaccine therapy (Sipuleucel-T, 
FDA approval in 2010), etc. Furthermore, novel targeted modalities are being designed 
such as anaerobic bacteria that may be applied in the future in combination with other 
treatments [22]. These bacteria could actively remove the poorly oxygenated part of the 
tumor and become inactive upon contact with well perfused tumor parts, whereas the 
other anti-cancer agent(s) could be active in the oxygenized part of the tumor. 
  In summary, cancer cells introduce many changes to their phenotype to gain 
advantage  over  their  neighbors.  Although  these  new  characteristics  allow  cancer  to 
survive in difficult circumstances, cancer cells also become greatly reliant on such features 
for their survival.  Therefore, detailed information on specific cancer characteristics in 
individual  patients  is  essential  in  order  to  select  or  design  an  effective,  unique  anti-
cancer treatment and compose the best drug combinations for cumulative or enhanced 
elimination of cancer cells.15
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Imaging cancer
  Unfortunately,  treatment  of  cancer  is  usually  not  curative  because  its 
effectiveness strongly depends on early diagnosis, precise localization of primary and 
metastatic lesions, and a well designed therapy regime. Therefore, early detection and 
characterization of cancer are essential for increasing patient survival. Cancer diagnosis 
can be performed by either invasive or non-invasive methods. The invasive approaches 
include techniques such as biopsy or surgery followed by pathological examination. They 
are limited to local tumor characterization (the metaphorical “tip of the iceberg”) and 
cannot provide a view of total cancer burden e.g. all metastatic lesions. The non-invasive 
approaches include (i) screening for cancer markers in blood (which does not provide 
any data on anatomic or functional cancer characteristics), (ii) imaging techniques such 
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Fig. 3. Positron emission tomography: A) the most common positron-emitting isotopes in PET; B) 
a scheme depicting principles of PET: the left and right panel shows accordingly a physical principle 
and a practical methodology. 16 Scope and overview of the thesis
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as sonography, CT (computed tomography) or MRI (magnetic resonance imaging) which 
show only anatomical changes, (iii) molecular imaging techniques like SPECT (single-
photon emission computed tomography) and PET (positron emission tomography), which 
show  biological  changes  [29,30].  PET  is  an  attractive  and  powerful  tool  in  oncology 
because it allows studying functions of intact cancer cells in their own environment in the 
intact living subject. 
  PET  is  a  highly-sensitive  nuclear  medicine  technique  which  uses  radioactive 
isotopes with positron decay (Fig. 3). Positrons are particles with the same mass as 
an electron but a positive rather than a negative charge. They are short-lived and their 
annihilation results in two 511 keV gamma photons which can be detected by a dedicated 
camera. PET can be employed to image many biological functions (e.g. flow, molecule 
expression, enzymatic activity or transport) either in the whole body or in a target organ 
(Fig.  3B)  [31].  The  concept  of  radionuclide-based  indicators  for  disease  monitoring 
originates from a Hungarian scientist, George von Hevesy, nowadays considered as the 
father of nuclear medicine and awarded with a Nobel Prize in Chemistry in 1943.  18F, 
11C, 13N and 15O are the isotopes commonly used in PET (Fig. 3A). During PET imaging, 
radioactively labeled molecules are injected in very low mass amounts into a subject’s body 
to detect and quantify molecular processes in one temporal and three spatial domains. 
The resulting time-activity curves, pharmacokinetic data and images enable localization 
and  staging  of  cancer,  make  prognosis  or  evaluation  of  treatment  outcome  possible, 
and therefore facilitate diagnosis and management of patients [30,32]. Furthermore, 
radioactive tracers may be used for studying the behavior of biomolecules not only in 
vitro but also in vivo. PET technology creates a direct link between basic sciences (biology, 
chemistry and physics) and research and treatment of patients (medicine).
  Although the PET scan was already available in the late 1970s, the widespread 
use of this technique in oncology did not occur earlier than the 1990s when whole-body 
FDG scans became a clinical possibility. PET was acknowledged as an important tool 
in oncology with the burst of targeted therapies for cancer at the end of this decade. 
PET imaging has to continuously adapt in order to accommodate the more personalized 
treatment of cancer. This is exemplified by creation of small-animal imaging PET, microPET, 
which accelerates development of novel PET tracers in diverse animal models [33] (Fig. 
3). Further progress was brought by the fusion of functional PET imaging with anatomic 
imaging modalities such as CT (available from 2000s) and MRI (introduced in 2010 by 
Siemens, in 2011 by Philips) which can provide a description of lesions “with surgical and 
pathological precision” [34] (Fig. 2). 
  The most common PET tracer in oncology, accounting for 90% of all oncologic 
scans, is 18F-fluorodeoxyglucose (18F-FDG). 18F-FDG is, however, a more universal tracer 
which monitors glucose metabolism in every cell without a great discrimination between 17
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Table 1. Examples of PET tracers used in oncology
cancerous and non-cancerous or malignant and non-malignant tissue [35]. Because there 
is more application for individualized imaging, new tracers for new targets are currently 
being designed [30]. Current tracers for oncology, which have been developed or are 
under development, monitor not only metabolism, but also features such as angiogenesis, 
hypoxia, apoptosis, gene expression, and tumor protein markers (Table 1).
Aim of the thesis
  The general purpose of this thesis is to describe the progress made in development 
of sigma ligands as a novel modality for cancer treatment and imaging.
Overview of chapters
  Sigma receptors are a class of proteins found to be highly expressed in tissues 
such as brain and tumor. There are two confirmed sigma receptor subtypes, sigma-1 
and sigma-2. Many artificial sigma receptor agonists and antagonists are available for 
studying functions of sigma receptors in the body. Activation or deactivation of signaling 
pathways downstream sigma-1 or sigma-2 receptors was shown to have an effect on cell 
proliferation and survival. Cancerous cells are significantly more susceptible than non-
cancerous cells to a negative regulation (growth inhibition or cell death after application 
of sigma ligands). Therefore, sigma receptors are emerging diagnostic and therapeutic 
targets in oncology. Current developments of sigma receptor research in the field of 
oncology are described in Chapter 2 (a published review article). This chapter includes 
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descriptions of the putative endogenous sigma receptor ligands and a literature survey of 
the proliferation-related expression of sigma receptors in cancerous and non-cancerous 
tissues. Subsequently, the chapter focuses on the tumoricidal effects of sigma ligands, 
in particular inhibition of proliferation, activation of death processes and involvement 
of the sigma-1 and sigma-2 receptor subtypes. Finally, an overview and comparison of 
radioactively labeled sigma ligands for PET and SPECT imaging is presented.
  The following thesis is divided into two experimental sections: an initial one 
concerning imaging and a second one concerning treatment of cancer.
  The  first  section  describes  application  of  the  sigma-1  ligand,  11C-labeled 
1-(3,4-dimethoxyphenethyl)-4-(3-phenylpropyl)piperazine  (11C-SA4503),  for  tumor 
imaging in experimental animals using microPET. Uptake of tracers may be affected by 
many factors such as blood flow, peripheral metabolism or competition by endogenous 
ligands [36]. Particularly the uptake of ligands binding to a saturable site, in contrast 
to radiolabeled substrates for transporter or enzyme proteins, can be very sensitive to 
endogenous ligand competition. Although the endogenous ligand for sigma receptors has 
not been identified with certainty, steroid hormones may bind to these sites. We therefore 
examined the in vitro and in vivo competition between 11C-SA4503 and steroid hormones 
for binding to sigma-1 receptors in tumor cells (Chapter 3). Modification (both an increase 
and a decrease) of the levels of endogenous progesterone had a significant impact on 
binding of the tracer to glioma cells. Thus, progesterone and  11C-SA4503 compete for 
occupancy of a limited number of sigma-1 receptors in tumors. This phenomenon may 
account for variability in the tumor uptake of sigma-ligands during PET studies of patients. 
Based on the results of our in vitro experiments, tracer uptake may also be affected by 
the levels of other sex hormones (e.g. testosterone) and their metabolites.  
  A  high  physiologic  uptake  of  sigma  ligands  in  the  central  nervous  system 
(because of a high expression of sigma-1 receptors in the brain) could limit the use of such 
tracers for PET imaging of brain and intracranial tumors [37]. Therefore, we examined 
if  11C-SA4503  can  detect  pituitary  adenoma,  a  spontaneously  developing  intracranial 
hormone-secreting tumor in aged rats (prevalence 41-66% in Wistar Hannover rats of 
Taconic Farms, and 22-51% in Charles River rats). The expression of sigma-1 receptors 
in pituitary tumors had not been previously examined. Chapter 4 describes microPET 
scans with 11C-SA4503 in aged rats. Tracer uptake in healthy pituitary glands and pituitary 
tumors was compared and the impact of a pituitary tumor on 11C-SA4503 uptake in the 
normal brain, thyroid and several peripheral organs was studied. Kinetic modeling was 
used to assess if increases of tracer uptake reflected an increased partition coefficient, 
an increased nondisplaceable binding potential or increases of both parameters. Pituitary 
tumors were well-visualized and the increased 11C-SA4503 uptake in tumors (as compared 
to the normal pituitary) appeared to reflect both an increased partition coefficient and an 19
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increased nondisplaceable binding potential of the tracer.  Tracer uptake in brain tissue 
was increased in animals with pituitary tumors as compared to uptake in the brain of 
healthy rats. This increased brain uptake reflected an increased partition coefficient of 
the tracer, without significant change of tracer nondisplaceable binding potential. These 
findings  may  indicate  that  sigma-1  receptors  are  overexpressed  in  pituitary  tumors 
compared to their tissue of origin and that 11C-SA4503 is a suitable tracer for detection of 
pituitary adenomas, using PET.
  The second part of this thesis concerns the use of sigma ligands for cancer 
treatment (either monotherapy or combination therapy with TRAIL). Sigma ligands are 
cytotoxic to cancer cells, but not toxic to most healthy cells. Relatively high concentrations 
(20-100 µM) of sigma ligands are required for this tumoricidal effect. This could be due 
to the fact that diffusion barriers must be passed to reach intracellular sites, or a large 
fraction of the sigma receptors must be occupied in order to induce a therapeutic effect. 
We have addressed this question in Chapter 5. Sigma receptor occupancies in rat glioma 
cells (C6) were correlated to oncolytic activity and metabolic changes in surviving cells, 
after in vitro treatment with various sigma ligands. A virtually complete occupancy of the 
entire sigma receptor population (both sigma-1 and sigma-2) appeared necessary for the 
therapeutic effect. Determination of sigma receptor levels and sigma receptor occupancy 
by therapeutic drugs (e.g. with 11C-SA4503 and PET) may be possible in oncology patients 
and be employed for patient selection and prediction of the therapeutic dose of a sigma 
ligand. Examination of early metabolic changes following sigma ligand administration 
may indicate which tracer is most suitable for evaluation of tumor responses to sigma 
ligand therapy.
  As a large increase of 18F-FDG uptake was noted in vitro after treatment of tumor 
cells with sigma ligands, these compounds (like hormones) appear to induce a transient 
increase of glucose metabolism preceding cancer cell death, known as “metabolic flare”. 
Since in vitro observations do not always match the in vivo situation, we examined if 
transient increases of 18F-FDG uptake can also occur during sigma ligand treatment in vivo 
(Chapter 6). Mice bearing subcutaneous human A375M melanoma tumors were treated 
with the sigma ligand, rimcazole. Early tumor responses to treatment were monitored 
with 18F-FDG and microPET.  A375M tumors responded to the treatment by a strong (4-
fold) reduction of their growth and  18F-FDG uptake appeared to be initially increased. 
Thus, sigma ligands can affect glucose metabolism in vivo.
  Malignant melanoma is characterized by early metastatic spread and pronounced 
therapy resistance. Cytokine-based therapy (interferon-gamma, IFNγ and soluble TNF-
related apoptosis inducing  ligand,  sTRAIL) has thus far provided the most promising 
results for treatment of melanoma. Therefore, a novel immunotherapeutic fusion protein, 
designated anti-MCSP:TRAIL, in which an anti-tumor antibody fragment directed against 20 Scope and overview of the thesis
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MSCP (scFvMCSP) is genetically fused to human soluble TRAIL, was developed in our 
institution.  Anti-MCSP:TRAIL  is  conditionally  inactive,  but  regains  potent  and  tumor-
selective pro-apoptotic activity after selective binding to tumor cell surface-expressed 
melanoma chondroitin sulfate proteoglycan (MCSP). MCSP is a cell surface transmembrane 
molecule that is selectively overexpressed on melanoma cells. Unfortunately, significant 
resistance of melanoma to sTRAIL was observed. Since sigma ligands have strong anti-
melanoma activity and such compounds can overcome drug resistance in cancer and 
can  synergistically  enhance  the  anti-cancer  effect  of  classic  chemotherapeutics  (e.g. 
doxorubicin, actinomycin D, vincristine, lomustin, paclitaxel and gemcitabine, see Chapter 
2),  we  examined  whether  combination  treatment  of  a  sigma  ligand,  rimcazole,  with   
anti-MCSP:TRAIL enhances apoptotic signaling and displays robust anti-cancer effects   
in  human  A375M  melanoma  (Chapter  7).  In  the  following  chapter  (Chapter  8)  we 
assessed early metabolic responses in cultured tumor (A375M melanoma) and determined 
the in vitro uptake of the PET tracers 18F-FLT and 18F-FDG. Combination of sigma ligands 
with TRAIL exerts robust anti-melanoma effects. 18F-FLT and 18F-FDG uptake can provide 
insight into underlying molecular events (inhibition of the cell cycle, decrease in cellular 
ATP levels).
  In a pilot study described in Chapter 9, we evaluated the anti-cancer properties 
of rimcazole-TRAIL combination treatment on ovarian cancer cells, derived from ascites 
or a solid tumor of six patients. Patients were divided into two groups, responders and 
non-responders, based on the effect of combination treatment. In one sample, dose-
dependency of the anti-tumor effect and caspase involvement were also studied. Based 
on the findings in this preliminary study, sigma ligands hold promise as adjuvants in 
chemotherapeutic protocols for ovarian cancer patients.
  Chapter 10 summarizes the experimental results of this thesis and Chapter 
11 presents perspectives for future studies. Chapter 12 is a summary in the Dutch and 
Polish language.C
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Abstract
Sigma receptors (subtypes sigma-1 and sigma-2) are a unique class of binding sites 
expressed throughout the mammalian body. The endogenous ligand for these sites has 
not been identified, but steroid hormones (particularly progesterone), sphingolipidderived 
amines and N,N-dimethyltryptamine can bind with fairly high affinity. Sigma receptors 
are overexpressed in rapidly proliferating cells, like cancer cells. Particularly the sigma-2 
subtype  is  upregulated  when  cells  divide  and  down  regulated  when  they  become 
quiescent. Sigma ligands, especially sigma-2 agonists, can inhibit proliferation and induce 
apoptosis by a mechanism involving changes in cytosolic Ca2+, ceramide and sphingolipid 
levels. Tumor cells are much more sensitive to such treatment than cells from their tissue 
of origin. Sigma ligands induce apoptosis not only in drug-sensitive but also in drug-
resistant cancer cells (e.g., cells with p53 mutations, or caspase dysfunction). Moreover, 
sigma ligands may abrogate P-glycoprotein-mediated drug resistance and at subtoxic 
doses, they can potentiate the effect of conventional cytostatics. Thus, sigma-2 agonists 
may be developed as antineoplastic agents for the treatment of drug-resistant tumors. A 
large number of radiolabeled sigma ligands has been prepared for SPECT (single-photon 
emission computed tomography) and PET (positron emission tomography) imaging. Such 
radiopharmaceuticals can be used for tumor detection, tumor staging, and evaluation 
of anti-tumor therapy. There is still a need for the development of ligands with (1) high 
selectivity for the sigma-2 subtype, (2) defined action (agonist or antagonist) and (3) 
optimal pharmacokinetics (low affinity for P-glycoprotein, high and specific tumor uptake, 
and rapid washout from non-target tissues).
Keywords: sigma ligands, tumor imaging, proliferation markers, anti-tumor therapy, 
chemosensitizers, P-glycoprotein, apoptosis, multidrug resistance.
Introduction
  Sigma receptors are unique proteins integrated in plasma, mitochondrial and 
endoplasmatic reticulum membranes of tissue derived from brain, kidney, liver, immune, 
endocrine  and  reproductive  organs  [1].  Sigma  receptors  were  initially  considered  as 
members of the opioid family because the compound SKF 10,047 acts as an antagonist at 
mu-opioid and as an agonist at sigma sites [2]. However, when selective ligands became 
available, sigma receptors were shown to be unlike any other known neurotransmitter or 
hormone binding protein [3]. Even after 30 years of extensive research, understanding 
of the molecular cascade triggered by these transmembrane proteins is still rudimentary 
[4]. 
  The two confirmed sigma receptor subtypes, 25 kDa sigma-1 and 21.5 kDa 27
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Table 1. Expression of sigma receptors in human tumor cell lines
3
3
Bmax values in % refer to the levels of mRNA compared to those of ß-actin
sigma-2 [5], are overexpressed in rapidly proliferating cells, like cancer cells from animal 
and human origin, as compared to healthy tissue (see Tables 1 and 2). While the sequence 28 Sigma receptors in oncology: therapeutic and diagnostic applications of sigma ligands
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Table 2. Expression of sigma receptors in rodent tumor cell lines
DEX = dextromethorphan, PEN = pentazocine
and partial structure of the sigma-1 receptor are established [6-8], the existence of the 
sigma-2  receptor  has  only  been  proven  pharmacologically  [9].  The  sigma-1  receptor 
gene is located on human chromosome 9, band p13, a region associated with various 
psychiatric disorders [10]. 
  Initial research on sigma receptors was focused on their role in the brain rather 
than in tumors.The endogenous ligand(s) for sigma receptors have not been identified 
with certainty. Early studies in extracts prepared from brain [11, 12] and liver [13] have 
indicated that such ligands exist. Various forms of stimulation (e.g., depolarization by 
veratradine or K+, focal electrical stimulation) resulted in a transient, Ca2+-dependent 
reduction of the binding of the sigma ligands  3H-1,3-di-(2-tolyl)-guanidine (DTG) and 
3H-(+)-3-PPP to rat hippocampal slices [14, 15], suggesting that an endogenous sigma 
ligand is released after activation of granule cells, particularly in the dentate gyrus. 
  It has been proposed that neuropeptide Y and peptide YY are endogenous ligands 
for sigma receptors since these peptides competed with nanomolar affinity for 3H-(+)-
SKF 10,047 binding in rat brain homogenates [16], and intracerebral administration of 29
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neuropeptide Y and peptide YY reduced the hippocampal binding of 3H-(+)-SKF 10,047 
in mouse brain in vivo [17]. However, this reduction was only minor (ca. 25%) and other 
research institutions could not reproduce the in vitro competition findings. 
  In  contrast  to  neuropeptide  Y,  endogenous  steroids  such  as  progesterone, 
pregnenolone and testosterone were definitely shown to interact with rodent and human 
sigma-1 receptors, both in vitro and in vivo [18-27]. Two steroid-like binding domains 
have been identified in the sigma-1 receptor molecule [28-31]. 
  In  recent  studies,  endogenous  compounds  with  an  alkylamine  structure 
were  shown  to  act  as  sigma-1  ligands.  Endogenous  amines  from  the  sphingolipid 
family (D-erythro-sphingosine, sphingamine) bind with sub-micromolar affinity to the 
sigma-1 receptor but not to the sigma-2 receptor protein. Because the phosphorylated 
form  of  such  compounds  (e.g.,  sphingosine-1-phosphate,  S1P)  has  negligible  affinity 
for both sigma receptor subtypes, the enzyme sphingosine kinase may inactivate the 
endogenous ligands. This hypothesis was confirmed by overexpression of sphingosine 
kinase in HEK- 293 cells. In kinase-overexpressing cells, D-erythro-sphingosine did not 
inhibit 3H-pentazocine binding to sigma-1 receptors, whereas a prominent inhibition was 
observed in non-overexpressing control cells [32].
  Another alkylamine, the hallucinogen N,N-dimethyltryptamine (DMT), has also 
been identified as an endogenous sigma-1 ligand [33]. A hypothetical signaling scheme 
triggered  by  the  binding  of  DMT  to  sigma-1  receptors  has  been  proposed.  However, 
the Kd of DMT binding at sigma-1 receptors (10-5 M range) is much higher than the 
concentrations of DMT which are reached in vivo. Thus, the physiological relevance of 
DMT signaling through sigma-1 receptors is not yet clear [34]. 
  Ionic zinc may function as an endogenous ligand for sigma-2 receptors. Zn2+ 
displaces 3H-DTG bound to these sites (IC50 110 mM), is released from zinc-containing 
mossy fibers upon electrical stimulation resulting in a reduction of the binding of 3H-DTG 
to hippocampal slices, and this reduction is blocked by the Zn2+ chelator, metallothionein 
peptide 1 [35]. 
  Sigma-1 knockout mice have been generated [36]. These animals are viable and 
fertile and do not display any overt phenotype. However, sigma-1 knockout mice differ 
from wild-type animals in three important respects: 
When challenged with sigma-1 agonists such as (+)SKF- 10,047 [36] or DMT [33],  1. 
sigma-1 knockout mice do not display a hypermotility response, or only an attenuated 
response. Thus, the psychostimulant action of sigma-1 agonists is suppressed in 
these mice. 
Formalin-induced tonic pain is strongly (approximately 55%) reduced in sigma-1  2. 
knockout  mice  [37]  and  in  normal  mice  treated  with  the  sigma-1  antagonist 
haloperidol [38]. A recent publication reported that increased sensitivity (allodynia) 30 Sigma receptors in oncology: therapeutic and diagnostic applications of sigma ligands
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DEX = dextromethorphan, PEN = pentazocine
Table 3. Expression of sigma receptors in tumors
to mechanical and thermal (cold) stimuli found after peripheral (sciatic) nerve injury 
is markedly attenuated or even absent in mice lacking sigma-1 receptors [39]. These 
experiments  support  a  role  for  sigma-1  receptors  in  the  regulation  of  non-acute 
pain. 
Under certain forms of stress, sigma-1 receptor knockout mice display a depressive- 3. 
like phenotype [40]. In wildtype mice, sigma-1 agonists are antidepressants [41]. 
  Other studies (discussed below) have indicated that sigma receptors are not 
only implied in psychiatric disorders and in the sensation of pain, but also in mechanisms 
controlling cellular proliferation and survival. These data suggested possible applications 
of sigma ligands in oncology.
Receptor overexpression in tumors and tumor cell lines 
  As shown in Tables 1 and 2, sigma receptors are expressed at very high densities 
in many cancer cell lines. Malignant cells show higher receptor expression than non-
malignant cells originatingfrom the same tissue [42]. The mRNA for sigma-1 receptors, 
for example, is 13- to 21-fold more abundant in small cell lung cancerthan in normal 
bronchial epithelium, and 8-fold more abundant inprostate cancer than in normal tissue 
from the prostate (Table 1). Sigma-2 receptor levels are generally much higher than 
those of the sigma-1 subtype [43]. 
  In an initial screening of human brain tumors, sigma receptors were detected 
in 15 of 16 tumors examined. Very strong receptor expression was observed in a brain 31
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metastasis from a lung adenocarcinoma and in a human neuroblastoma passaged in nude 
mice [44]. Sigma receptors were found to be 2- to 5-fold overexpressed in renal and colon 
carcinomas ([45], see Table 3). A much higher number of binding sites was observed for 
the non-subtype-selective sigma agonist [3H]DTG than for the sigma-1-subtype selective 
agonist [3H]3-PPP [45]. This may indicate that in renal and colon carcinomas, like in 
cancer  cell  lines,  the  sigma-2  receptor  is  more  abundant  than  the  sigma-1  subtype. 
Immunocytochemical  staining  detected  sigma-1  receptors  in  the  majority  of  human 
primary breast carcinomas, particularly in tumors with a positive progesterone receptor 
status [46, 47]. 
  Over-expression (1.5- to 4-fold) of the sigma-2 receptor was observed in human 
high-grade carcinomas of the urinary bladder, in contrast to low-grade carcinomas where 
sigma-2 receptor densities were comparable to normal tissue [48]. In bovine high-grade 
carcinomas of the urinary bladder, a 25- to 44-fold overexpression of the sigma-2 receptor 
was observed, whereas low-grade carcinomas showed 3- to 5-fold higher sigma-2 receptor 
densities than the normal bladder wall [49]. 
  The over-expression of sigma receptors in malignant tissue and the large number 
of copies of the receptor proteins per tumor cell suggested that sigma receptor expression 
could be a biomarker of cellular proliferation and that tumors might be visualized using 
radiolabeled sigma receptor ligands and medical imaging techniques.
Sigma receptor expression and cellular proliferation
  The  relationship  of  sigma-2  receptor  density  and  cellular  proliferation  was 
explored in an important study from 1997. The authors used the 66 cell line (murine 
mammary adenocarcinoma) to acquire pure populations of proliferative and quiescent 
cells [50]. [3H]DTG was used as the radioligand in the presence of 0.1 mM unlabeled 
(+)-pentazocine, to mask sigma-1 sites. Proliferative cells were found to have 10-times 
more sigma-2 receptors than quiescent cells, although full downregulation of the sigma-2 
receptor was reached only several (> 3) days after the cells had become quiescent [50]. 
Thus, the half-life of the sigma-2 receptor appeared to be rather long (> 12 h). 
  A  subsequent  study  examined  the  relationship  between  sigma-1  receptor 
expression and the cell cycle in human breast (T47D and MCF-7) and prostate cancer (DU-
145) cell lines, using the sigma-1-subtype-selective radioligand [125I]-PAB. When mitosis 
was stimulated by treating cells with insulin or by providing them with fresh serum, 
radioligand binding was increased. The highest binding of [125I]-PAB was observed in cells 
arrested in the M-phase with colcemid, and the lowest binding in cells arrested in G1   
by serum starvation. Cells synchronized in G1/S phase by aphidicolin had lower sigma-1 
receptor binding than cells in M phase. These data suggest that sigma-1 receptors are 
upregulated prior to mitosis [51]. 32 Sigma receptors in oncology: therapeutic and diagnostic applications of sigma ligands
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  The impact of other factors than proliferation on sigma-2 receptor expression 
was  later  examined.  Proliferative  cells  of  the  67  line  (aneuploid  mouse  mammary 
adenocarcinoma) were found to have 8 times more sigma-2 receptors than quiescent cells. 
Since this aneuploid line showed the same results as were previously reported in diploid 
66 cells, ploidy appears to not substantially affect sigma-2 receptor expression [52]. 
Like 66 cells, 9L cells form a “plateau phase” in cell culture. However, unlike 66 cells, the 
plateau phase observed with 9L cells arises from a birth-death equilibrium, not through 
the formation of a quiescent population of cells. A similar density of sigma-2 receptors 
was observed in the plateau and exponential phases of 9L cells. This observation suggests 
that sigma-2 receptors are downregulated in quiescent (i.e., plateau phase) 66 cells vs. 
exponentially growing (i.e., proliferative) 66 cells. The reduction in sigma-2 receptors 
in plateau phase 66 cells was not due to some other environmental factor such as cell-
cell contact, nutrient depletion, or altered metabolism since that would have also been 
observed in the 9L cells [52]. When quiescent 66 cells or quiescent 67 cells were seeded 
at low density in new culture flasks with fresh medium, the return from the quiescent to 
the proliferative state was accompanied by a rapid increase of sigma-2 receptor density 
[52]. Finally, when MCF-7 breast cancer cells were treated with low concentrations of 
the cytostatic drug, tamoxifen, the sigma-2 receptor density was decreased. The extent 
of this decrease was similar to the decrease of other biomarkers of cellular proliferation, 
like the Ki-67 and IdU labeling indexes or AgNOR scores [52]. Thus, sigma-2 receptor 
expression in cancer cells appears to reflect their proliferative status but not the ploidy, 
the metabolic status or the number of cell-cell contacts. 
  In a subsequent study, proliferating 66 and 67 cells grown as solid tumors in nude 
mice were labeled with BrdU. Tumor tissue was subsequently excised and dissociated. 
Sigma-2 receptor binding in the resulting cell suspension was found to be related to the 
fraction  of  proliferative  cells,  and  calculated  ratios  of  sigma-2  receptor  expression  in 
proliferative and quiescent cells were similar to those observed in vitro. Thus, sigma-2 
receptor expression may be a biomarker of cellular proliferation in solid tumors [53].
Cytotoxic effect of sigma ligands
  An early study showed that the growth of human lung cancer cells (non-small 
cell  NCI-H157,  and  small-cell  NCI-H187)  was  dose-dependently  inhibited  by  SKF-
10,047 at concentrations greater than 100 nM. Strong growth inhibition was observed   
at an 1 mM concentration of this prototypical sigma-1 agonist. The inhibition occurred 
within a few hours of exposure, and it was irreversible after 24 h. The growth inhibition 
seemed to be related to sigma rather than opioid receptors, since it could not be blocked 
by  the  opioid  antagonist,  naloxone  [54].  In  a  later  study,  the  sigma  ligands  2-IBP, 
haloperidol, and IPAB were found to inhibit the growth of small cell lung cancer cells 33
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(NCI-N417) at 10 mM concentration [55]. 
  Neuroleptics  in  100  mM  concentration  (particularly  haloperidol,  reduced 
haloperidol  [RHAL],  fluphenazine  and  perphenazine)  induced  marked  changes  in  the 
morphology of C6 glioma cells within 3 h (rounding, retraction of cellular extensions). 
Prolonged incubation resulted in cessation of cell division and ultimately in cell death. 
The cytotoxic activity of neuroleptics was closely related to their binding affinity at sigma 
receptors. Dopamine, serotonin, NMDA, muscarinic or beta-adrenoceptor antagonists did 
not show this effect. Thus, sigma receptors appear to be involved in the regulation of 
cellular viability [56]. 
  An Australian study examined the effect of the sigma ligands (+)-SKF10,047, 
(-)-SKF10,047, DTG, haloperidol, RHAL, rimcazole, (+)-pentazocine and (-)-pentazocine 
on proliferation of other cultured cells, viz. human mammary adenocarcinoma (MCF-7, 
MDA), colon carcinoma (LIM1215, WIDr) and melanoma (Chinnery) cells [57]. Dose-
dependent rounding, detachment and cell death were observed in all cell lines. Rimcazole 
and RHAL were the most potent inhibitors of cellular proliferation. Ligands for dopamine 
receptors  (SCH23390,  raclopride),  serotonin  receptors  (mianserin),  NMDA  receptors 
((+)-MK801),  beta-adrenoceptors  (propranolol)  or  opioid  receptors  (naloxone)  were 
generally ineffective, although mianserin and raclopride showed some effect in Chinnery 
and WIDr cells [57]. Ligands for the sigma-1 binding site produced much smaller effects 
than ligands binding to both sigma-1 and sigma-2 sites. Cells lines with long doubling 
times (e.g., 32 h) were less sensitive to treatment with sigma ligands than cells with 
shorter doubling time (e.g., 15 h). The morphological changes triggered by sigma ligands 
suggested an apoptotic rather than a necrotic mechanism of cell death [57]. 
  Sigma  ligands  were  found  to  have  similar  effects  in  SK-N-SH  and  SH-SY5Y 
neuroblastoma,  NCB-20  hybridoma,  NG108-15  neuroblastoma-glioma  hybrid,  COS-7 
(immortalized  green  monkey  kidney  cells),  MRS-5  (human  lung  cell  line),  and  PC12 
pheochromocytoma [58]. The pH of the culture medium was found to strongly affect 
the experimental outcome. EC50 values were lowered when the pH was increased from 
7.3 to 8.4, and they were markedly increased when the pH was lowered from 7.3 to 
6.6. Various mechanisms may be underlying this effect of medium pH. Most likely, only 
the deprotonated form of the ligands interacts with the sigma-1 receptor. Since all test 
compounds  were  amines,  they  were  protonated  at  acidic  and  deprotonated  at  basic 
pH. Deprotonated molecules may also more easily cross the cell membrane and may 
then interact with intracellular sigma-1 sites (e.g. in the endoplasmatic reticulum or in 
mitochondria). Finally, a low pH can inhibit intracellular calcium fluxes and may thus 
interfere with the cytotoxic action of sigma ligands [58]. 
  RHAL  (50  and  100  mM)  increased  the  levels  of  cytoplasmic  free  calcium  in 
WIDr colon and MCF-7 breast adenocarcinoma cell lines, due to release of calcium from 34 Sigma receptors in oncology: therapeutic and diagnostic applications of sigma ligands
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intracellular  stores  (endoplasmatic  reticulum  and  mitochondria).  This  disturbance  of 
calcium  homeostasis  appears  to  trigger  apoptosis  [59].  Later,  it  was  shown  that  the 
inositol  1,4,5-triphosphate  (IP3)  receptor  is  involved  in  the  sigma-2-agonist  induced 
release of intracellular calcium [60]. The increase of cytosolic Ca2+ is accompanied by 
a rapid drop of metabolic activity and cellular ATP concentrations (within 10 min) which 
finally results in cell death [60].
Receptor subtype involved in cell killing 
  Initially, a general correlation was reported between the cytotoxic potency of 
sigma ligands and their affinity at sigma-1 sites labeled with [3H](+)-pentazocine [58]. 
However, later studies showed that the effects of sigma ligands on cellular morphology 
and apoptosis correlated much better with their affinity to sigma-2 rather than sigma-1 
sites (see [61] and abstracts cited therein). In a study from our own institution on C6 
glioma cells, competition binding assays were performed with the radioligand 1-(3,4-di-
11C-methoxy-phenethyl)-4-(3-phenylpropyl)piperazine (11C-SA4503), and cell death was 
quantified  after  incubation  with  (+)-pentazocine  (sigma-1  agonist),  AC915  (sigma-1 
antagonist),  rimcazole  (nonsubtype-  selective  sigma  ligand)  and  haloperidol  (non-
subtypeselective sigma ligand). Cytotoxicity of the test drugs and changes of cellular 
metabolism (glycolytic rate, thymidine kinase 1 activity, choline kinase activity) were not 
observed at low drug doses associated with occupancy of the sigma-1 subpopulation, 
but only at high doses resulting in occupancy of all sigma receptors (both sigma-1 and 
sigma-2, for > 98%). Cytotoxicity of the test compounds was related to their affinity for 
sigma-2 but not sigma-1 receptors [62]. Thus, our PET data confirmed that in C6 cells, 
death is induced via sigma-2 receptors [61, 62]. The apoptotic component of haloperidol-
induced cell death in rat pheochromocytoma (PC12) and mouse neuroblastoma (N2a) cells 
has also been shown to be mediated via sigma-2 receptors [63]. Therefore haloperidol, 
which is generally considered as a non-subtype-selective sigma antagonist, may in fact 
act as an agonist at sigma-2 receptors. 
  An Italian study examined growth inhibition by nine newly synthesized sigma 
ligands in two human breast cancer cell lines (MCF-7 and MDA-MB231). Compounds with 
significant sigma-2 affinity were found to be more potent than compounds which bind 
mainly to sigma-1 receptors. EC50 values were in the 40 to 100 mM range [64]. 
  Very potent antitumoral activity was reported for the sigma ligand SR31747A 
in  human  epithelial  breast  and  prostate  cancer  cell  lines.  Nanomolar  concentrations 
of  this  compound  already  caused  a  dramatic  inhibition  of  cell  proliferation  in  both 
hormoneresponsive and unresponsive cells. However, since SR31747A binds to multiple 
sites including sigma-1 receptors, sigma-2 receptors, the enzyme sterol isomerase and 
SR37147A-binding protein-2, cytotoxicity of this drug may be based on other mechanisms 35
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than its interaction with sigma receptors [65, 66]. 
  An interesting study in SK-N-SH (human neuroblastoma) and C6 (rat glioma) 
cells  correlated  the  antiproliferative  and  cytotoxic  activities  of  sigma-2  agonists  and 
sigma-1 antagonists to affinities of the test compounds at sigma receptors [67]. PB28 
(sigma-2 agonist) was a potent inhibitor of growth, whereas AC927 (sigma-2 antagonist) 
was inactive. On  the other hand, NE-100 (sigma-1 antagonist) inhibited  proliferation 
while (+)-pentazocine (sigma-1 agonist) displayed a very low antiproliferative potential. 
The cytotoxic and antiproliferative effects of DTG and haloperidol reflected their sigma-1 
antagonist and sigma-2 agonist activities. The antiproliferative activity of PB28 (sigma-2 
agonist) could be partially blocked by pretreating cells with AC927 (sigma-2 antagonist). 
Apparently, sigma-2 receptor activation and sigma-1 receptor inhibition produce similar 
anti-cancer effects in cell proliferation and cytotoxicity assays [67]. Later studies confirmed 
that sigma-1 antagonists can be effective antitumor agents and can fully inhibit growth 
of A427 lung cancer cells at a concentration of 20 mM [68]. Bicyclic ligands with combined 
sigma-1 and sigma-2 affinity can be more potent than cisplatin [69].
Mechanisms underlying cytotoxicity 
  The mechanisms underlying cytotoxic effects of sigma-1 antagonists have been 
examined in detail. IPAG, rimcazole, BD1047, RHAL, and BD1063 showed pronounced 
anti-cancer effects. They mediated caspase activation via a rapid increase of cytoplasmic 
calcium resulting in apoptotic cell death. Sigma-1 agonists such as (+)-SKF10,047 and 
(+)-pentazocine  attenuated  these  three  processes.  However,  the  sensitivity  of  cells 
towards sigma-1-antagonist triggered apoptosis appears to be not related to sigma-1 
receptor expression but rather to coupling of existing receptors to the cell death pathway. 
Thus, sigma-1 receptor-rich neurons and several other normal cells such as fibroblasts and 
epithelial cells are resistant to sigma-1 antagonists, whereas tumor cells are susceptible. 
Cells  that  can  promote  autocrine  survival  such  as  lens  epithelial  and  microvascular 
endothelial cells are equally susceptible as tumor cells [70]. The sensitivity of lens cells 
was confirmed in a later study which showed that their exposure to sigma-1 receptor 
antagonists (rimcazole, BD1047) leads to growth inhibition and the production of pigment 
granules. Apparently, the sigma-1 receptor has a protective function and it normally 
minimizes the harmful effects of photo-oxidation in the human eye [71]. The importance 
of sigma-1 receptors for cellular viability was further demonstrated by treating FHL124 
human lens cells with sigma-1 receptor siRNA. Such treatment (72 h) led to a 70% loss 
of sigma-1 receptor mRNA, a 60% loss of receptor protein and a striking increase of 
caspasedependent cell death [72]. In a paper from another group, sigma antagonists like 
haloperidol and RHAL (1-10 mM range) were shown to induce an early decrease in the ATP 
content of melanoma cells (murine B16, human SK-MEL-28) and to cause G1 arrest [73]. 36 Sigma receptors in oncology: therapeutic and diagnostic applications of sigma ligands
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The inhibitory effects of a sigma-1 antagonist (4-IBP) and of many psychiatric drugs with 
sigma-1 affinity on the duration of cell division and glioblastoma migration have recently 
also been examined with time-lapsed phase-contrast microscopic imaging [74, 75]. 
  An interesting study from Italy examined the dose-dependent effects of PB28, a 
sigma-2 agonist and sigma-1 antagonist, in two breast cancer cell lines: MCF7 (low P-gp) 
and MCF7 ADR (high Pgp). The MCF7 line has a high sigma-2 receptor expression (1226 
± 150 fmol/mg protein) but a low expression of the sigma-1 subpopulation (434 ± 50 
fmol/mg protein), whereas the MCF7 ADR line has a high expression of both the sigma-2   
(1727 ± 150 fmol/mg protein) and the sigma-1 subtypes (1936 ± 200 fmol/mg protein). 
In both cell lines, PB28 strongly inhibited cell growth. The inhibitory effect did not occur 
within 24 h but it was evident after 48 h of treatment (IC50 15 to 25 nM). Cells were 
arrested  in  G0-G1  and  they  showed  a  significant  increase  of  caspase-independent 
apoptosis.  In  addition  to  the  apoptotic  effect,  PB28  (100  nM,  48  h  treatment)  also 
decreased the expression level of P-gp (by 60% in MCF7 cells and by 90% in MCF7 
ADR cells, respectively). Due to the downregulation of P-gp, doxorubicin accumulation 
was strongly increased after treatment of cells with 20 nM PB28 (by 50% in MCF7 cells 
and  by  75%  in  MCF7  ADR).  Thus,  sigma-2  agonists  like  PB28  can  be  applied  either 
in monotherapy or in combination therapy with conventional cytotoxic drugs, and are 
potentially capable of overcoming P-gp-mediated multidrug resistance [76]. 
  Besides P-gp, sigma ligands have been shown to modulate the activity and/or the 
expression of several other proteins involved in drug resistance, such as glucosylceramide 
synthase [77], Rho guanine nucleotide dissociation inhibitor [77], Akt kinase [78] and 
Bcl-2 family members [63]. Mutations in the TP53 gene, which are strong determinants 
of  chemoresistance,  do  not  affect  the  sensitivity  of  cancer  cells  to  sigma-2-induced 
apoptosis [63, 79-81]. Moreover, sigma-2 induced apoptosis can be caspase-independent 
[80, 81] and may therefore also occur in cells with caspase dysfunction. However, the 
mechanism  of  cell  death  induced  by  sigma-2  ligands  is  dependent  both  on  the  type 
of ligand and the type of tumor cell. In pancreatic cells, the sigma-2 selective ligand, 
WC26, has been shown to induce caspase-dependent apoptosis [82]. Yet, the previously 
mentioned observations support the idea that sigma ligands in general, and sigma-2 
agonists in particular, may be used to treat drug-resistant tumors and to reverse cancer 
cell resistance to chemotherapeutics.
Antitumor effect of sigma ligands in experimental animals 
  In an early pilot study, low doses of the sigma ligands IPAB or 2-IBP (4 mg/kg 
daily) were found to retard the proliferation of human small cell lung cancer xenografts in 
female athymic nude mice [55]. 
  Later studies with SR31747A demonstrated potent growth inhibition of human 37
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breast  carcinoma  (MDA-MB231)  and  various  prostate  cancer  (PC3,  DU145,  LNCaP) 
xenografts  in  nude  mice  ([65,  66],  see  Table  4).  Although  SR31747A  alone  was  not 
efficient at inhibiting growth of MCF-7 tumors, it induced tumor regression after 30-40 
days of combination treatment with tamoxifen (1 mg/kg daily) and it prevented regrowth 
of MCF-7 tumors after > 50 days of tamoxifen treatment [65, 66]. In hormone-dependent 
LNCaP tumors, SR31747A acted synergistically with the anti-androgen flutamide ([65, 
66], see Table 4). Thus, sigma ligands appear to have potential as chemotherapeutics, 
particularly in combination treatment. 
Table 4. Antitumor Effects of Sigma Ligands in Tumor-bearing Mice38 Sigma receptors in oncology: therapeutic and diagnostic applications of sigma ligands
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  In an animal model of lung cancer (murine alveolar cell carcinoma LIC2 cells 
implanted s.c. in the suprascapular area of BALB/c mice), sigma-1 receptor agonists 
(PRE-084, cocaine) were found to promote tumor growth and to induce expression of 
interleukin- 10 (IL-10) at the tumor site. Stimulation of tumor growth could be prevented 
by administration of anti-IL-10 neutralizing antibodies or by administration of a specific 
sigma-1  receptor  antagonist  (BD1047).  Thus,  sigma-1  receptor  agonists,  including 
cocaine, appear to augment tumor growth through an IL-10 dependent mechanism [83, 
84]. 
  In  contrast,  a  seminal  study  from  the  UK  demonstrated  that  systemic 
administration  of  sigma-1  antagonists  (water-soluble  rimcazole,  but  also  cis-U50488 
and  haloperidol)  significantly  inhibits  the  growth  of  mammary  carcinoma  xenografts, 
orthotopic prostate tumors and lung carcinoma xenografts in immuno-compromised mice 
without adverse effects ([70], overview in Table 4). The authors suggested that sigma-1 
receptors normally inhibit apoptosis, and that release of a sigma-1-receptor-mediated 
brake on apoptosis could be a novel approach to cancer treatment. 
  In an allograft model of pancreas cancer, daily treatment with the sigma-2 ligand 
SV119 (1 mg/kg) was not very effective in suppressing tumor growth and increasing 
animal survival. However, combination treatment of animals with SV119 and a relatively 
low dose of gemcitabine or paclitaxel led to tumor stability and in some cases even 
to tumor regression. All tumors resumed growing shortly after treatment was stopped, 
but the tumors in mice which had received combination treatment grew slower than 
tumors in untreated mice or in mice which had received monotreatment. Since SV119 
potentiated conventional chemotherapy and lowered the rate of tumor regrowth after 
termination  of  treatment,  and  since  no  significant  toxicities  were  observed  in  serum 
examination, immunohistochemistry and necropsy, these results suggest that SV119 may 
be a useful “chemosensitizer” for treatment of pancreatic cancer by cell cycle specific 
chemotherapeutic drugs [85]. 
Radiolabeled sigma ligands for SPECT
  The development of radiotracers for tumor imaging has been an active area of 
research for at least two decades. Sigma receptorbinding radiotracers could combine high 
tumor uptake with low uptake in inflammatory tissue and provide valuable information 
about a tumor’s proliferative status. 
  A SPECT ligand for sigma receptors was already developed in 1991, although the 
target to which the tracer bound was not known at that time (see Table 5). Michelot and 
co-workers prepared N-(2-diethylaminoethyl)-4-iodobenzamide (abbreviated as IDAB or 
IBZA) as an imaging agent for malignant melanoma. The compound was labeled both 
with 125I (for biodistribution studies) and with 123I (for imaging). In mice bearing murine 39
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Table 5. Radiolabeled Sigma Ligands for SPECT
B16 melanoma tumors, very high tumor-to-muscle ratios (of about 95) were reached at 
24 h after injection [86]. This encouraging result prompted a phase II scintigraphic trial 
with 123I-IDAB in 110 patients which indicated that 123I-IDAB is useful for the diagnosis of 
malignant melanoma (sensitivity 81%, accuracy 87%, specificity 100%) [87]. A clinical 
follow-up study from the same group in 48 patients also reported positive results and it 
was concluded that IDAB scintigraphy is a useful tool for staging of malignant melanoma 
[88]. Less favorable results were reported in a study from Brussels, where twenty-six 40 Sigma receptors in oncology: therapeutic and diagnostic applications of sigma ligands
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patients  with  melanoma  and  eight  patients  with  non-small-cell  lung  cancer  (NSCLC) 
were examined with IDAB scintigraphy. That study indicated a lower sensitivity for the 
technique in malignant melanoma (64%). Hepatic lesions and lesions originating from an 
amelanotic melanoma could not be detected. The sensitivity of an IDAB scan for detecting 
mediastinal lymph nodes of NSCLC was very poor (22%). The authors concluded that 
IDAB scintigraphy may be used to confirm the melanoma nature of lesions that are not 
easily accessible to biopsy. However, in patients with NSCLC the value of IDAB-SPECT is 
questionable [89]. 
  Other  researchers  discovered  that  IDAB  is  a  potent  and  subtype-selective 
sigma-1 receptor ligand (Table 5) [90]. In vivo imaging and receptor blocking studies 
were performed with a structurally related radioiodinated benzamide, IPAB, which has 
been labelled with 125I (for biodistribution studies) and with 131I (for imaging). IPAB binds 
with very high affinity to sigma-1 receptors and with lower affinity to the sigma-2 subtype 
(Table 5). This tracer showed similar tumor-to-muscle ratios in nude mice with human 
malignant melanoma xenografts (A2058) as IDAB, i.e. about 95 at 24 h after injection. 
Binding of  125I-IPAB to A2058 cells in vitro was dose-dependently blocked by the cold 
compound [90]. However, sigma-1 receptor binding may not be the only mechanism 
responsible for the high uptake of IDAB and IPAB in malignant melanomas, since these 
benzamide tracers can also interact with the melanin pigment [86, 87]. 
  In a later study, three regioisomers of a single lead structure were prepared. 
The most promising ligand in terms of selectivity for sigma over dopamine D2 receptors 
was  [125I]-N-(N-benzylpiperidin-4-yl)-4-iodobenzamide  (4-IBP,  see  Table  5).  Saturable 
binding of the compound was demonstrated to sigma-2 receptors in human breast cancer 
cells (MCF-7, Bmax 4000 fmol/mg protein) [91]. The biodistribution of 4-125I-IBP was 
also examined in healthy rats which were either untreated or pretreated with the sigma 
antagonist haloperidol. Specific binding of the tracer (up to 68% of total tissue uptake) 
was observed in brain, kidney, heart and lung. The authors concluded that 4-IBP had 
potential for imaging sigma receptors in vivo and could be tested for imaging of breast 
cancer  [92]  Another  ligand,  [125I]N-[2-(4-iodophenyl)ethyl]-N-methyl-2-(1-piperidinyl)
ethylamine (4-IPEMP) showed a highaffinity, saturable binding to melanoma (A375) and 
breast cancer (MCF-7) cells which could be blocked with a sigma receptor pharmacology. 
However,  co-injection  of  non-radioactive  4-IPEMP  with  the  radioiodinated  compound 
resulted in only a small decrease of tracer uptake in rat liver and brain (37% and 35%, 
respectively) suggesting that the compound displays a rather strong nonspecific binding 
in vivo [93]. 
  Waterhouse  et  al.  developed  several  piperidine-based  sigma  ligands  as 
melanoma imaging agents. The most promising derivative was 123I-1-(2-hydroxyethyl)-
4-(4-iodophenoxymethyl) piperidine, which showed very good tumor-to-muscle ratios (> 41
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30) at 48 h after injection in nude mice bearing B16 or A375 tumors. However, blocking 
studies  with  the  non-radioactive  sigma  ligand  DuP734  produced  unexpected  results. 
Although a significant reduction of radioactivity was observed in organs known to possess 
sigma receptors such as brain, lung, heart and liver, the tumor uptake of the radioligand 
was significantly and strongly increased. These data suggest that tumor uptake of the 
radiolabeled piperidine is largely mediated by a mechanism other than sigma receptor 
binding [94, 95].
  In an attempt to prepare a 99mTc-labeled sigma ligand for SPECT, Bowen and co-
workers prepared 99mTc-BAT-EN6, a bisaminothiol (BAT) chelate appended with a sigma-
receptor pharmacophore. The tracer showed a high degree of specific binding (> 90%) in 
human breast ductal carcinoma cells (T47D) in vitro and some specific binding to rat liver 
(31%) and kidney (54%) in vivo [96].
  More promising results than with the previous compounds were obtained with 
a novel radioiodinated benzamide, 2-125I-N-(Nbenzylpiperidin-4-yl)-2-iodobenzamide (2-
IBP). This ligand showed a dose-dependent saturable binding to both sigma-1 and sigma-2 
receptors in LnCAP human prostate tumor cells (Table 5). Biodistribution studies in nude 
mice bearing human prostate tumor xenografts (DU-145) indicated that the tumors had 
the highest uptake of radioactivity of all organs both at 4 and 24 h after injection. Tumor 
uptake was significantly reduced (for > 50%) after pretreatment of animals with the 
sigma antagonist haloperidol. These data suggest that 2-IBP labeled with 123I or 131I rather 
than 125I may be a promising tracer for SPECT imaging of prostate tumors [97]. 
  The  same  authors  developed  a  novel  class  of  sigma  receptor  ligands,  the 
substituted  halogenated  arylsulfonamides.  One  of  these,  4-iodo-N-[2-(1’-piperidinyl)
ethyl]benzyl-sulfonamide (4-IPBS), was radiolabeled with 125I and tested in cell binding 
and biodistribution studies. The compound has a > 400-fold higher affinity to sigma-1 
than  to  sigma-2  receptors  (Table  5).  Competition  studies  suggested  that  exclusively 
sigma-1 receptors are labeled by 4-IPBS in brain homogenates. The imaging potential of 
4-IPBS was assessed by biodistribution studies in C57 black mice bearing B16 melanoma 
xenografts. High tumor uptake and tumor retention of the tracer were observed up to 
24 h after injection. Much lower uptake of radioactivity was noted in all other organs. 
Thus, radiohalogenated benzenesulfonamides like 4-IPBS could be useful for melanoma 
imaging [98]. 
  With  exception  of  IDAB,  all  previously  mentioned  sigma  ligands  were  only  evaluated 
in  experimental  animals.  A  more  extensive  evaluation  (both  in  experimental  animals 
and humans) was performed for N-[2-(1’-piperidinyl)ethyl]-3-iodo-4-methoxybenzamide 
(PIMBA). PIMBA binds with fairly high affinity to sigma-1 receptors and with lower affinity 
to the sigma-2 subtype (Table 5). In Lewis rats bearing syngeneic RMT breast cancers, 
tumor-tomuscle uptake ratios of about 3 were reached 4 h after injection [99]. Very good 42 Sigma receptors in oncology: therapeutic and diagnostic applications of sigma ligands
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results were obtained in biodistribution studies with 125I-labeled PIMBA in BALB/c nude 
mice bearing human prostate tumor (DU145) xenografts. Tumor-to-muscle and tumor-
to-blood ratios both reached a value of 70 in this animal model at 6 h after injection, due 
to prolonged retention of the tracer in the tumors compared to non-target tissues [100]. 
In a small pilot study with 123I-labeled PIMBA in breast cancer patients, a focally increased 
tracer accumulation was observed in scintigraphic images of 8 out of 10 patients with 
histologically confirmed breast cancer (mean tumor-to-background ratio 2.04). No uptake 
was seen in a case of lymphatic adenitis. Thus, PIMBA accumulated in breast tumors but 
not in a benign lesion of the breast [101]. 
  The  first  sigma-2  subtype-selective  SPECT  ligand  was  reported  in  2001:  [(N-[2-((3’-
N’-propyl-[3,3,1]aza-bicyclononan-3alpha-yl)(2”-methoxy-5-methyl-phenylcarbamate)
(2-mercaptoethyl)amino)acetyl]-2-aminoethanethiolato] 99mTc-technetium(V) oxide. The 
non-radioactive rhenium surrogate bound potently to sigma-2 receptors but showed much 
lower affinity for the sigma-1 subtype (Table 5). Biodistribution studies were performed 
in mice bearing a mouse mammary adenocarcinoma (cell line 66). Stereoselectivity of 
the binding was observed in vivo, as one of the two enantiomers showed significantly 
better tumor-to-blood and tumor-to-muscle ratios than the other enantiomer. Tumor-to-
muscle ratios of the racemic compound reached a maximum of 4.8 at 4 h after injection. 
Tumor uptake of the tracer was reduced (by about 30%) after treatment of animals with 
haloperidol, and at 1 h after injection, tumor tissue contained only parent compound. 
Thus, it may be possible to visualize breast tumors with a sigma-2 subtype-selective 
SPECT ligand. However, a very strong uptake of radioactivity in liver, kidneys and bladder 
may be a problem in using the tracer for examination of the abdomen [102, 103]. 
  The same authors also developed a radioiodinated sigma-2 ligand, 5-iodo-2,3-
dimethoxy-N-[2-(6,7-dimethoxy-3,4-dihydro-1H-isoquinolin-2-yl)-butyl]-benzamide, 
which was labeled both with 125I and 123I. The non-radioactive bromine analog bound with 
high affinity to sigma-2 receptors and it showed very high subtype selectivity (~1600-
fold, Table 5). Biodistribution studies in BALB/c mice bearing mouse mammary tumors 
(EMT6) indicated that tumor-to-muscle ratios of about 7 were reached 2 h after injection. 
However, in microSPECT scans the tumors were hardly visualized, suggesting that ligands 
with  strong  tumor  uptake  and  very  high  target-to-nontarget  ratios  are  required  for 
successful microSPECT imaging [104]. 
  Researchers from Japan prepared radioiodinated analogs of the sigma-1 agonist 
SA4503.  1-[2-(3,4-dimethoxyphenyl)ethyl]-4-(2-iodophenylpropyl)  piperazine  (o-BON) 
was most successful. This compound binds with high and virtually equal affinities to both 
sigma-1 and sigma-2 receptors (Table 5). Biodistribution studies in nude mice bearing 
human A375 melanoma tumors indicated that tumor-to-muscle ratios of around 7 were 
reached, 24 h after injection. Even higher values were reached in B16 melanomas (about 43
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15) and lower values in SK-N-SH neuroblastomas, ME180 cervical carcinomas and C6 
gliomas. A good relationship was observed between the accumulation of [125I]o-BON and 
sigma receptor expression in the tumors (r = 0.84). This suggests that it may be possible 
to non-invasively assess sigma receptor density, using SPECT and a radioiodinated sigma 
ligand. However, the authors did not present any microSPECT images [105]. 
  A group from India reported in vivo data for a  99mTc-nitrido heterocomplex of 
piperidine. Only moderate tumor-to-muscle ratios were reached at 24 h after injection 
in Swiss mice bearing fibrosarcoma tumors or C57BL6 mice bearing melanomas (2.0 
and 3.5, respectively). Binding of the complex in the tumors appeared to be partially to 
sigma-1 receptors, since it was reduced by 40% after pretreatment of animals with 25 mg 
of (+)-pentazocine [106]. 
  Outstanding tumor-to-muscle ratios (> 20 at 48 h after injection) have been 
reported for a radioiodinated analog of vesamicol, (+)-2-[4-(4-131I-iodophenyl)piperidno] 
cyclohexanol, or (+)-pIV, in mice bearing human prostate tumors (DU-145). Tumor uptake 
of the radioligand was inhibited (for about 60%) after pretreatment of animals with non-
radioactive sigma ligands (haloperidol, SA4503 or (+)-pIV). However, a prolonged high 
uptake of radioactivity in liver and kidneys may preclude use of this ligand for examination 
of the abdomen [107]. 
  In conclusion: 
Some  early  SPECT  tracers  showed  very  high  tumor-to-background  ratios  in  1. 
melanomas,  but  tracer  accumulation  was  based  upon  another  mechanism  than 
sigma receptor binding; 
A  common  finding  with  most  sigma  ligands  has  been  prolonged  high  uptake  of  2. 
radioactivity in liver, kidneys and intestines. Thus there is a need for receptor-binding 
radiotracers with improved pharmacokinetics (e.g., rapid urinary excretion); 
Sigma-1  subtype-selective,  non-subtype-selective  and  sigma-2  subtype-selective  3. 
SPECT ligands have been developed showing specific binding to sigma receptors in 
tumors and other target tissues in vivo; 
Since some sigma-1 subtype-selective tracers (4-IPBS, o-BON) have produced nice  4. 
results in preclinical studies (high uptake and specific binding in tumors), sigma-1 
ligands may be useful for particular indications, e.g. detection of melanoma and 
breast cancer; 
Yet, sigma-2 subtype-selective ligands may be the tracers of choice for SPECT studies  5. 
in  oncology  because  this  subtype  is  overexpressed  in  virtually  every  tumor  and 
generally most abundant, whereas sigma-1 overexpression is much less common.
Radiolabeled sigma ligands for PET
  Since the early 1990s, radiochemists from several imaging institutions have also 44 Sigma receptors in oncology: therapeutic and diagnostic applications of sigma ligands
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tried to develop labeled sigma receptor ligands for positron emission tomography (PET, 
see Table 6 and Fig. 1). Interest in such tracers was primarily fuelled by the idea that PET 
studies of sigma receptors could lead to greater insight in the mechanisms underlying 
movement disorders and psychosis. Because of the overexpression of sigma receptors 
in many types of tumors, such radiotracers could also be employed as tumor-imaging 
agents. 
  Thus, initial research focused on imaging sigma receptors in the healthy brain 
rather than in tumors. Several ligands were labelled with positron emitters and evaluated 
for studies of the brain. These include  11C-DTG [108], three radioactive derivatives of 
DTG (1-[4-([11C]methoxy)phenyl]-3-(1-adamantyl) guanidine, 1-[4-([11C] methoxy)-2-
methylphenyl]-3-(1-adamantyl)guanidine and 1-[4-([18F]-fluoro)-2-methylphenyl]-3-(1-
adamantyl)guanidine) [109], 11C-L-687,384 [110], 1-[3-18F-fluoro-(1-propyl)-4-[2-(3,4-
dichlorophenyl)ethyl]-piperazine [111, 112],  18F-haloperidol [113, 114],  18F-BMY14802 
[115, 116], and (+)-11C-cis-N-benzyl-normetazocine [117, 118] (see Table 6 for further 
details). 
  Encouraging results for tumor imaging were obtained with  18F-1-(3-Fluoropropyl)-
4-(4-cyanophenoxy-methyl)piperidine (FPS). This compound binds with sub-nM affinity 
and moderate subtype selectivity to sigma-1 receptors in vitro (Table 6) and it shows the 
optimal lipophilicity for uptake in the brain (logP at pH 7.5 = 2.8) [119]. As expected, the 
tracer showed high uptake in rat brain (2.5% ID/g). Moreover, uptake in target organs 
Table 6. Radiolabeled Sigma Ligands for PET45
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Table 6. Contd...
(brain, lung, heart, kidney) was significantly reduced after pretreatment of animals with 
nonradioactive sigma ligands (unlabeled FPS, DuP734, haloperidol) but not by dopamine 46 Sigma receptors in oncology: therapeutic and diagnostic applications of sigma ligands
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D2 [(-)-eticlopride], serotonin 5-HT2 (ritanserin) or muscarinic antagonists (atropine). 
In nude mice bearing B16 melanoma tumors, the tracer exhibited a tumor/blood ratio of 
124 and a tumor/muscle ratio > 7 at 4 h after injection [120]. The binding of 18F-FPS in 
several brain regions (cerebellum, striatum, hippocampus, hypothalamus, occipital cortex) 
and in peripheral target organs (lung, spleen, heart) proved sensitive to competition by 
endogenous steroids which are known to interact with sigma-1 receptors (progesterone, 
testosterone, DHEA) [26] Preclinical toxicity studies in three animal species (rats, rabbits, 
dogs) and dosimetry estimates indicated that  18F-FPS can be safely used for imaging 
studies in humans up to doses of 5 mCi and 2.8 mg per injection [121]. The time course of 
18F-FPS binding appears to be not ideal for kinetic modeling, since there is no significant 
loss of radioactivity from rat (or human) brain during a 4 h study period [26, 120]. 
For this reason, a ligand with slightly lower affinity than FPS was developed, 18F-1-(2-
fluoroethyl)-4-[(4-cyanophenoxy)-methyl]piperidine (SFE), and that compound showed 
Fig.  1.  Chemical  structures  of  some  sigma  ligands  discussed  in  this  review:  A)  sigma-1 
subtype-selective  compounds  (pentazocine,  BD1047,  11C-SA4503,  18F-FBP);  B)  sigma-2  subtype-
selective radioligands.
A B47
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better kinetics in rodent brain (40% washout over a 90 min period) while retaining the 
favorable properties of FPS [122, 123]. No tumor imaging appears to have been performed 
with 18F-SFE. 
  Nice results were also obtained with a structurally different radioligand, N-(N-
benzylpiperidin-4-yl)-2-[18F]fluorobenzamide  (FBP).  This  compound  binds  with  high 
affinity and reasonable subtype selectivity to sigma-1 receptors in vitro (Table 6). Blocking 
studies with haloperidol (2.5 mg/kg) in rats indicated that more than 90% of tracer uptake 
in various brain regions (striatum, cerebellum, hippocampus, brain stem) reflects binding 
to sigma receptors. In SCID mice bearing human breast tumors (MDA-MB231, or grown 
from primary explants) an adequate tumor-to-muscle contrast was observed (up to 7.8 
at 1 to 2 h post injection), and this value was almost reduced to unity by pretreatment 
of animals with haloperidol. Thus, [18F]-FBP is potentially useful for tumor imaging [124-
126]. 
  Analogs of FBP, such as 2-[18F](N-fluorobenzylpiperidin-4-yl)-4-iodo-benzamide 
(FBI) [127], and analogs of FPS, such as 1-(4-[18F]fluorobenzyl)-4-(4-cyanophenoxy-
methyl)piperidine (FBnCNE) [128] have been prepared but these radioligands were never 
evaluated in tumor-bearing animal models (see Table 6). Several other ligands were also 
only evaluated for studies in the brain, such as the sigma-1 antagonist N,N-dipropyl-2-
[4-methoxy-3-(2 phenylethoxy)phenyl]ethylamine (NE-100) which was labelled with 11C 
in two different positions [129], the sigma-1 ligand [11C]-SA6298 [130], the benzamide 
[11C]-nemonapride (YM-09151-2) [131, 132] and the dopamine D4/sigma-1 antagonist 
3-(4-chlorobenzyl)-8-[11C]methoxy-1,2,3,4-tetrahydrochromeno[3,4-c]pyridin-5-one 
[133]. 
  Tumor  imaging  has  also  been  attempted  with  fluorinated  acetamides.  18F-N-
4’-Fluorobenzyl-4-(2-fluorophenyl)-acetamide  binds  with  high  affinity  and  moderate 
selectivity to sigma-1 receptors in vitro (Table 6). Its uptake in rat brain was reduced 
for > 90% by pretreatment of animals with non-radioactive sigma receptor antagonists. 
Blocking  studies  with  sigma-1  selective  and  nonsubtype-  selective  sigma  ligands 
indicated that the tracer labels sigma-1 but not sigma-2 receptors in vivo [134]. 18F-N-4’-
Fluorobenzyl-4-(3-bromophenyl)-acetamide binds with high affinity to sigma-1 receptors, 
but its subtype selectivity is negligible (Table 6). This acetamide was evaluated in mice 
implanted with mouse mammary adenocarcinoma cells (line 66). A reasonable tumor-
to-muscle ratio was observed (6.2 at 2 h post injection). The tumor-to-blood ratio was 
slightly reduced but tumor-to-muscle and tumor-to-lung ratios were significantly improved 
by pretreating mice with a cold sigma-1 ligand. These data suggest that for breast tumor 
imaging, a radiotracer with selectivity for the sigma-2 subtype should be better than a 
non-subtype-selective or sigma-1 subtype- selective ligand, since it will result in better   
tumor-to-background contrast [135, 136]. 48 Sigma receptors in oncology: therapeutic and diagnostic applications of sigma ligands
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  The  sigma  ligand  which  has  been  most  widely  used  for  PET  imaging  is  11C-
SA4503. This compound is a sigma-1 agonist with moderately high affinity and reasonable 
subtype selectivity (Table 6). Pre-, co- and postinjection of unlabeled SA4503 in rats 
decreased the uptake of  11C-SA4503 in brain, spleen, heart, lung, kidney and skeletal 
muscle. Brain uptake of the ligand was also significantly reduced by pretreatment of 
animals with haloperidol (to about 30% of control). Ex vivo autoradiography confirmed 
that 11C-SA4503 binding in rat brain is region-specific, a higher uptake being observed in 
cortex than in caudate putamen. No radioactive metabolites were detected in the brain 
at 30 min after injection, in contrast to plasma where approximately 20% of radioactivity 
represented  metabolites  [137].  In  mouse  brain,  uptake  of  11C-SA4503  was  reduced   
by 60-70% after co-injection of haloperidol or cold SA4503, but not affected by dopamine 
D2, histamine H1, muscarinic or serotonine 5-HT2 antagonists. In cat brain, about 60-
65% of total uptake in cortex and cerebellum at 76 min after injection appeared to reflect 
specific binding [138]. 11C-SA4503 is not a substrate for P-gp in the blood-brain barrier, in 
contrast to [3H]-(+)-pentazocine [139]. Administration of non-radioactive SA4503 to mice 
results in a small reduction of cerebral binding of the dopamine D2 receptor antagonist 
11C-raclopride probably because of increased release of dopamine from nerve endings in 
the striatum, but administration of non-radioactive raclopride does not affect cerebral 
binding of 11C-SA4503 [140]. Thus, 11C-SA4503 appears to be a suitable ligand for studies 
of sigma-1 receptors, both in the brain and in peripheral organs. 
  11C-SA4503 has been successfully applied to PET studies of sigma-1 receptors in 
monkey [141, 142] and human [143-148] brain, including changes of receptor density 
in Alzheimer’s disease [149], Parkinson’s disease [150] or normal healthy ageing [142, 
144], and assessment of sigma-1 receptor occupancy by CNS drugs [151-153]. 
  The tracer was also used for studying sigma-1 receptors in rabbit eyes [154, 
155] and in animal tumors [156, 157]. A study from our institution showed that the in 
vivo binding of 11C-SA4503 to tumors is sensitive to competition by endogenous steroids. 
Tumor-to-muscle  contrast  is  increased  after  steroid  depletion  and  decreased  after 
administration of exogenous progesterone [24]. In rats bearing a C6 glioma, a single 
treatment with doxorubicin (8 mg/kg i.p.) resulted in a significant 25-30% reduction 
of  11C-A4503  uptake  in  the  treated  tumor  with  a  corresponding  decrease  of  sigma-1 
receptor expression as determined by post mortem receptor assays [158]. However, a 
pilot PET study with 11C-SA4503 in patients with NSCLC produced disappointing results 
[159]. Tumor lesions showing high FDG-uptake were cold spots in 11C-SA4503 scans. In 
3 tumors, a rim of increased uptake of 11C-SA4503 was found surrounding the cold spots. 
In one patient many bone metastases were detected with FDG, while hot spots in the 
skeleton and bone marrow were also noted with 11C-SA4503. Fused images showed that 
the FDG and 11C-SA4503 hot spots were not at identical locations. In two patients, hot 49
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spots in FDG-scans showed only slight uptake in 11C-SA4503 scans with a surrounding 
cold region. Brain metastases detected with FDG were visible as cold spots in 11C-SA4503 
scans, whereas the surrounding healthy brain tissue showed a normal distribution pattern 
of sigma-1 receptors. Because of the high background uptake of  11C-SA4503 in lung 
tissue and brain, and because an up-regulation of sigma-1 receptors was observed only 
in small areas of the tumors,  11C-SA4503 appeared to be not suitable as a diagnostic 
tool for visualization of NSCLC and its brain metastases in cancer patients. Investigation 
of other tumor types is necessary to further elucidate the potency of sigma-1 receptor 
imaging of cancer. Two studies with 11C-SA4503 in experimental animals suggest that a 
non-subtype-selective sigma ligand or a selective sigma-2 ligand may be more suited 
for  tumor  imaging  than  a  selective  sigma-1  agonist  like  11C-SA4503.  In  rat  glioma 
cells, uptake of  18F-FESA5845 (non-subtype-selective) but not of  11C-SA4503 (sigma-1 
selective) appeared to be strongly correlated to cellular proliferation [157]. In rabbits 
bearing VX-2 carcinomas, 11C-SA5845 (non-subtype-selective) showed better target-to-
background ratios than 11C-SA4503 (sigma-1 selective), probably because of the fact that 
sigma-2 receptors are present at much higher densities than sigma-1 receptors in this 
tumor type [156]. 
  Several radioligands for sigma receptors have been developed using SA4503 
as lead compound, e.g.  18F-FESA4503 [160, 161] and  18F-FMSA4503 [162] but these 
tracers were never used for tumor imaging. 18F-FESA5845 showed a similar distribution 
in conscious monkey brain as 18F-FESA4503, but the binding potential of this ligand was 
2- to 3-fold higher [161]. In receptor binding assays, FESA5845 showed high affinity 
for both sigma-1 and sigma-2 receptors (Table 6). Binding studies with  18F-FESA5845 
in C6 glioma cells indicated interaction of the ligand with two sites which could either 
be  subtypes  1  and  2  of  the  sigma  receptor,  or  sigma  receptors  located  in  different 
intracellular compartments. Biodistribution studies in tumor-bearing rats (Ham HSD RNU 
rnu with C6 gliomas in the right shoulder) indicated a tumor-to-muscle ratio of 4.9 after 
60 min, which was reduced to 2.0 after pretreatment of animals with haloperidol [157]. 
In rats bearing both a C6 tumor and a sterile inflammation (induced by intramuscular 
injection of turpentine), 18F-FESA5845 was found to accumulate in the tumor but hardly 
in the inflamed muscle [163]. The uptake of 18F-FESA5845 in tumor cells was > 5-fold 
reduced when the cells moved from log phase to quiescence. In tumor-bearing animals, 
a significant reduction of tracer uptake was noted with increasing tumor size, probably 
because of growth inhibition in the center of the tumor. Thus,  18F-FESA5845 showed 
some potential for tumor imaging and uptake of the tracer appeared to be related to 
cellular proliferation [157]. However, after 24 h of treatment of glioma cells with two 
cytostatic agents (doxorubicin, cisplatin), a paradoxical increase rather than a decrease 
of 18F-FESA5845 uptake was noted, and treatment with a cytotoxic dose of 5-fluorouracil 50 Sigma receptors in oncology: therapeutic and diagnostic applications of sigma ligands
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did not affect 18F-FESA5845 uptake at all [164]. 
  (+)-p-Methylvesamicol,  an  analog  of  the  vesicular  acetylcholine  transporter 
(VAChT) ligand vesamicol, is a sigma-1 antagonist and has been labeled with 11C (Table 
6). This compound has only been tested for studies of the brain [165, 166]. Another 
ligand with interesting in vivo properties, N-4’-fluorobenzylpiperidin-4yl (2-fluorophenyl) 
acetamide (FBFPA), was also only used for studies of the CNS [27]. 
  Two cyclohexyl piperidine derivatives developed by Italian pharmacochemists 
have been labeled with  11C and tested in experimental animals. PB167, a compound 
possessing high affinity to sigma-2 receptors and high or moderate affinity to sigma-1 
receptors (Table 6) was labeled in the methoxy group and injected into mice bearing 
mammary tumors (EMT-6). Unfortunately, uptake in tumor tissue was found to be the 
same as in normal healthy muscle. This disappointing result may be due to the fact that 
PB167 is a substrate for P-gp and is actively expelled from tumors with a multi-drug-
resistant  (MDR)  phenotype  [167,  168].  Another  cyclohexyl  piperidine,  11C-PB28,  with 
a  high  affinity  to  sigma-2  receptors  and  a  moderate  affinity  to  the  sigma-1  subtype 
(Table 6), has only been evaluated in healthy mice. The compound showed a rapid and 
homogeneous uptake in all brain structures, which could not be blocked by pretreatment 
of  animals  with  unlabeled  PB28  or  with  the  sigma-2  ligand  SM-21.  Thus,  11C-PB28 
appears to be not suitable for sigma-2 receptor imaging since its in vivo binding is largely 
nonspecific [169]. A third compound, PB183, has been proposed for imaging of prostate 
adenocarcinoma, but thus far it has only been evaluated in vitro [170]. 
  Mach  et  al.  prepared  four  carbon-11  labeled  ligands  with  high  affinity  and 
selectivity for sigma-2 receptors but different lipophilicities. The radiopharmaceuticals 
were evaluated in female BALB/C mice bearing EMT-6 breast tumors. Optimal tumor uptake 
was observed at a log P of + 2.75. The best results were obtained with 2-methoxy-11C-
N-(4-(3,4-dihydro-6,7-dimethoxy-isoquinolin-2(1H)-yl)butyl)-5-methylbenzamide (Table 
6). Although tumor-to-muscle ratios were only fair (about 3 at 30 min post injection), 
they were better than those of the nucleoside 18F-FLT. The poor results with 18F-FLT may 
have been due to the fact that mice were not pretreated with phosphorylase in order to 
deplete them from endogenous thymidine [171]. 
  Better results were obtained with a radiobrominated subtypeselective sigma-2 
ligand,  5-76Br-bromo-N-(4-(3,4-dihydro-6,7-dimethoxy-isoquinolin-2(1H)-yl)butyl)-2,3-
dimethoxybenzamide.  This  compound  binds  with  rather  high  affinity  to  the  sigma-2 
receptor and has negligible affinity for the sigma-1 subtype (Table 6). In mice bearing 
EMT-6 tumors, tumor-to-muscle ratios of almost 10 were reached at 4 h after injection 
and tumors were visualized. Tumor-to-muscle ratios were strongly reduced (from 8.6 to 
3.6 at 2 h) after pretreatment of animals with a non-radioactive sigma ligand. Prolonged 
high  uptake  of  radioactivity  in  the  liver  after  injection  of  the  radioligand  will  likely 51
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prevent imaging of hepatic lesions. However, the high tumor-to-muscle ratios which were 
observed for implanted breast tumors suggest that it may be possible to image tumors in   
the lung, head and neck region, or the lower abdomen, using a radiolabeled sigma-2 ligand   
and PET [172]. 
  Four  fluorine-18  labeled  benzamide  analogues  with  high  sigma-2  receptor 
selectivity were also prepared and evaluated for tumor imaging. One of these substances, 
N-(4-(6,7-dimethoxy-3,4-dihydroisoquinolin-2(1H)-yl)butyl)-2-(2-[18F]-fluoroethoxy)-5-
iodo-3-metho-xy-benzamide, showed almost equally good results in the EMT-6 tumor-
bearing  mouse  model  as  the  radiobrominated  compound  [173].  However,  18F-WC-59,   
a subsequently developed radioligand with sub-nanomolar sigma-2 affinity and very high 
sigma-2  selectivity  (Table  6)  produced  rather  disappointing  results  (tumor-to-muscle 
ratio  in  the  EMT-6  tumor-bearing  mouse  model  maximally  2.5)  [174].  18F-WC-59  is   
a radiolabeled [3.3.1]azabicyclononane. Azabicyclononane compounds do not appear to 
work as well as benzamide analogs in vivo, even though both classes of compounds have 
a high affinity and selectivity for sigma-2 versus sigma-1 receptors. The reason for this 
discrepancy is not known. 
  In conclusion: 
Sigma-1  subtype-selective,  non-subtype-selective  and  sigma-2  subtype-selective  1. 
PET  ligands  have  been  developed  showing  specific  binding  to  sigma  receptors   
in tumors; 
Radioligands  for  sigma-1  receptors  may  be  useful  for  special  indications    2. 
(e.g. melanoma imaging), since some sigma-1 subtype-selective tracers (FPS) have 
produced good results in preclinical research; 
Yet, for a variety of reasons, sigma-2-subtype-selective ligands may be the tracers  3. 
of choice for PET imaging in oncology. First, this subtype is overexpressed in a much 
larger spectrum of tumors than the sigma-1 subtype. Second, sigma-2 receptors 
are  usually  much  more  abundant  than  sigma-1  receptors  in  tissues  expressing 
both receptor subtypes. Sigma-2 ligands may therefore display greater tumor-to-
background contrast than sigma-1-selective or non-subtype-selective radiotracers 
Third, sigma-2 receptor density appears to be more closely and strongly related to 
cellular proliferation than sigma-1 receptor expression. PET scans of the sigma-2 
receptor may be a unique strategy to assess the ratio of proliferative over queiescent 
cells in individual tumors and may thus provide important information for therapy 
selection [175]; 
There  is  still  opportunity  for  the  development  of  positron-emitting  ligands  which  4. 
combine high selectivity for the sigma-2 subtype with optimal pharmacokinetics.52 Sigma receptors in oncology: therapeutic and diagnostic applications of sigma ligands
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Epilogue
  Both sigma-1 and sigma-2 receptors are involved in the regulation of cellular 
proliferation and death or survival. Under normal conditions, sigma-1 receptors promote 
proliferation and inhibit apoptosis. Sigma-1 agonists stimulate tumor growth, whereas 
sigma-1  antagonists  suppress  growth  and  facilitate  apoptosis.  Release  of  a  sigma-1-
receptor-mediated brake on apoptosis could be a novel approach to cancer treatment. 
Sigma-2 agonists are powerful inducers of apoptosis in tumor cells but not in normal 
healthy  tissue.  The  mechanism  of  apoptosis  involves  cytosolic  calcium  and  can  be 
caspase-  and  p53-independent.  Therefore,  sigma-2  agonists  may  kill  both  sensitive 
and drug-resistant tumor cells. Such compounds can also down-regulate P-gp, a key 
player in multidrug resistance, and they potentiate the antitumor effects of conventional 
cytostatics when administered at subtoxic doses. For these reasons, sigma-2 agonists 
and sigma-1 antagonists may be developed as antineoplastic agents and be used either 
in monotherapy or as adjuvants in chemotherapy. 
  The over-expression of sigma receptors in malignant tissue and the very large 
number of copies of the sigma-2 receptor protein per tumor cell suggest that tumors 
may be visualized using radiolabeled sigma ligands. Promising results have indeed been 
obtained in preclinical SPECT and PET imaging. Moreover, sigma-2 receptor expression 
was found to closely reflect the proliferative status but not the ploidy, the metabolic 
status or the number of cell-cell contacts of tumor cells and sigma-2 receptor density 
may be a biomarker of cellular proliferation in solid tumors. Radiopharmaceuticals which 
bind to sigma receptors may be used for tumor detection, tumor staging, and evaluation 
of anti-tumor therapy. However, there is still a need for novel ligands combining a high 
selectivity for the sigma-2 subtype, low affinity for P-gp, prolonged high uptake in tumor 
tissue and rapid washout from non-target organs.53
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Abstract
Sigma  receptors  are  implicated  in  memory  and  cognitive  functions,  drug  addiction, 
depression and schizophrenia. In addition, sigma receptors are strongly overexpressed 
in many tumors. Although the natural ligands are still unknown, steroid hormones are 
potential candidates. Here, we examined changes in binding of the sigma-1 agonist 11C-
SA4503 in C6 glioma cells and in living rats after modification of endogenous steroid 
levels. Methods: 11C-SA4503 binding was assessed in C6 monolayers by gamma counting 
and in anaesthetized rats by microPET scanning. C6 cells were either repeatedly washed 
and incubated in steroid-free medium or exposed to five kinds of exogenous steroids (1 h 
or 5 min before tracer addition, respectively). Tumor-bearing male rats were repeatedly 
treated  with  pentobarbital  (a  condition  known  to  result  in  reduction  of  endogenous 
steroid levels) or injected with progesterone. Results: Binding of 11C-SA4503 to C6 cells 
was increased (~50%) upon removal and decreased (~60%) upon addition of steroid 
hormones (rank order of potency: progesterone > allopregnanolone = testosterone = 
androstanolone  >  dehydroepiandrosterone-3-sulphate,  IC50  progesterone  33  nM). 
Intraperitoneally administered progesterone reduced tumor uptake and tumor-to-muscle 
contrast (36%). Repeated treatment of animals with pentobarbital increased the PET 
standardized uptake value of  11C-SA4503 in tumor (16%) and brain (27%), whereas 
the kinetics of blood pool radioactivity was unaffected. Conclusions: The binding of 11C-
SA4503 is sensitive to steroid competition. Since not only increases but also decreases 
of steroid levels affect ligand binding, a considerable fraction of the sigma-1 receptor 
population  in  cultured  tumor  cells  or  tumor-bearing  animals  is  normally  occupied  by 
endogenous steroids.
Keywords:  steroid  hormones,  positron  emission  tomography  (PET),  glioma,  sigma 
receptor ligand, 11C-SA4503
Introduction
  The use of positron emission tomography (PET) for imaging of cancer has a 
successful  history  spanning  more  than  three  decades.  Suitable  radiopharmaceuticals 
have been designed to track molecular events in the body, to monitor the time course 
of disease and to assess treatment outcome. Although 18F-FDG and other metabolic PET 
tracers (18F-FLT, 11C-methionine, 11C-choline, etc.) are widely available for the diagnosis of 
cancer and monitoring of treatment response, these tracers are not tumor specific and/
or have only moderate cellular uptake [1,2]. For this reason, there is much interest in the 71
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development and validation of novel radiopharmaceuticals with greater tumor selectivity. 
Attractive candidates are sigma ligands since sigma receptors are strongly overexpressed 
in rapidly proliferating cells [3–6].
  Sigma  receptors  are  proteins  with  a  highly  conserved  sequence  (87–92% 
identity and 90–93% homology for sigma-1 receptor) [7]. They are found in kidney, liver, 
immune, endocrine and reproductive organs [8]. Furthermore, sigma receptors are widely 
distributed in the brain and are implied in memory function, cognition, drug addiction, 
depression  and  schizophrenia  [9].  Importantly,  sigma  receptors  were  demonstrated   
to play a role in tumor cell proliferation and cancer cell death. These binding sites are 
therefore important targets in the development of novel anti-cancer drugs [10]. Although 
the endogenous ligands for sigma receptors have not yet been identified, steroid hormones 
(in particular progesterone) are potential candidates [11,12].
  Recent  work  has  demonstrated  regulation  of  sigma-1  receptor  availability   
by  endogenous  steroids.  Such  steroids  modulate  the  efficacy  of  a  sigma-1  receptor 
agonist in stress and depression [12]. Binding of neurosteroids to sigma receptors affects   
the  release  of  substance  P  from  nociceptor  endings  in  mice  [13]  and  the  release  of 
glutamate  and  norepinephrine  in  rat  prelimbic  cortex  and  hippocampus  [14,15]. 
Furthermore, such binding reduces subjective craving in cocaine addiction [16]. Based 
on their effects on substance P and norepinephrine release, progesterone was proposed 
to  be  a  sigma  antagonist,  whereas  dehydroepiandrosterone-3-sulphate  (DHEA-S)   
and pregnenolone sulphate were considered as sigma agonists [13,15]. Multiple sequence 
analyses revealed the presence of two steroid-like binding domains (SBDLI and SBDLII) 
in the guinea pig sigma-1 receptor (amino acids 91–109 and 176–194, respectively) 
[17,18]. Recently, it was shown that administration of steroids reduces in vivo binding   
of the sigma-1 receptor ligand 18F-FPS in rodent brain [19].
  Although an interaction between cerebral sigma receptors and steroids has been 
established, our knowledge about competition between sigma ligands and endogenous 
steroids in cancer cells is still rudimentary. Moreover, it remains necessary to examine 
how steroid hormones affect the binding of radiopharmaceuticals other than 18F-FPS, since 
sigma ligands may bind to different receptor subtypes [20] and to different binding sites 
within the sigma-1 receptor molecule (e.g. the agonist binding site and the phenytoin-
binding site [21]).
  Here, we examine the impact of steroid competition on binding of the sigma-1 
agonist  11C-SA4503.  11C-SA4503 has been used extensively for PET studies of animal 
tumors [2,22–24] and the human brain [25–28]. For in vitro tests of steroid competition, 72 Steroid hormones affect uptake of 11C-SA4503
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we used C6 rat glioma cells, a tumor line which expresses both sigma-1 and sigma-2 
receptors [3]. As an in vivo model we used C6 glioma-bearing Wistar rats. Tumor cells 
were either repeatedly washed and incubated in steroid-free medium or exposed to five 
different exogenous steroids. Rats were either repeatedly injected with pentobarbital, 
a treatment known to reduce the levels of endogenous steroids [29], or injected with 
progesterone. If the binding of  11C-SA4503 is sensitive to competition by endogenous 
steroids,  we  expected  to  find  increased  tracer  binding  after  prolonged  anaesthesia   
and decreased binding after steroid addition. Such competition, if present, could result 
in intrasubject variability of the binding potential of  11C-SA4503 in women during the 
menstrual cycle and also in intersubject variability in aged subjects which may show 
widely different endogenous steroid concentrations.
Materials & Methods
Culture media and drugs 
  Dulbecco’s  minimum  essential  medium  (DMEM),  fetal  calf  serum  (FCS)  and 
trypsin  were  products  of  Invitrogen.  Allopregnanolone  acetate  (5α-pregnan-3β-ol-20-
one 3β-acetate), dehydroepiandrosterone 3-sulphate sodium salt (DHEA-S), haloperidol, 
progesterone (cell culture tested, P8783) and trypan blue (0.4% solution in phosphate-
buffered saline) were purchased from Sigma. Androstanolone (5α-androstan-17β-ol-3-
one) and testosterone were obtained from Fluka. MatrigelR came from Becton Dickinson. 
Arachid oil was a product of Levo BV, Franeker, Holland. Stock solutions of steroids and 
of  haloperidol  were  prepared  in  ethanol  unless  otherwise  indicated.  The  radioligand   
11C-SA4503  was  prepared  by  reaction  of  11C-methyl  iodide  with  the  appropriate   
4-O-methyl  precursor  [30].  The  decay-corrected  radiochemical  yield  was  9–11%,   
the specific radioactivity >11 TBq/mmol at the moment of injection and radiochemical 
purity >95%.
Cell culture
  C6 rat glioma cells obtained from the American Type Culture Collection were 
grown as monolayers in DMEM (high glucose) supplemented with 7.5% FCS in a humidified 
atmosphere of 5% CO2/95% air at 37°C. Before each experiment, the cells were seeded 
in 12-well plates (Costar). An equal number of cells were dispensed in each well in 1.1 ml 
of serum-containing medium: DMEM (high glucose) supplemented with 7.5% FCS.73
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Binding studies
  Binding studies were performed 48 h after seeding cells in 12-well plates when 
confluency had reached 80–90%. In some experiments, cells were steroid-depleted by 
removal of the normal medium, repeated (3 ×) washing with phosphate-buffered saline 
(PBS, 1 ml) and addition of DMEM (high glucose) without serum and phenol red, 1 h 
before addition of the radiotracer. Various concentrations of an unlabelled competitor 
(haloperidol or a steroid) were dispensed to the culture medium in the wells. Steroids 
investigated  were  allopregnanolone,  androstanolone,  DHEA-S,  progesterone  and 
testosterone. After 2 min, 4 MBq of  11C-SA4503 in <30 µl of saline (containing 30% 
ethanol) were added to each well. After 45–60 min of incubation, the medium was quickly 
removed and the monolayer was washed 3 times with PBS. Cells were then treated with 
0.2 ml of trypsin. When the monolayer had detached from the bottom of the well, 1 ml 
of DMEM (high glucose) supplemented with 7.5% FCS was added to stop the proteolytic 
action.  Cell  aggregates  were  resolved  by  repeated  (at  least  tenfold)  pipetting  of  the 
trypsin/DMEM mixture. Radioactivity in the cell suspension (1.2 ml) was assessed using 
a gamma counter (Compugamma 1282 CS, LKB-Wallac, Turku, Finland). A sample of the 
suspension was mixed with trypan blue solution (1:1 v/v) and was used for cell counting. 
Cell numbers were determined manually, using a phase contrast microscope (Olympus, 
Tokyo, Japan), a Bürker bright-line chamber (depth 0.1 mm; 0.0025 mm2 squares) and a 
hand tally counter. All experiments were performed as a quadruplicate study with at least 
two repeats.
Animal model 
  The animal experiments were performed by licensed investigators in compliance 
with the Law on Animal Experiments of The Netherlands. The protocol was approved by 
the Committee on Animal Ethics of the University of Groningen.
  C6 glioma cells [2.5 × 106, in a 1:1 mixture of Matrigel and DMEM (high glucose 
with 7.5% FCS)] were subcutaneously injected into the right shoulder of male Wistar rats. 
The animals were maintained at a 12 h light/12 h dark regime and were fed standard 
laboratory chow ad libitum. They were scanned after 9–10 days, when tumors had grown 
to above 0.5 g.
MicroPET scanning 
  Two rats were scanned simultaneously in each scan session, using a Siemens/
Concorde microPET camera (Focus 220). A list mode protocol was used (60 min, brain, 74 Steroid hormones affect uptake of 11C-SA4503
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tumor  and  upper  half  of  both  lungs  in  the  field  of  view).  These  organs  were  clearly 
visualized, as reported previously [24]. The scanning was started during injection into the 
first rat; the second rat was injected 30 s later. Body temperature of anaesthetized animals 
in the scanner was kept at 37.5 ± 0.5°C, using rectal probes, individual temperature 
controllers and electronic heating (M2M Imaging).
  Two microPET scans of five rats were made in order to explore the effect of 
anaesthesia duration on the in vivo binding of 11C-SA4503 (23–27 MBq administered as a 
0.3 ml bolus, tail vein catheter, mass <2 nmol). For the first scan, the tracer was injected 
shortly (<20 min) after the induction of pentobarbital anaesthesia (first scan = control 
condition). When this scan had been finished, the animal was kept under anaesthesia and 
remained at a fixed position in the microPET scanner. 11C-SA4503 was once more injected 
after prolonged anaesthesia [four intraperitoneal injections of a sodium pentobarbital 
solution  in  water  (60  mg/ml):  first  injection  1  ml/kg  body  weight,  and  then  three 
subsequent 0.3 ml/kg body weight at 30–40 min intervals, total anaesthesia duration 
>3.5 h] in order to acquire the second scan.
Table 1. Effect of prolonged anaesthesia and progesterone administration on biodistribution of 11C-
SA4503.
SUV values of 11C, 60 min after injection of 11C-SA4503
a Data were obtained from the control and progesterone-treated rats, respectively, after the PET scan of Fig. 4
b Data were obtained from the rats which had undergone the two PET scans of Fig. 375
C
h
a
p
t
e
r
 
3
  For examination of the effect of an exogenous steroid on 11C-SA4503 binding, 
microPET scans were made of four pairs of rats. One rat of each pair was treated with 
progesterone (three intraperitoneal injections of 10 mg each at 1.5 h intervals, in arachid 
oil,  progesterone-treated  group),  whereas  the  other  animal  was  treated  with  carrier 
(arachid oil) only (control group). In the arachid oil- and progesterone-treated rats, the 
tracer 11C-SA4503 was injected shortly (< 20 min) after the induction of pentobarbital 
anaesthesia.
  List mode data were reframed into a dynamic sequence of 4 × 60 s, 3 × 120 s, 
4 × 300 s and 3 × 600 s frames. The data were reconstructed per time frame employing 
an interactive reconstruction algorithm (OSEM2D). The final data sets consisted of 95 
slices with a slice thickness of 0.8 mm and an in-plane image matrix of 128 × 128 pixels 
of size 1 × 1 mm2. Data sets were fully corrected for random coincidences, scatter and 
attenuation. A separate transmission scan was acquired for attenuation correction. This 
scan was performed right after the last emission scan.
  Three-dimensional regions of interest (3-D ROIs) were manually drawn around 
the entire tumor, brain and peripheral area of the right lung, avoiding hilar structures, 
as described previously [24]. Time-activity curves (TACs) and volumes (cm3) for the 
ROIs were calculated, using standard software (AsiPro VM 6.2.5.0, Siemens-Concorde, 
Knoxville, TN, USA). TACs were normalized for body weight and injected dose as indicated 
in the figure legends.
Biodistribution studies
  After the scanning period, the anaesthetized animals were terminated. Blood 
was collected, and plasma and a cell fraction were obtained from the blood sample by 
short  centrifugation  (5  min  at  1,000  g).  Several  tissues  (see  Table  1)  were  excised.   
The complete tumor was removed and separated from muscle and skin. All tissue samples 
were weighed. Radioactivity in tissue samples was measured using a gamma counter, 
applying a decay correction. The results were expressed as dimensionless standardized 
uptake values (SUVs). The parameter SUV is defined as: [tissue activity concentration 
(MBq/g) * body weight (g) / injected dose (MBq)].
Results 
Cell experiments
  The growth medium of C6 cells (DMEM-high) contains steroid hormones since 76 Steroid hormones affect uptake of 11C-SA4503
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it is supplemented with FCS (7.5% v/v). This medium also contains the indicator phenol 
red  which  may  interact  with  hormone  binding  sites,  particularly  estrogen  receptors 
[31]. Yet, the addition of non-radioactive steroids to normal growth medium (50 µM of 
progesterone, allopregnanolone, testosterone or androstanolone) resulted in measurable 
competition  with  the  radioligand  11C-SA4503  for  binding  to  cellular  sigma  receptors 
(Fig. 1). In contrast, the administration of 50 µM DHEA-S had no statistically significant 
effect. 
  C6 cells were depleted from endogenous steroids by removal of growth medium, 
repeated washing of the monolayer with PBS and addition of medium without FCS and 
phenol red. Such steroid depletion resulted in a significant (49 ± 4%) increase of the 
specific binding of 11C-SA4503 to intact cells (Fig. 1).
  When  the  steroid  supplementation  experiment  was  repeated  in  steroid-free 
medium, a stronger effect of exogenous steroids was observed than in the normal growth 
medium. Even 50 µM DHEA-S caused now a significant decrease of cellular 11C-SA4503 
Fig.1. Competition of exogenous steroids (concentration 50 μM) and haloperidol (50 μM) with 11C-
SA4503 binding to C6 cells in normal culture medium and in steroid-free medium (expressed as a 
percentage of the binding to untreated cells in normal culture medium). All treatments resulted in a 
statistically significant effect on tracer binding, with exception of the DHEA-S effect in normal culture 
medium.
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Fig.2. Dose-response plot of progesterone competition with 11C-SA4503 binding to C6 cells in steroid-
free medium. Specific binding was defined as total binding minus the residual binding observed in the 
presence of an excess of haloperidol (50 μM).
binding  (Fig.  1).  Both  in  normal  and  in  steroid-depleted  medium,  the  observed  rank 
order of potency was: progesterone > androstanolone = testosterone = allopregnanolone 
>  DHEA-S.  A  dose-response  plot  was  made  for  the  most  potent  steroid  competitor, 
progesterone.  The  IC50  value  of  this  compound  for  inhibition  of  cellular  11C-SA4503 
binding was 33 nM (Fig. 2). 
  Addition of the anaesthetic pentobarbital to C6 cells (up to concentrations of 1 
mM in normal medium) did not result in any inhibition of 11C-SA4503 binding (values not 
shown).
Animal data
  No  behavioural  changes  were  observed  in  the  animals  up  to  10  days  after 
inoculation of C6 cells. Tumors appeared after 5 days and grew exponentially, as reported 
previously [24]. Body weight of the animals at the time of PET scanning was 326 ± 22 g. 
Tumor size was then 1.3 ± 0.7 g (mean ± SD, range 0.48–2.39 g). No significant tumor 
necrosis was observed, as reported previously [2].
MicroPET scans
  Pentobarbital anaesthesia is known to affect steroid metabolism. A strong (> 
70%) decline of endogenous steroid levels in the brain (progesterone, pregnenolone) 
occurs upon treatment of male rats with anaesthetic amounts of sodium pentobarbital 
(0.2 mmol/kg i.p., [29]). Plasma progesterone in female rats is also decreased after 
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Fig.3. Time-activity curves of 11C-SA4503-derived radioactivity in tumor, brain and blood pool. Solid 
line: animals scanned after short pentobarbital anaesthesia (< 20 min, control condition, n = 5); 
dotted line: same animals scanned after protracted pentobarbital anaesthesia (>3.5 h, n = 5). The 
PET data were normalized to a body weight of 330 g and an injected radioactivity dose of 20 MBq, as 
described previously [24]. The effect of protracted anaesthesia on brain uptake (after >10 min) and 
tumor uptake (after >20 min) was statistically significant, in contrast to the effect on radioactivity in 
the blood pool.79
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Fig.4. Time-activity curves of 11C-SA4503-derived radioactivity in tumor, brain and blood pool. Solid 
line: animals scanned at baseline (treated with arachid oil only, control group, n = 4); dotted line: 
other animals scanned after repeated injections of progesterone in arachid oil (progesterone-treated 
group, n = 4). The PET data were normalized to a body weight of 330 g and an injected radioactivity 
dose of 20 MBq, as described previously [24]. The effect of progesterone addition on tumor uptake 
(but not brain or blood pool uptake) was statistically significant.80 Steroid hormones affect uptake of 11C-SA4503
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pentobarbital administration [32]. Thus, competition of endogenous steroids with  11C-
SA4503 binding in target organs was expected to be reduced after repeated treatment 
of Wistar rats with pentobarbital. A significant increase of tracer SUV in target organs 
(brain 27%, C6 tumor 16%) was indeed observed after prolonged anaesthesia (Fig. 3). 
However, anaesthesia duration did not significantly affect the kinetics of radioactivity in a 
blood pool from the right lung (Fig. 3). 
  Pretreatment of animals with a high dose of progesterone resulted in a significant 
decrease of ligand SUV in the C6 tumor (36 %), but did not significantly affect tracer 
kinetics in the brain or blood pool (Fig. 4). 
  MicroPET images of a single rat acquired after short and prolonged anaesthesia 
are shown in Fig. 5. Images of solvent (arachid oil)- and progesterone-pretreated animals 
are presented in Fig. 6. 
Biodistribution studies
  Biodistribution  experiments  confirmed  the  outcome  of  the  microPET  studies 
(Table 1). Prolonged anaesthesia with pentobarbital resulted in a significant increase of 
sigma ligand binding in C6 tumor, brain (particularly cerebellum and cerebral cortex), bone 
and bone marrow, large intestine, blood cells and spleen. Plasma levels of radioactivity 
were not changed under these conditions and the amount of radioactivity in the liver was 
significantly decreased.
  Pretreatment of animals with progesterone caused a 31% decrease of sigma 
ligand binding in the C6 tumor, but did not significantly affect tracer uptake in any other 
organ or in plasma (Table 1).
Discussion
In vitro steroid competition
  Although  an  interaction  of  steroid  hormones  with  sigma  receptors  has  been 
described  in  many  publications,  there  are  few  reported  observations  of  competition 
between endogenous steroids and sigma receptor ligands in intact cancer cells. Here, we 
demonstrate that altered steroid levels result in changes of 11C-SA4503 binding to sigma 
receptors in the C6 glioma cell line. Steroid depletion (removal of FCS from the growth 
medium and washing of cells with steroid-free medium) resulted in a 49% increase of 11C-
SA4503 binding. Apparently, high steroid levels in the normal growth medium result in 
reduced tracer binding and can obscure the effects of steroids which bind with rather low 81
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Fig.5. MicroPET images of a single animal scanned with 11C-SA4503 after short (<20 min, left panel) 
and protracted (>3.5 h, right panel) pentobarbital anaesthesia. Images are summed data from 1 to 60 
min after injection. The positions of tumor and brain are indicated by capitals T and B.
Fig.6. MicroPET images of two different rats scanned with 11C-SA4503 after pretreatment with solvent 
(arachid oil, left panel) or progesterone (right panel). Images are summed data from 1 to 60 min after 
injection. The positions of tumor and brain are indicated by capitals T and B.82 Steroid hormones affect uptake of 11C-SA4503
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affinity to sigma receptor proteins. Enhanced competition of DHEA-S and other steroids 
with 11C-SA4503 binding was observed when cells were washed and incubated in steroid-
free medium, 1 h before tracer addition.
  Testosterone  (50  µM),  an  androgen  secreted  by  the  testis,  caused  a  40% 
reduction  of  radioligand  binding  to  C6  cells  in  steroid-free  medium.  Androstanolone 
(dihydrotestosterone),  a  metabolite  of  testosterone  which  mediates  many  of  the 
biological  actions  of  testosterone,  had  a  similar  effect  as  the  parent  compound. 
Dehydroepiandrosterone sulphate, a steroid sigma agonist with antidepressant actions 
and an allosteric modulator of γ-aminobutyric acid (GABA)A receptors, was the weakest 
competitor  for  11C-SA4503  binding.  The  most  potent  steroid  inhibitor  proved  to  be 
progesterone (secreted by the corpus luteum in females) which reduced cellular  11C-
SA4503 binding by 60%. Allopregnanolone, an important metabolite of progesterone, 
was less potent than its parent compound, but still caused a 33% reduction of radioligand 
binding. Non-specific binding (defined as binding of the radioligand to C6 cells in the 
presence of an excess of haloperidol) was about 25% in normal growth medium and 18% 
in steroid-free medium (Fig. 1).
  The  results  of  our  experiments  in  cancer  are  in  accordance  with  previous 
studies which have employed different radioligands and have focused on healthy tissue. 
Progesterone and testosterone were shown to compete with the binding of 3H-SKF-10,047 
and 3H-haloperidol to sigma receptors in homogenates from guinea pig brain and spleen 
[33]. These steroids were also potent inhibitors of the binding of 3H-haloperidol to sigma-1 
receptors in human placenta [11], and they reduced binding of the sigma-1 ligand 18F-FPS 
to isolated membrane fragments and to the brain of intact rats [19]. Progesterone acted 
like a sigma-1 antagonist in the rat hippocampus, mimicking the effects of haloperidol 
on  3H-norepinephrine  release  [15].  Progesterone  but  not  dehydroepiandrosterone 
sulphate reduced the in vivo binding of 3H-SKF-10,047 to sigma-1 receptors in the mouse 
hippocampus and cortex [34].
In vivo steroid competition
  Progesterone supplementation reduced tumor SUV (from 0.83 ± 0.11 to 0.57 
± 0.14) and the tumor-to-muscle concentration ratio (from 4.6 to 2.8), as indicated by 
our biodistribution data (Table 1). TACs in microPET indicated a progesterone-mediated 
decrease of 11C-SA4503 binding in the C6 tumor (by 36%), but not in the brain (Fig. 4). 
The reason for the absence of an effect of progesterone supplementation on radioligand 
binding  in  the  brain  of  intact  rats  is  unknown.  P-glycoprotein  (P-gp)  function  in  the 83
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blood-brain barrier hampers the entry of exogenous progesterone into the brain [35], 
whereas C6 tumors do not express P-gp (personal observations). Therefore, exogenous 
progesterone can freely enter the implanted C6 tumor, but can enter the brain only to a 
limited extent.
  Our data suggest that not only steroid supplementation - as reported previously 
for  other  sigma  ligands  -  but  also  removal  of  steroid  is  accompanied  by  changes  of   
the in vivo binding of  11C-SA4503. Repeated treatment of animals with pentobarbital 
increased tumor SUV (from 0.83 to 1.52) and the tumor to muscle ratio (from 4.6 to 7.2, 
Table 1). Tracer SUV in cerebellum and cerebral cortex was also increased (from 1.66 to 
2.41 and from 1.50 to 2.38, respectively, Table 1). TACs in the microPET experiments 
indicated increased 11C-SA4503 binding both in the C6 tumor (by 16%) and in the brain 
(by 27%, Fig. 3). Prolonged pentobarbital anaesthesia and progesterone supplementation 
were  not  accompanied  by  any  significant  change  of  the  blood  activity  curves  of  11C-
SA4503 (Figs. 2 and 3). Altered tracer binding to sigma-1 receptors in tumor and brain 
appears therefore to be related to changes within target tissue rather than to altered 
tracer delivery to the target organs. Since pentobarbital has multiple effects on cerebral 
biochemistry, our data do not prove that the effect of prolonged anaesthesia is due to 
an interference of pentobarbital with steroid metabolism. However, the information from 
our microPET and biodistribution studies is consistent with the hypothesis that prolonged 
pentobarbital anaesthesia results in reduced levels of endogenous steroid hormones.
Conclusion
  Steroid competition affects binding of the sigma ligand 11C-SA4503 in tumor cells 
and tumor-bearing rats. Progesterone, the most potent steroid competitor of 11C-SA4503 
binding, showed an IC50 value in tumor cells of 33 nM, or 10 ng/ml (Fig. 2). Similar levels 
of progesterone (3–28 ng/ml) are reached in human plasma during the luteal phase 
of the menstrual cycle [36] and even higher levels occur during hormone treatment. 
Moreover,  steroid  levels  may  change  during  chemotherapy,  both  in  male  and  female 
patients [37–40]. Therefore, (patho)physiological variations of these levels can result in 
variability of the binding potential of 11C-SA4503 and should be taken into account in PET 
studies of patients and healthy volunteers.84
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Abstract
Spontaneous pituitary tumors occur in rats over one year of age and are the most common 
cause of rodent death. In an ongoing study of changes of sigma-1 agonist binding related 
to ageing, several of our rats developed such tumors. The aim of the current study was 
to assess the kinetics of 11C-SA4503 in tumor and brain, and to compare cerebral binding 
of the ligand in healthy and tumor-bearing animals. Methods: MicroPET scans of the 
brain region of male Wistar Hannover rats (age 18 to 32 months) were made, using a 
Siemens/Concorde Focus 220 camera and the agonist 11C-SA4503. The time-dependent 
uptake of 11C in the entire brain, individual brain regions, tumor or normal pituitary, and 
thyroid was measured. A cannula in a femoral artery was used for blood sampling and 
determination of the time course of activity in arterial plasma. Two-tissue compartment 
model (2TCM) was fitted to the PET data, using metabolite-corrected plasma radioactivity 
as input function. Results: (all values mean ± SEM): Pituitary tumors showed up as bright 
hot spots in the scans. The total distribution volume (VT) of the tracer in malignant tissue 
(105.0 ± 47.6, n = 5) was significantly increased (P < 0.05) compared to the normal 
pituitary (11.6 ± 1.0, n = 8). Surprisingly, an increase in VT was also seen in the brain (P 
< 0.001) and thyroid tissue (P < 0.01) of animals with pituitary tumors (25.5 ± 3.3; n 
= 5 and 39.3 ± 5.5; n = 4, respectively) compared to brain tissue of healthy rats (11.8 
± 1.2 and 23.1 ± 1.9, respectively; n = 8). Kinetic analysis showed that the increase in 
brain and thyroid was not related to a change of nondisplaceable binding potential (BPND) 
but rather to an increase of the partition coefficient (K1/k2 ratio) of  11C-SA4503. The 
increase in VT in the malignant tissue on the other hand was accompanied by a significant 
increase in BPND (10.7 ± 1.7, n = 5 vs 4.6 ± 0.5, n = 8, P < 0.01). Conclusion: Our results 
indicate that the BPND of 11C-SA4503 to sigma-1 receptors is increased in pituitary tumors 
compared to their tissue of origin and that this tracer may have promise for the detection 
of pituitary adenomas, using PET.
 
Keywords: sigma receptor, 11C-SA4503, spontaneous pituitary tumor, Wistar rats, kinetic 
analysis, microPET
Introduction
  Pituitary tumors (adenoma of pituitary gland) are among five most common 
intracranial  neoplasms  [1,2].  Pituitary  adenomas  grow  slowly  and  metastasize  rarely 
[3]. Despite their benign nature, they can cause significant morbidity [4]. For example, 
pituitary tumors can lead to Cushing syndrome, pituitary hyperthyroidism, acromegaly, 
Nelson syndrome or impotence [5,6]. Unfortunately, pituitary tumors are very difficult to 89
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diagnose and often remain undetected until post-mortem examination or during late-stage 
disease [7,8]. At late stages, the majority of pituitary tumors will be macroadenomas 
with a low surgical cure rate [3]. Diagnostic problems arise from the fact that they can 
manifest themselves by varying symptoms: 1. functioning tumors hypersecrete various 
hormones (e.g. prolactin, thyroid-stimulating hormone, and growth hormone), and 2. 
non-functioning tumors (non-secreting), grow usually undetected until they compress 
surrounding structures (e.g. optic nerves) or prevent normal functioning of the pituitary 
gland [9]. In addition, large pituitary tumors can cause occasionally fatal damage to the 
brain due to a sustained increase in the intracranial pressure [10].
  Because  hormonal  or  symptom  examination  gives  a  rather  poor  differential 
diagnosis,  current  diagnostic  methods  include  imaging  techniques  such  as  computed 
tomography  (CT)  or  magnetic  resonance  imaging  (MRI).  CT  and  MRI  imaging  allows 
avoidance of biopsies and improves significantly pituitary tumor localization [9,11,12]. 
However,  CT  and  MRI  cannot  distinguish  between  tumor  and  scar  tissue  or  monitor 
biochemical and functional aspects of the tumor. 
  There is no tracer of first choice for pituitary tumor imaging using nuclear medicine 
[4], although such lesions have been visualized also e.g. with  18F-fluorodeoxyglucose 
(18F-FDG), radioactively labeled somatostatin analogs, such as  111In-pentetreotide, and 
dopamine D2 receptor-targeting radiopharmaceuticals, such as 18F-fluoroethyl-spiperone 
(18F-FESP) [1,4,7]. The widespread use of 18F-FDG in positron emission tomography (PET) 
imaging in the last two decades increased the detection of incidentalomas of the pituitary 
gland [7,13]. However, pituitary tumors are slowly growing and highly differentiated, 
which  makes  18F-FDG  unsuitable  for  their  imaging  [4].  Furthermore,  18F-FDG  poorly 
distinguishes between non-/neoplastic lesion, benign/malignant lesions or inflammation, 
and accumulation of this tracer in pituitary gives an ambiguous interpretation [7,13-15]. 
Huyn et al. showed that only 40.8% of the patients with focal pituitary  18F-FDG accumulation 
presented with pathologic lesions [7]. In addition, somatostatin receptor- and dopamine 
D2 receptor-targeting radiopharmaceuticals have only limited clinical usefulness, because 
expression of these receptors is dependent on the hormones that the pituitary tumor 
secretes (e.g. higher expression of somatostatin receptors in tumors producing growth 
hormone/thyroid-stimulating hormone or higher expression of dopamine D2 receptors in 
non-secretive tumors) [4,12,16]. 
  Tumor cells frequently overexpress sigma receptors. Sigma receptors are unique 
transmembrane proteins, classified into two subtypes, sigma-1 and sigma-2 [17]. Sigma-1 
receptors were studied in more detail than sigma-2 receptors since the sigma-1 gene 
has been sequenced and cloned [18], and selective ligands and antibodies are available 
for the sigma-1 but not for the sigma-2 subtype. Sigma-1 receptors were shown to be 
an intraorganelle signaling and cell survival modulator at the endoplasmic reticulum-90 Detection of spontaneous pituitary tumors with 11C-SA4503 PET
(submitted)
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mitochondria  junctions  [19].  An  increase  of  sigma-1  receptor  expression  counteracts 
the ER stress response, whereas a decrease in sigma-1 receptors can enhance apoptosis 
[19].  Sigma-1  receptor  function  is  related  to  processes  such  as  neuroplasticity  and 
neuroprotection in the brain and cell death or survival in tumors [20,21]. 
  Sigma-1  receptors  are  also  expressed  in  the  pituitary  gland  [22,23],  where 
they were shown to be directly and functionally coupled to Kv1.4 K+ channels [24,25]. 
In  the  rat  posterior  pituitary,  sigma-1  receptor  activation  by  agonistic  ligands  or  co-
expression of sigma-1 receptors and K+ channels reduces the peak current amplitude of 
the neurohypophysial K+ currents in a G protein-independent manner [26]. However, the 
presence of sigma-1 receptors in pituitary tumors has not yet been examined. 
  11C-SA4503  (11C-labeled  1-[2-(3,4-dimethoxyphenthyl)]-4-(3-phenylpropyl)-
piperazine  dihydrochloride)  is  a  ligand  with  high  affinity  for  sigma-1  receptors,  IC50 
= 17.4 nM, and commonly employed for PET [21]. We have previously reported that 
microPET with 11C-SA4503 shows high tracer accumulation in the mammalian brain [27]. 
11C-SA4503 was already tested in healthy volunteers, and in patients with Alzheimer’s 
disease  [28,29]  or  Parkinson’s  disease  [17,29,30].  Furthermore,  microPET  with  11C-
SA4503 in rats successfully detected subcutaneously-grown C6 gliomas, had 10-fold C6 
tumor selectivity over a turpentine-induced sterile inflammation, and showed an early 
decrease in tumor uptake following systemic doxorubicin treatment which corresponded 
to a loss of sigma-1 receptors from the tumors [31,32]. 
  In an ongoing study of changes of sigma-1 agonist binding related to ageing, 
several of our Wistar Hannover rats developed pituitary tumors. In the current study 
we examined if spontaneously developed pituitary tumors in aged rats (Figure 1) can 
Fig.1. Brain specimens from aged rats with spontaneous pituitary tumors. Arrows indicate the position 
of the tumor.91
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be detected and distinguished from the normal pituitary by microPET imaging with 11C-
SA4503. Also, we performed kinetic analysis of tracer uptake in the brain, pituitary tumors 
and thyroid gland, using a 2-tissue compartment model (2TCM) to assess changes in 
partition coefficient (K1/k2), nondisplaceable binding potential (BPND = k3/k4) and total 
distribution volume (VT). Finally, the impact of a pituitary tumor on uptake of 11C-SA4503 
in peripheral organs was examined.
Materials & Methods
11C-SA503 Synthesis
  The  radioligand  1-[2-(3,4-dimethoxyphenethyl)]-4-(3-phenylpropyl)piperazine 
(11C-SA4503)  was  prepared  by  reaction  of  11C-methyl  iodide  with  1-[2-(4-hydroxy-
3-methoxy-penthyl)]-4-(3-phenylpropyl)piperazine  dihydrochloride  (4-O-demethyl 
SA4503), according to a published method [33]. The decay corrected radiochemical yield 
was ~ 24%, the specific radioactivity was > 100 TBq/mmol at the moment of injection 
and radiochemical purity > 98%. The 11C-SA4503 solution had pH 6.0 to 7.0.
Animal Model
  Experiments were performed in male Wistar Hannover rats (HsdHan™:WIST) 
aged  18  to  32  months.  Animals  were  either  purchased  from  Harlan  (Boxmeer,  The 
Netherlands)  or  acquired  from  Semmelweis  University  (Budapest,  Hungary).  It  was 
previously reported that more than 37% of male Wistar Hannover rats above 1-year 
of age may develop pituitary tumors [34]. The rats were housed in Macrolon cages on 
a layer of wood shavings in a room with constant temperature (21 ± 2°C) and fixed 
12-hour  light-dark  regime  (light  phase  from  7:00  to  19:00  hours).  Food  (standard 
laboratory chow, RMH-B, Hope Farms, The Netherlands) and water were available ad 
libitum. After arrival the rats were acclimatized for at least seven days. Experiments were 
performed by licensed investigators in compliance with the Law on Animal Experiments 
in The Netherlands. The protocol was approved by the Committee on Animal Ethics of the 
University of Groningen. Animals were assigned to the healthy control (n = 8) or tumor-
bearing group (n = 5) after autopsy.
Arterial Blood Sampling
  Before microPET scanning, an arterial cannula was placed in each rat for blood 
sampling  and  determination  of  the  time  course  of  radioactivity  in  plasma.  For  this 
purpose, rats were anesthetized with isoflurane (Pharmachemie BV, The Netherlands, 5% 
in medicinal air for induction 2% for maintenance). An incision was made parallel to the 
femoral artery. The femoral artery was separated from the femoral vein and temporarily 92 Detection of spontaneous pituitary tumors with 11C-SA4503 PET
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ligated to prevent leakage of blood. A small incision was made in the artery and a cannula 
was inserted (0.8 mm outer, 0.4 mm inner diameter). The cannula was secured to the 
artery with a suture and attached to a syringe filled with heparinized saline. 
  From  each  rat,  fifteen  arterial  blood  samples  (volume  0.1  to  0.15  ml)  were 
collected at 0.25, 0.5, 0.75, 1, 1.25, 1.5, 2.0, 3, 5, 7.5, 10, 15, 30, 60 and 90 minutes after 
11C-SA4503 injection and start of the microPET scan. Plasma was obtained from the blood 
by centrifugation (5 min in Eppendorf-type centrifuge at 13,000 rpm). Radioactivity in 
plasma samples (25 µl) was determined using a calibrated gamma counter (CompuGamma 
CS 1282, LKB-Wallac, Turku, Finland). In a separate group of animals, larger volumes of 
blood (0.4 to 2 ml) were collected at 5, 10, 20, 40 and 60 min, and a metabolite analysis 
was performed by reversed-phase HPLC, using a previously published method for  11C-
SA4503 [35]. Plasma data was corrected for metabolites based on the age of the rat.
MicroPET Scan
  Two rats were scanned simultaneously in each scan session, using a Siemens/
Concorde microPET camera (Focus 220). They were positioned in the camera in transaxial 
position with their heads and neck in the field of view. First, a transmission scan of 515 
seconds with a Co-57 point source was obtained for attenuation and scatter correction 
of 511 keV photons by tissue. Subsequently, the first rat was injected through the penile 
vein with 11C-SA4503 (15-35 MBq, volume < 1 ml). The emission scan was started with 
tracer injection of the first rat; whereas the second animal was injected 16 min later. A list-
mode protocol was used with 90 min acquisition time (analysis performed for first 74 min 
from tracer injection). Reconstructions were performed using microPET Manager 2.3.3.6; 
ASIPro  6.3.3.0  (Siemens).  The  list-mode  data  of  the  emission  scans  were  reframed 
into a dynamic sequence of 8x30s, 3x60s, 2x120s, 2x180s, 3x300s, 3x600s, 1x720s, 
1x960s frames. The data were reconstructed per time frame employing an interative 
reconstruction algorithm (OSEM2D with Fourier rebinning, 4 iterations and 16 subsets). 
The final datasets consisted of 95 slices with a slice thickness of 0.8 mm, and an in-plane 
image matrix of 128 x 128 pixels. Voxel size was 0.5 x 0.5 x 0.8 mm. The linear resolution 
at the center of the field-of-view was about 1.5 mm. Data sets were fully corrected for 
decay, random coincidences, scatter and attenuation.
MicroPET Data Analysis
  The images obtained from the scan were co-registered with a MRI template [36] 
for drawing the three-dimensional regions of interest (ROIs) over the whole brain and 
healthy pituitary. ROIs were also drawn over the thyroid and pituitary tumor using Inveon 
Research Workplace software (Siemens Medical Solutions, Knoxville, TN). Time-activity 
curves (TACs) were calculated for each of these regions. Tracer uptake was expressed as 93
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a PET-SUV(mean), assuming a specific gravity of 1 g/cm3 for brain tissue and blood plasma. 
The parameter SUV is defined as: [tissue activity concentration (MBq/g) × animal body 
weight (g) / injected dose (MBq)].
  Kinetic analysis was performed by fitting a 2TCM to the dynamic PET data, using 
metabolite-corrected plasma radioactivity from arterial blood samples as input function. 
Fig.2.  11C-SA4503 microPET images of: A) a healthy aged rat; B) an aged rat with spontaneous 
pituitary tumor weighing 17 mg. TRANS = transverse, COR = coronal, SAG = sagittal view. Solid 
arrows indicate the healthy pituitary or pituitary tumor, dashed arrow position of the thyroid gland.94 Detection of spontaneous pituitary tumors with 11C-SA4503 PET
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Software  routines  for  MatLab  7  (The  MathWorks,  Natick,  MA),  written  by  Dr.  A.T.M. 
Willemsen (University Medical Center Groningen), were used to assess the K1/k2 and BPND 
= k3/k4 of 11C-SA4503. The blood volume was fixed at 0.036. VT was calculated as K1/k2 
* (1+ k3/k4). 
Ex vivo Biodistribution
  After the scanning period, animals were terminated by extirpation of the heart. 
Blood was immediately collected, and plasma and a cell fraction were separated by short 
centrifugation  (5  min  at  1,000  ×  g).  Several  tissues  (see  Table  1)  were  excised.  All 
tissue samples were weighed. Radioactivity in tissue samples and in a sample of the 
injected tracer solution (infusate) was measured using a gamma counter with automatic 
decay correction. The data are presented as SUV. Tissue-to-plasma, tumor-to-muscle and 
tumor-to-brain concentration ratios of radioactivity were calculated.
Statistics
  The biodistribution results are expressed as mean ± SD and all other results are 
expressed as mean ± SEM. Differences between groups were examined by two-tailed 
unpaired t-test or 1-way ANOVA, followed by a post-hoc Bonferroni test, if applicable. A 
P value < 0.05 was considered statistically significant.
Results
Tumor visualization on PET images 
  Pituitary tumors apperared in approximately 45% of tested aminals. Spontaneous 
pituitary tumors were clearly visible in 11C-SA4503 scans (Figure 2). The brains of animals 
with pituitary tumor appeared to take up more tracer than normal brain. Thyroid gland 
was visualized and it took up more of tracer in the tumor bearing rats than in the normal 
aged rats (Figure 2).
Kinetics of radioactivity in plasma and brain
  Kinetics of radioactivity in the plasma after a bolus injection of 11C-SA4503 is 
shown in Figure 3A. Plasma values from four of the normal rats were not included in this 
analysis; three due to non availability of plasma samples (failure of the cannula) and 
one due to changed kinetics because of a small depot during tracer injection. A rapid 
biexponential clearance was observed in both normal and tumor bearing animals. The 
presence of the pituitary tumor did not affect plasma kinetics of the tracer.
  Kinetics of  11C-SA4503 in pituitary and pituitary tumor, the brain and thyroid 
are presented in Figures 3B-D. Tracer uptake was rapid in normal brain, normal pituitary 95
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Fig.3. Time-activity curves of 11C-SA4503 in: A) plasma of normal (n = 5) and tumor-bearing rats (n 
= 4); B) normal pituitary (n = 7) and pituitary tumors (n = 5); C) brain of normal (n = 7) and tumor-
bearing rats (n = 5); D) thyroid of normal (n = 7) and tumor-bearing aged (n = 5). Data are expressed 
as mean ± SEM, differences were tested with repeated measures 2-way ANOVA and Bonferroni post 
hoc analysis.
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and brain with tumor, with the peak appearing within 5 min of tracer injection and was 
followed  by  a  slow  washout.  The  pituitary  tumor  uptake  while  also  rapid,  reached  a 
plateau within 10 min and no appreciable washout was seen within the scan duration.   
The brain uptake of the tracer in the tumor-bearing rats was about 50% higher than in 
normal aged rats. The tumor uptake was significantly higher (P ranging from <0.05 to 
<0.001) than the normal pituitary 7 min onwards and was about 3-fold higher by the end 
of the scan. It was also significantly higher (P ranging from <0.05 to <0.01) than the 
brain uptake in tumor bearing rats from 30 min onwards and was about 2-fold higher by 
the end of the scan.96 Detection of spontaneous pituitary tumors with 11C-SA4503 PET
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Fig.4. Kinetic modeling parameters of 11C-SA4503 in: A) normal pituitary (n = 8) and pituitary tumor 
(n = 5); B) brain of normal (n = 8) and tumor bearing (n = 5) rats; C) thyroid of normal (n = 8) and 
tumor bearing (n = 5) rats. Data are expressed as mean ± SEM and were tested with unpaired, two-
tailed t-test.
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Kinetic analysis
  2TCM was fitted to ROIs drawn around whole brain, normal pituitary, pituitary 
tumor and thyroid using metabolite-corrected arterial plasma as input. Where plasma 
data was not available, a population mean values corrected for injected dose and weight 
of individual animal was used as input. The VT (Figure 4A) of the tracer was significantly 
increased (P < 0.05) in malignant tissue (105.0 ± 47.6) compared to the normal pituitary 
(11.6 ± 1.0). An increase in VT was also seen in the brain tissue of animals with pituitary 
tumors compared to brain tissue of normal rats (25.5 ± 3.3 vs 11.8 ± 1.2, P < 0.001) 
(Figure 4B) and in thyroid of rats with pituitary tumors compared to thyroid of normal rats 
(39.3 ± 5.5 vs 23.1 ± 1.9, P < 0.01) (Figure 4C). 
  Further analysis showed that the increase of VT in the brain was not related to a 
change in BPND, but rather to an increase in partition coefficient (K1/k2) of 11C-SA4503 (6.6 
± 1.3 vs 2.4 ± 0.4, P < 0.01, Figure 4B). Similarly, the increase in VT in the thyroid was 
related to an increase in K1/k2 (8.8 ± 1.3 vs 5.1 ± 0.8, P < 0.05, Figure 4C) rather than 
BPND. VT, BPND and K1/k2 between brain and thyroid were well correlated (Figures 5A-C). 
Particularly VT and K1/k2 showed a close correlation (R2 > 0.8). However, increases of VT 
in the tumor were associated with significant increases in both BPND (10.7 ± 1.7 vs 4.6 
± 0.5, P < 0.01) and K1/k2 (10.5 ± 4.5 vs 2.2 ± 0.3, P < 0.05) (Figures 3B and 3C). The 
values for K1/k2 (but not VT and BPND) from brain and pituitary or tumor had a significant 
correlation (R2 = 0.38, P < 0.05; data not shown).
Biodistribution
  The mass of a normal pituitary was 12.7 ± 3.3 mg (mean ± SD, n = 5, range 
8.6 to 17.7 mg). Spontaneous pituitary tumors weighed 70.5 ± 93.1 mg (mean ± SD, n 
= 8, range 14.0 to 274.7 mg). Representative specimens of pituitary tumors are shown in 
Fig.5. Correlation of  11C-SA4503 kinetic parameters (A: VT, B: BPND, C: K1/k2) in the thyroid and 
brain.
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Figure 1. The figure shows one of the larger tumors (143 mg) still attached to the skull, 
and the position of the tumor with respect to the brain.
  Biodistribution data for the brain areas and peripheral organs are listed in Table 
1. The presence of the pituitary tumor was associated with a significant increase in the 
SUV and tissue-to-plasma ratio of the tracer in all brain areas. SUV values in peripheral 
organs of normal and tumor-bearing rats were not significantly different, but tissue-to-
plasma ratios in brain, small intestine, liver and spleen of tumor-bearing animals were 
significantly increased. 
  Biodistribution  data  of  11C  90  min  after  injection  of  11C-SA4503  showed  a 
significantly  higher  uptake  (SUV),  tissue-to-plasma  ratio  and  tissue-to-brain  ratio  in 
pituitary tumors than the normal pituitary (Figure 6). 
Discussion
  This study demonstrates that spontaneous pituitary tumors in aged rats can be 
detected and distinguished from normal pituitary and brain by microPET imaging with the 
sigma-1 ligand, 11C-SA4503 (Figure 2B). To the best of our knowledge, this is the first 
report identifying sigma-1 receptors in pituitary tumors. 
  For a good visualization of tumor lesions, the ratio of tracer uptake in tumor 
versus surrounding tissue must be >> 1. In biodistribution experiments, we observed a 
rapid uptake, retention and high accumulation of 11C-SA4503 in spontaneous intracranial 
pituitary tumors (SUV 10.3 ± 2.1) (Figures 3B and Figure 6B). Accumulation of  11C-
Fig.6. Tracer SUV, tissue-to-plasma (T/P) and tissue-to-brain (T/B) ratio of 11C-SA4503 in the normal 
pituitary (n = 5) and spontaneous pituitary tumors (n = 6, two rats which had large necrotic tumors 
were not included in this analysis). Data are expressed as mean ± SD and were tested with unpaired, 
two-tailed t-test.
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SA4503 in tumor tissue was ~ 6-fold higher than in the adjacent brain, ~ 3-fold higher 
than in the normal pituitary gland and ~ 100-fold higher than in blood plasma (Figure 
6B). Kinetic modeling indicated that VT in pituitary tumors is increased (by 10-fold) with 
respect to the normal pituitary. These changes in VT result from increases in both BPND and 
K1/k2 (2.3-fold and 4.9-fold, respectively) (Figure 4A). 
  Increases of the partition coefficient of the tracer in pituitary tumors could be 
caused by increased vascularization. However, an increase of K1/k2 was observed not 
only in the tumor, but also in the brain and thyroid. Tracer VT in the brain of pituitary 
tumor-bearing rats was increased (by 2.4-fold) compared to brain of healthy rats, due 
to  an  increase  in  K1/k2  (by  2.7-fold),  whereas  BPND  was  unaltered  (Figure  4B).  This 
observation suggests that increases of VT are not limited to tumor tissue and are therefore 
related to changes of vascular permeability or altered blood flow rather than increased 
vascularization.  A  1.7-fold  increase  of  K1/k2  (but  not  BPND)  was  also  observed  in  the 
Table.1. Biodistribution of  11C-SA4503 in various tissues derived from normal aged (n = 7) and 
tumor-bearing (n = 5) aged rats. 
                        SUV          T/P Ratio  
 
Tissue 
 
Normal Aged   With Tumor   P#  Normal Aged   With Tumor   P#  
Cerebellum    1.21 ± 0.32  2.08 ± 0.57  <0.001 
 
7.06 ± 2.67  20.67 ± 4.29  <0.001 
Cerebral cortex    1.55 ± 0.14  2.31 ± 0.36  <0.01    8.97 ± 2.09  23.30 ± 4.76  <0.001 
Rest of brain    1.28 ± 0.13  1.87 ± 0.41  <0.05    7.41 ± 1.85  18.55 ± 2.54  <0.001 
Adipose tissue    0.32 ± 0.26  0.38 ± 0.43  NS  1.91 ± 1.73  3.59 ± 3.89  NS 
Bladder    3.09 ± 3.41  2.28 ± 2.08  NS  19.81 ± 24.50  22.82 ± 19.28  NS 
Bone    0.43 ± 0.21  0.62 ± 0.18  NS 
 
2.48 ± 1.46  6.45 ± 2.68  NS 
Bone marrow  3.55 ± 2.92  2.72 ± 2.01  NS  18.77 ± 13.46  28.00 ± 19.50  NS 
Heart  0.61 ± 0.13  0.93 ± 0.12  NS  3.49 ± 0.97  9.43 ± 2.24  NS 
Large intestine  2.41 ± 0.70  2.94 ± 0.35  NS  14.30 ± 6.22  30.74 ± 11.58  NS 
Small intestine  3.50 ± 1.00  5.41 ± 1.18  NS  20.26 ± 8.13  55.59 ± 18.85  <0.01 
Kidney  3.50 ± 0.66  4.08 ± 1.24  NS  20.40 ± 6.20  41.62 ± 15.14  NS 
Liver  11.05 ± 1.67  11.68 ± 2.59  NS  63.83 ± 15.44  115.42 ± 14.92  <0.001 
Lung  2.21 ± 0.38  3.85 ± 1.35  NS  12.71 ± 3.13  39.32 ± 15.51  NS 
Muscle  0.30 ± 0.16  0.47 ± 0.19  NS  1.70 ± 0.86  4.83 ± 2.07  NS 
Pancreas  5.74 ± 2.67  5.31 ± 1.72  NS  33.23 ± 18.07  55.07 ± 22.99  NS 
Plasma  0.18 ± 0.04  0.10 ± 0.02  NS  1.00       1.00        
Red blood cells  0.09 ± 0.05  0.06 ± 0.02  NS  0.50 ± 0.27  0.64 ± 0.14  NS 
Spleen  4.10 ± 0.76  5.77 ± 1.72  NS  24.13 ± 8.29  58.12 ± 17.49  <0.01 
Submandibular gland  6.67 ± 2.20  4.90 ± 2.17  NS  37.24 ± 10.40  53.76 ± 36.77  NS 
Urine 
 
4.76 ± 5.47  3.68 ± 3.77  NS 
 
31.26 ± 39.06  40.07 ± 41.19  NS 
Data are expressed as mean ± SD and were tested with 2-way ANOVA followed by Bonferroni posttest 
(brain and peripheral organs were analyzed separately).100 Detection of spontaneous pituitary tumors with 11C-SA4503 PET
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thyroid gland (Figure 4C). Since BPND values in the brain and thyroid of tumor-bearing 
rats were not increased in contrast to K1/k2, sigma-1 receptor expression in these organs 
appears to be not affected by a pituitary tumor. 
  An  increased  partition  coefficient  of  11C-SA4503  in  the  brain  and  thyroid  of 
tumor-bearing animals may be caused by altered blood flow or blood pressure rather 
than increased permeability of the vascular endothelium. Pituitary tumors are known to 
exert global effects on blood flow [37]. Regional blood pressure can either be increased 
or decreased since levels of e.g. adrenocorticotropic hormone, vasopressin or thyroid-
stimulating  hormone  are  significantly  altered  [37].  If  the  permeability-surface  area 
product of a tracer remains constant, decreased perfusion will lead to increased tracer 
extraction and rises of VT because of slower transit of the tracer through the capillary bed. 
A global reduction of perfusion is suggested by the fact that the presence of a pituitary 
tumor is associated with significant increases of the tissue-to-plasma ratio of 11C-SA4503 
in the brain, small intestine, liver and spleen (P << 0.01) (Figure 6A). 
  If  the  affinity  of  11C-SA4503  to  sigma-1  receptors  remains  constant  during 
malignant transformation, as has been reported for nonneural tumors [38], the observed 
increase  of  BPND  in  tumor  tissue  should  reflect  upregulation  of  sigma-1  receptors  in 
pituitary tumors, consistent with the moderate (generally 2-3-fold) overexpression of 
sigma-1  receptors  in  other  tumor  tissues  [21,38,39].  The  reason  for  upregulation  of 
sigma-1 receptors in tumor tissue is still unclear but it may provide the tumor cells with 
an additional brake on apoptosis [40]. 
  In this study, we did not find any correlation between BPND and tumor size (data 
not shown). Similarly, in a study on 95 breast cancer patients no correlation was observed 
between sigma-1 receptor levels and tumor size, histological grade or expression of the 
proliferation marker, Ki-67, although a positive correlation was reported between sigma-1 
receptor levels, hormone receptor positivity (in particular progesterone receptor), Bcl-2 
expression and the period of disease-free survival [41]. Low ratios (< 1) of pro-survival 
Bcl-2 and pro-apoptotic Bax expression predominate in non-functioning pituitary tumors 
and pituitary microadenomas [42]. 
  The very high uptake of 11C-SA4503 in pituitary adenomas indicates that it may 
be worthwhile to test 11C-SA4503-PET in a clinical setting. Even very small tumors were 
clearly detected (the mass of the specimen in Figure 2 was 17 mg). This suggests that 11C-
SA4503 may be applied for the detection of microadenomas. Future studies are needed 
to  answer  the  question  whether  11C-SA4503-PET  can  detect  pituitary  adenomas  and 
can discriminate between symptomatic, hormone-secreting and non-functioning (non-
symptomatic,  non-secretive)  tumors.  Clinical  experiments  may  be  performed  rapidly, 
because of the frequent occurrence and re-growth of pituitary tumors and the fact that 
11C-SA4503 has been previously used in human volunteers. 101
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Conclusions
  Our results indicate that the BPND of 11C-SA4503 to sigma-1 receptors is increased 
in  pituitary tumors  compared to  their  tissue  of  origin  and  that  this  tracer may  have 
promise for the detection of pituitary adenomas, using PET.102
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Abstract
Tumor cells can be selectively killed by application of sigma ligands; high concentrations 
(20–100  µM)  are  often  required,  however,  because  either  diffusion  barriers  must  be 
passed to reach intracellular sites or the entire sigma receptor population should be 
occupied to induce cell death. We measured receptor occupancies associated with the 
cytotoxic effect and dose-dependent changes of cellular metabolism in a tumor cell line. 
Methods: C6 cells (rat glioma) were grown in monolayers and exposed to (+)-pentazocine 
(sigma-1 agonist), AC915 (sigma-1 antagonist), rimcazole (sigma-1/sigma-2 antagonist), 
or haloperidol (sigma-1/sigma-2 antagonist). Occupancy of sigma receptors by the test 
drugs was measured by studying the competition of the test drugs with cellular binding 
of  the  ligand  11C-SA4503.  Metabolic  changes  were  quantified  by  measuring  cellular 
uptake  of  18F-FDG,  18F-FLT,  11C-choline,  or  11C-methionine.  Cytotoxicity  was  assessed 
by cellular morphology observation and cell counting after 24 h. Results: IC50 values 
(drug concentrations resulting in 50% occupancy of the available binding sites) of the 
test drugs for inhibition of cellular  11C-SA4503 binding were 6.5, 7.4, 0.36, and 0.27 
µM for (+)-pentazocine, AC915, rimcazole, and haloperidol, respectively. EC50 values 
(dose required for a 50% reduction of cell number after 24 h) were 710, 819, 31, and 
58 µM, for pentazocine, AC915, rimcazole, and haloperidol, respectively. Cytotoxic doses 
of sigma ligands were generally associated with increased uptake of 18F-FDG, decreased 
uptake of 18F-FLT and 11C-choline, and little change in 11C-methionine uptake per viable 
cell. Conclusion: IC50 values of the test drugs reflect their in vitro affinities to sigma-2 
rather  than  to  sigma-1  receptors.  Because  cytotoxicity  occurred  at  concentrations  2 
orders of magnitude higher than IC50 values for inhibition of cellular 11C-SA4503 binding, 
high  (99%)  occupancy  of  sigma-2  receptors  is  associated  with  loss  of  cell  viability.   
18F-FLT, 11C-choline, and 18F-FDG responded most strongly to drug treatment and showed 
changes corresponding to the cytotoxicity of the test compounds. 
Keywords: PET, sigma receptor occupancy, cellular proliferation, glioma cells,  18F-FLT, 
18F-FDG, 11C-choline, 11C-methionine
Introduction
  Sigma receptors are unique proteins integrated in plasma and endoplasmatic 
reticulum membranes of tissue derived from immune, endocrine, and reproductive organs; 
kidney; liver; and brain [1]. Sigma receptors were initially considered as a subtype of 
the opioid receptor but were later shown to be unlike any other known neurotransmitter 
or hormone binding site [2]. After 30 years of extensive research, understanding of the 109
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molecular cascade triggered by these transmembrane proteins is still rudimentary [3]. 
The two confirmed sigma receptor subtypes, 25 kDa sigma-1 and 21.5 kDa sigma-2 [4], 
are strongly overexpressed in rapidly proliferating cells, for example, in cancer cells from 
animals and humans, as compared with healthy tissue [5–7]. Although the sequence and 
partial structure of the sigma-1 receptor are already established [8,9], the existence of 
the sigma-2 receptor has been proven only pharmacologically [10].
  Many natural substances from plant extracts and newly synthesized compounds 
were tested for sigma receptor binding, resulting in the availability of a broad range of   
sigma receptor ligands today [11]. Interestingly, some of these compounds were shown 
to be effective antineoplastic agents [12,13]. Later, in vitro [14–16] and in vivo [17,18] 
studies confirmed that sigma ligands, such as haloperidol and rimcazole, inhibit growth 
of both cultured cancer cells and in vivo tumors, whereas they do not affect proliferation 
or survival of the noncancer tissue [18]. These studies highlighted the potency of sigma 
ligands to kill cancer cells with minimal side effects. In most cell lines, including in C6 
rat  glioma,  cell  death  was  observed  only  after  administration  of  high  concentrations   
(20–100 µM) of a sigma-1 receptor antagonist or a sigma-2 receptor agonist [12,13]. The 
reason for the requirement of high concentrations is unknown. Possibly biomembranes 
limit drug access to intracellular sites, or a high fraction of the sigma receptor population 
should be occupied to kill tumor cells.
  If  a  suitable  radioligand  for  sigma  receptors  is  available,  dose-dependent 
occupancy of the receptor population by an exogenous ligand can be assessed by performing 
a  competition  assay  in  intact  cells.  Measured  occupancy  values  can  be  subsequently 
compared  with  the  dose-dependent  effects  of  test  drugs  on  cellular  morphology  and 
growth. The sigma-1 agonist SA4503, labeled with the positron emitter 11C, is available 
for this purpose [19]. We used C6 cells as an in vitro model for the measurement of both 
sigma receptor occupancy and cytotoxic effects. This rat glioma cell line has been used 
extensively in previous research because it expresses high densities of both sigma-1 and 
sigma-2  receptors  [6].  Rimcazole  (sigma-1/sigma-2  receptor  antagonist),  haloperidol 
(sigma-1/sigma-2  receptor  antagonist),  (+)-pentazocine  (sigma-1  receptor  agonist), 
and  AC915  (sigma-1  receptor  antagonist)  were  chosen  as  our  model  compounds 
because these drugs are commercially available and are potent sigma receptor ligands 
[20–23]. Several metabolic PET tracers, such as  18F-FDG, 3’-deoxy-3’-fluorothymidine 
(18F-FLT), 11C-choline, and 11C-methionine, are routinely produced in our laboratory. These 
radiopharmaceuticals track changes in cellular metabolism and may show altered uptake 
kinetics after antitumor therapy [24]. Thus, we could assess the dose-dependent effects 
of sigma ligands on cellular biochemistry.
  The present study aimed to answer the following questions: Which concentrations 
of sigma ligands should be administered to occupy a substantial fraction of the intracellular 110 Change cellular metabolism following sigma-2 receptor binding
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receptor population and kill C6 cells? At which level of receptor occupancy does cell death 
occur? Can PET tracers detect any changes of cellular metabolism after sigma ligand 
binding? Which PET tracer is the most sensitive indicator of reduced cellular viability?
Materials & Methods
Culture Medium and Drugs
  Dulbecco’s  minimum  essential  medium  (DMEM),  fetal  calf  serum  (FCS),  and 
trypsin were products of Invitrogen. AC915, haloperidol, (+)-pentazocine, rimcazole, and 
trypan blue (0.4% solution in phosphate-buffered saline) were purchased from Sigma. 
AC915 was dissolved in water with slight heating, and haloperidol and rimcazole were 
dissolved in ethanol. Stock solutions of (+)-pentazocine were made in 0.1N hydrochloric 
acid.
RadiopharmaceuticalsL
  11C-methionine,  11C-choline,  18F-FLT,  and  18F-FDG  were  prepared  by  standard 
procedures  reported  in  the  literature  [25].  11C-SA4503  was  prepared  by  reaction  of 
11C-methyl iodide with the appropriate 4-O-methyl precursor [26]. Specific radioactivity 
at the end of synthesis was greater than 22 TBq/mmol. All radiochemical purities were 
greater than 95%.
Cell Culture 
  C6 rat glioma cells obtained from the American Type Culture Collection were 
grown as monolayers in DMEM (high glucose) supplemented with 7.5% FCS in a humidified 
atmosphere of 5% CO2/95% air at 37°C. Before each experiment, the cells were seeded 
in 12-well plates (Costar). An equal number of cells was dispensed in each well and was 
supplied with 1.1 mL of DMEM (high glucose) supplemented with 7.5% FCS.
Binding Studies
  Binding  studies  were  performed  48  h  after  seeding  cells  in  12-well  plates, 
when confluency reached 80%–90%. Various concentrations of an unlabeled competitor 
(AC915, haloperidol, (+)-pentazocine, or rimcazole; range, 10–8 to 10–3 M, in triplicate) 
were dispensed to the culture medium in the wells. After 2 min, 4 MBq of 11C-SA4503 
in less than 30 µL of saline (containing 30% ethanol) were added to each well. After 
about 45 min of incubation, the medium was quickly removed, and the monolayer was 
washed 3 times with phosphate-buffered saline. Cells were then treated with 0.2 mL 
of trypsin. When the monolayer had detached from the bottom of the well, 1 mL of 
DMEM (high glucose) supplemented with 7.5% FCS was applied to stop the proteolytic 111
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action. Cell aggregates were resolved by repeated (at least 10-fold) pipetting of the 
trypsin/DMEM mixture. Radioactivity in the cell suspension (1.2 mL) was assessed using 
a gamma-counter (Compugamma 1282 CS; LKB-Wallac). A sample of the suspension was 
mixed with trypan blue solution (1:1 v/v) and used for cell counting. Cell numbers were 
manually determined, using a phase-contrast microscope (Olympus), a Bürker bright-line 
chamber (depth, 0.1 mm; 0.0025 mm2 squares), and a hand-tally counter. 
  Uptake of radioactivity normalized to the number of viable cells was plotted 
against the logarithm of the dose of the competing drug (in [M]). A 3-parameter curve 
(single-site competition model) was fitted to these data, using the following equation: 
 
  Y = bottom + (top - bottom) / (1 + 10(X - logIC50)),
where IC50 is drug concentration resulting in 50% occupancy of the available binding 
sites.  GraphPad  Prism  (GraphPad  Software)  was  used  for  curve  fitting  and  graphical 
presentation of data. Less than 6% (in most wells << 5%) of the administered tracer 
dose was bound to the cells under these conditions. 
Treatment with Sigma Ligands and Scoring of Morphologic Effects
  Sigma ligands were administered 24 h after seeding cells in 12-well plates when 
confluency had reached 40–45%. Final concentrations in culture medium were 1, 3, 10, 
30, and 100 (in some cases also 300) times the IC50 value of the test drug for inhibition 
of 11C-SA4503 binding to cellular sigma receptors (determined as described above). 
  After 20–24 h of incubation with sigma ligands, the cells were monitored by 
phase-contrast microscopy. The effect of each compound and concentration was scored 
relative to a control receiving only solvent vehicle. Scoring was performed as described 
previously  [12].  Experiments  were  performed  in  quadruplicate  and  repeated  at  least 
twice. Decreases of cell number after drug treatment were quantified by harvesting and 
resuspending cells in medium containing FCS, followed by manual counting as described 
above. 
Uptake Studies
  Cellular uptake of metabolic PET tracers was determined after 24 h of treatment 
with either vehicle or a sigma ligand. Experiments were performed in quadruplicate and 
repeated at least twice. At time zero, a PET tracer (4 MBq of 11C-methionine or 11C-choline 
or 2 MBq of 18F-FDG or 18F-FLT in <20 µL of saline) was added to each well. After 45 min 
of incubation, cells were washed, and cellular radioactivity was assessed as described 
above. Less than 1% (11C-methionine), 2% (18F-FDG), or 4% (11C-choline and 18F-FLT) of 
the administered tracer dose was taken up by the cells under these conditions. 112 Change cellular metabolism following sigma-2 receptor binding
Journal of Nuclear Medicine. 2008;49:2049-2056.
C
h
a
p
t
e
r
 
5
Statistics
  Differences between groups were examined using 1-way ANOVA. A P value of 
less than 0.05 was considered statistically significant. 
Results
Receptor Occupancy
  Curves describing competition between the test drugs and the radioligand 11C-
SA4503 for cellular sigma receptors are presented in Figure 1. The data were best fitted 
by  a  1-site  competition  model.  IC50  values  were  either  in  the  submicromolar  range 
(rimcazole, 0.36 µM; haloperidol, 0.27 µM) or in the micromolar range ((+)-pentazocine, 
6.5 µM; AC915, 7.4 µM).
Subtype Involvement
  Table 1 lists literature values for the affinities (Kd) of the test compounds to 
sigma-1 and sigma-2 receptors, determined by in vitro binding assays using membrane 
Fig.1. Dose-dependent increase of cellular 11C-SA4503 binding by (+)-pentazocine (n), haloperidol 
(r), AC915 (q), and rimcazole (s). Error bars indicate SEM. Specific binding was calculated by 
subtracting nonspecific binding (i.e., residual binding of radioligand in presence of highest dose of 
competing drug) from total binding; it amounted to 70%–80% of total radioactivity uptake by cells.113
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Table 1. Binding of Test Compounds to Sigma Receptor Subtypes
fragments isolated from rodent tissues. We observed much higher (60- to 1,500-fold) 
IC50 values in intact cells than known Kd values at sigma-1 receptors, particularly in 
the case of AC915, (+)-pentazocine, and haloperidol. However, IC50 values of all test 
compounds corresponded closely to their Kd values at sigma-2 receptors. Here, only 
minor (<3-fold) differences were observed. Therefore, IC50 values for inhibition of 11C-
SA4503 binding to intact cells corresponded to the sigma-2 Kd rather than to the sigma-1 
Kd of the test compounds. 
Cytotoxicity
  When  the    sigma-antagonists  rimcazole,  haloperidol,  or  AC915  were  applied 
to  C6  cells  in  culture,  a  dose-dependent  growth  inhibition  was  observed  after  24  h 
(Fig. 2). Low doses of the test drugs did not affect cellular growth. Above a certain 
threshold concentration (rimcazole, 20 µM; haloperidol, 25 µM; and AC915, 220 µM), a 
reduction in cell number became apparent. EC50 values of the test compounds (effective 
concentrations  resulting  in  50%  cell  loss)  were  somewhat  higher  than  the  threshold 
for cytotoxicity (rimcazole, 31 µM; haloperidol, 58 µM; and AC915, 819 µM). Virtually 
complete cell death was observed after 24 h of treatment with either 100 µM rimcazole 
or 150 µM haloperidol (Fig. 2). Even 200 µM sigma-1 agonist (+)-pentazocine did not yet 
affect cell division or viability. Here, the EC50 value for growth inhibition was 710 µM. 
Receptor Occupancy at Cytotoxic Dose
  By comparing EC50 values of the test compounds with their IC50 values for 
inhibition of 11C-SA4503 binding in intact cells, sigma receptor occupancies at cytotoxic 
doses of the test drugs could be estimated, using the curves presented in Figure 1 or the 
formula for a single-site competition model (see “Materials and Methods”). Because EC50 
values were about 2 orders of magnitude higher than the corresponding IC50 values of 
the test drugs, cell death appeared to be associated with virtually complete (i.e., 99%) 
occupancy of the sigma receptor population (Table 2). 114 Change cellular metabolism following sigma-2 receptor binding
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Changes of Cellular Metabolism
  The metabolic PET tracers that we used responded differently to treatment of C6 
cells with sigma receptor ligands. Cytotoxic doses of (+)-pentazocine, haloperidol, and 
rimcazole were generally associated with increases of the uptake of 18F-FDG, decreases 
of the uptake of 18F-FLT and 11C-choline, and little change of 11C-methionine uptake per 
viable cell (Figs. 3–6). 
  Significant  increases  of  18F-FDG  uptake  were  observed  only  when  a  certain 
threshold concentration was exceeded. The threshold dose for haloperidol and rimcazole 
was 10 µM but in the case of (+)-pentazocine was 30 µM (Fig. 3). Maximal increases 
of  18F-FDG  uptake  (+111%,  +150%,  and  +166%  for  haloperidol,  rimcazole,  and 
(+)-pentazocine, respectively; all statistically significant) occurred at doses of 100 µM 
Fig.2. Dose-dependent cell loss after 24 h of incubation with (+)-pentazocine (n), haloperidol (r), 
AC915 (q), and rimcazole (s). Note that x-axis scales of Figures 1 and 2 are different. Error bars 
indicate SEM.
Table 2. Receptor Occupancy at Cytotoxic Dose115
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Fig.3. Dose-dependent increase of cellular 18F-FDG uptake by  (+)-pentazocine (n), haloperidol (r), 
AC915 (q), and rimcazole (s).
Fig.4. Dose-dependent inhibition of cellular 18F-FLT uptake by (+)-pentazocine (n), haloperidol (r), 
AC915 (q), and rimcazole (s). 116 Change cellular metabolism following sigma-2 receptor binding
Journal of Nuclear Medicine. 2008;49:2049-2056.
C
h
a
p
t
e
r
 
5
for haloperidol, 112 µM for rimcazole, and 660 µM for (+)-pentazocine. Higher doses of 
test drug could not be examined, because these resulted in a complete loss of cells after   
24 h. In contrast to the previously mentioned sigma ligands, AC915 in doses of up to   
776 µM did not increase cellular 18F-FDG uptake. A slight but statistically significant decline 
(–21%) of  18F-FDG uptake was observed after incubation of cells with 220 µM AC915   
(Fig. 3). 
  Treatment of C6 cells with rimcazole, (+)-pentazocine, and haloperidol resulted 
in a dose-dependent depression of  18F-FLT uptake when drug concentrations exceeded 
threshold values of 20, 50, and 80 µM, respectively (Fig. 4). Strong and statistically 
significant  depression  of  18F-FLT  uptake  was  observed  after  a  24-h  incubation  of  the 
cells with 50 (rimcazole), 100 (haloperidol), or 645 µM ((+)-pentazocine), to 6%, 17%,   
and 26% of the control, respectively. In contrast to the previously mentioned sigma 
ligands, AC915 did not depress cellular 18F-FLT uptake but caused a biphasic increase with 
a maximum occurring at a drug dose of 74 µM (Fig. 4). 
  Cellular uptake of  11C-choline was depressed by all drug treatments (Fig. 5).   
A  decline  occurred  when  the  ligand  concentration  of  (+)-pentazocine  and  AC915 
exceeded 70 µM (20 µM for haloperidol and 15 µM for rimcazole). At concentrations 
of 650 ((+)-pentazocine), 711 (AC915), or 45 µM (rimcazole),  11C-choline uptake was 
reduced  more  than  80%,  whereas  a  concentration  of  60  µM  for  haloperidol  resulted   
in a 55% decline (Fig. 5). 
  No statistically significant changes of 11C-methionine uptake occurred after 24 h 
of treatment of C6 cells with (+)-pentazocine, haloperidol, or AC915 (Fig. 6). In contrast, 
rimcazole at concentrations greater than 10 µM depressed uptake of the amino acid up to 
40% (Fig. 6). 
Discussion
Competition Assays
  11C-SA4503 has been reported to bind preferentially to sigma-1 receptors (IC50, 
17.4 nM at the sigma-1 and 1,784 nM at the sigma-2 subtype [27]; IC50, 4.7 nM at 
sigma-1 and 63.1 nM at sigma-2 receptors in a later study [28]). Therefore, we expected 
that the potent sigma-1 selective ligands (+)-pentazocine and AC915 would compete 
more  efficiently  (i.e.,  at  lower  IC50  values)  with  cellular  binding  of  11C-SA4503  than 
would the non–subtype-selective antagonists rimcazole and haloperidol, which bind less 
potently to sigma-1 receptors. In reality, however, rimcazole and haloperidol inhibited 
11C-SA4503 binding more potently (IC50 values, 0.36 and 0.27 µM, respectively) than 
did (+)-pentazocine and AC915 (IC50 values, 6.5 and 7.4 µM, respectively; Fig. 1). The 
IC50 values corresponded closely to the sigma-2 Kd but not to the sigma-1 Kd of the test 117
C
h
a
p
t
e
r
 
5
Fig.5. Dose-dependent increase of cellular  11C-choline uptake by (+)-pentazocine (n), haloperidol 
(r), AC915 (q), and rimcazole (s).
Fig.6. Dose-dependent increase of cellular 11C-methionine uptake by  (+)-pentazocine (n), haloperidol 
(r), AC915 (q), and rimcazole (s). MET = methionine.118 Change cellular metabolism following sigma-2 receptor binding
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compounds (Table 1). 
  This outcome of our competition assays can be understood when the applied 
mass of 11C-SA4503 is considered. To have acceptable count statistics even at high doses 
of a competing drug after 60 min of incubation, it was necessary to add 4 MBq of 11C-
SA4503. At a specific radioactivity of 22 TBq/mmol, this corresponds to a ligand mass of 
0.2 nmol and a ligand concentration of 200 nM in each well. The receptor Kd reported by 
Matsuno et al. [27] predict that at this radioligand concentration, saturation of sigma-1 
receptors will occur and specific binding will be observed mainly at the sigma-2 subtype. 
  Thus, the methods described in this article investigated the relationship between 
cytotoxicity  and  sigma-2  receptor  occupancy,  using  the  relatively  low  affinity  of  11C-
SA4503 for sigma-2 receptors. During in vivo scans with 11C-SA4503 in humans, ligand 
concentrations in the 10–8 or 10–7 M range will never be reached. Human SA4503-PET 
scans will, therefore, reflect the regional distribution of sigma-1 rather than sigma-2 
receptors. 
Cytotoxic Effects
  According to the literature, relatively high doses of sigma-antagonists (20–100 
µM for rimcazole or haloperidol [12,13]) are required for the killing of glioma cells. Our 
data confirm these reports (EC50, 31 µM for rimcazole and 58 µM for haloperidol; Fig. 
2). Even higher doses of (+)-pentazocine and AC915 were necessary to induce cell death 
(EC50 values, 710 and 819 µM, respectively; Fig. 2). Such high doses are not required 
because  diffusion  barriers  limit  drug  access  to  intracellular  sites,  for  half-maximal 
occupancy of the sigma receptor population is reached already at concentrations 100-fold 
lower than the EC50 for cell killing (Table 2). Because we observed a decrease in cellular 
viability only at drug concentrations 2 orders of magnitude higher than the corresponding 
IC50 values for inhibition  of  11C-SA4503 binding, our data indicate that cell death is 
associated with virtually complete (>98%) occupancy of the sigma receptor population. 
Because 11C-SA4503 binding occurred mainly at sigma-2 receptors under the conditions 
of our assay, the data also suggest that cell death is induced via the sigma-2 rather than 
via the sigma-1 subtype if the observed cytotoxic effects are really mediated through 
sigma receptors. 
  The  curves  describing  cell  loss  after  24  h  of  treatment  with  rimcazole  and 
(+)-pentazocine  have  a  steep  slope,  indicating  rapid  cell  killing  when  the  drug  dose 
exceeds  a  sharp  threshold  concentration  (Fig.  2).  In  contrast,  cell  death  induced  by 
haloperidol and AC915 occurs more gradually (Fig. 2). These different curve shapes may 
signify that haloperidol and AC915 are partial agonists at sigma-2 receptors, whereas 
rimcazole and (+)-pentazocine are full agonists. It is also possible that rimcazole and 
(+)-pentazocine induce cell death via an additional mechanism, which occurs in parallel 119
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and independently of occupancy of the sigma-2 receptor population. Sigma-2 receptor–
mediated cell death is suggested by the fact that losses of cell viability always occur   
at concentrations 2 orders of magnitude higher than the IC50 of the 4 test compounds 
for inhibition of 11C-SA4503 binding to cellular sigma-2 receptors (Table 2). An additional 
mechanism of cell death is suggested by the different shapes of the cell-loss curves   
(Fig. 2) and by a cellular morphology that is different after treatment of the cells with 
different sigma ligands (data not shown). 
  On  the  basis  of  these  data,  rimcazole  appears  to  be  the  most  interesting 
compound for further study as an anticancer drug. 
Metabolic Changes
  In our in vitro model, we observed a large increase of  18F-FDG uptake after 
24 h of incubation with sigma ligands (Fig. 3). A similar increase of 18F-FDG uptake has 
been observed after some forms of chemo- and radiotherapy in which the increase of 
uptake preceded cell death [29,30]. This increase may be a “metabolic flare” due to 
increased energy consumption as a consequence of DNA and membrane repair [29]. 
Glucose transporters (glucose transporter 1 and sodium-dependent glucose transporter 
1) are known to be overexpressed after various cellular stresses, including hypoxia and 
heat shock [31]. Rimcazole and (+)-pentazocine interfered strongly with cellular  18F-
FDG uptake, whereas haloperidol and AC915 had smaller effects on glucose metabolism   
(Fig. 3). 
  18F-FLT  traces  the  salvage  pathway  of  DNA  synthesis.  The  retention  of  this 
nucleoside is a measure of thymidine kinase 1 activity within the cells [32,33]. After 
treatment  of  C6  cells  with  sigma  ligands,  we  observed  striking  decreases  of  18F-FLT 
uptake. (+)-Pentazocine, rimcazole, and haloperidol induced more than a 70% decline of 
cellular 18F-FLT uptake at a dose 100 times greater than the IC50 for inhibition of cellular 
11C-SA4503 binding (Fig. 4). However, AC915 caused a less marked inhibition of 18F-FLT 
uptake, which is consistent with a smaller reduction of cellular proliferation (Fig. 4). The 
rank order of drug effects on 18F-FLT uptake was the same as for 18F-FDG. In the range 
of 3–30 times IC50 for inhibition of cellular 11C-SA4503 binding, AC915 induced a small 
increase of  18F-FLT uptake, which may reflect activation of repair processes within the 
cells. 
  We  tested  11C-choline  uptake  after  treatment  of  C6  cells  with  sigma  ligands 
because total choline levels and phosphatidylcholine synthesis are known to be elevated 
in cancers of different origin, as compared with healthy tissue, and are related to cellular 
proliferation. We observed the expected strong decrease of 11C-choline uptake when cells 
were treated with sigma ligands (Fig. 5). Above the threshold rimcazole concentration, 
the uptake of  11C-choline was reduced rapidly, whereas (+)-pentazocine, AC915, and 120 Change cellular metabolism following sigma-2 receptor binding
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haloperidol  resulted  in  slower  but  progressive  inhibition  of  phospholipid  metabolism. 
These results are consistent with the fact that 11C-choline uptake by cancer cells is related 
to the activity of the enzyme choline kinase [34], which is generally directly proportional 
to the proliferative status of the cell. 
  In  contrast  to  18F-FLT  and  11C-choline,  11C-methionine  did  not  behave  as   
a  proliferation  marker,  and  11C-methionine  uptake  per  viable  cell  showed  hardly  any 
change (Fig. 6). Thus, 11C-methionine appeared to trace cell number rather than cellular 
viability after sigma ligand treatment. The methyl group of methionine, which contains 
the  11C  label,  is  implicated  in  many  metabolic  processes  such  as  protein  synthesis, 
transmethylation,  and  polyamine  synthesis.  Therefore,  11C-methionine  has  a  complex 
metabolism, and uptake of 11C-methionine by tumor cells may be a reflection of several 
processes, which are affected differently by anticancer treatment, some being increased 
and others showing a decrease [35]. The lack of change in 11C-methionine uptake may 
also indicate unaltered transport of this amino acid through the cell membrane and slow 
transmethylation processes [31]. 
  Our  data  indicate  that  18F-FLT  and  11C-choline  are  the  tracers  of  choice  for 
evaluation  of  the  effects  of  sigma  ligands  on  cellular  proliferation.  18F-FDG  may  also 
provide useful information, but 11C-methionine uptake is a reflection of the cell number 
rather than the proliferation state. 
  Growth  reduction  of  glioma  cells  and  changes  of  cellular  metabolism  were 
observed only at ligand concentrations more than 30-fold higher than those required 
for 50% occupancy of the sigma-2 receptor population. Strong decreases of the number 
of viable cells occurred at drug concentrations greater than or equal to 100-fold higher 
than the IC50 for inhibition of 11C-SA4503 binding. Thus, cell death was associated with 
virtually complete (99%) occupancy of the intracellular sigma-2 receptor pool. 
  Although  high  levels  of  receptor  occupancy  and  drug  doses  in  the   
10–5 M range are required for rapid cell killing, sigma ligands appear to have potential 
as cancer therapeutics for the following reasons. First, preliminary studies, both from 
our own laboratory and from other institutions [18], have demonstrated that cell death   
is limited to tumor cells and occurs only at much higher concentrations in healthy normal 
cells. Adverse effects could be further diminished by local application or selective drug 
targeting. Second, significant inhibition of in vivo tumor growth has been observed in a 
variety of tumor models in response to sigma ligands given systemically [17,18]. Third, 
because  sigma-2  ligands  trigger  cell  death  both  by  caspase-dependent  and  caspase-
independent  mechanisms,  such  compounds  may  be  suitable  for  treatment  of  a  wide 
variety of tumors, including caspase-deficient tumor types [36]. Last, subtoxic doses   
of sigma ligands can be applied in combination therapy and can potentiate the antitumor 
effects of “classic” cytostatic agents [36,37]. Because of the therapeutic potential of sigma 121
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ligands, radiopharmaceuticals for sigma receptors may be used not only as diagnostic 
imaging agents but also as tools to assess sigma receptor occupancy during experimental 
tumor therapy. 
Conclusion
  In the present study, treatment of tumor cells with cytotoxic doses of sigma 
ligands resulted in strong increases of the uptake of  18F-FDG and decreases of  18F-FLT 
and 11C-choline uptake per viable cell. Cell-specific uptake of 11C-methionine was largely 
unaltered under these conditions. 18F-FLT, 11C-choline, and 18F-FDG responded strongly to 
drug treatment and were suitable tools in the evaluation of the cytotoxicity of the test 
compounds. These PET tracers may, therefore, be used in future in vivo studies.122
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Abstract
Sigma ligands can kill tumor cells. Previously we have shown that a short incubation of 
tumor cells with sigma ligands (24 h) results in a dose-dependent increase of cellular 
18F-FDG uptake, and that the magnitude of this increase is predictive of subsequent cell 
death. Here, we aimed to assess if the sigma ligand, rimcazole, inhibits growth of A375M 
melanoma xenografts in mice, and if rimcazole treatment changes 18F-fluorodeoxyglucose 
(18F-FDG) uptake in vivo. Methods: Athymic mice were inoculated with A375M melanoma 
cells in matrigel. After two weeks, tumors had appeared and had reached a size of 0.041 
± 0.006 cm3. We then started a 14-day treatment schedule with daily drug dosing. Control 
animals were intraperitoneally injected with water, treated animals with rimcazole (26 
mg/kg) in water. Three microPET scans with 18F-FDG were made: on day 0, 7 and 14 of 
treatment. After the last scan, animals were terminated and a biodistribution study was 
performed. Results: Rimcazole treatment resulted in a > 4-fold reduction of tumor weight 
in comparison to controls at day 14 (0.100 ± 0.026 vs 0.436 ± 0.117 g, respectively, P 
< 0.03). Treatment did not affect the levels of (non-radioactive) glucose in blood, animal 
weight, behavior or appearance. Anti-tumor activity of rimcazole was accompanied by 
a “metabolic flare” manifested by a temporary increase of 18F-FDG uptake in the tumor 
(measured at day 7). Significant increase of  18F-FDG uptake at day 14 was observed 
in liver and pancreas. Conclusion: Rimcazole strongly inhibited the growth of A375M 
melanoma xenografts. This growth inhibition may be predicted from the early increase of 
18F-FDG uptake in the tumor.
Keywords:  sigma  receptors,  rimcazole,  melanoma,  fluorodeoxyglucose,  microPET, 
metabolic flare
Introduction
  Melanoma, a neoplasm arising from pigment-producing melanocytes, is highly 
metastatic  and  the  most  deadly  dermatologic  malignancy.  If  spread  to  distant  sites, 
patients have a median survival rate of 6 months. This is because the disease is frequently 
diagnosed in the advanced stages and metastasized melanoma is refractory to current 
therapeutic modalities (such as radiotherapy, chemotherapy, and immunotherapy) [1]. 
Therefore, new targets which can induce melanoma cell death and/or overcome melanoma 
resistance may lead to improved treatment of refractory melanomas. 
  Melanomas  can  be  divided,  based  on  their  ability  to  produce  the  pigment 
(melanin), into melanotic melanomas and, more aggressive, amelanotic melanomas [2]. 
Both melanoma types possess moderate to high levels of sigma receptors, as shown by 127
C
h
a
p
t
e
r
 
6
a pronounced uptake of several sigma ligands labeled for positron emission tomography 
(PET)  [3],  single  photon  emission  computed  tomography  (SPECT)  [4-6]  and  by 
immunohistochemical (IHC) staining of sigma-1 receptors in primary human melanomas 
(www.proteinatlas.com). 
  Sigma  receptors  are  proteins  integrated  into  cell  membrane,  endoplasmic 
reticulum, mitochondrial membrane, nuclear envelope and lysosomes [7,8]. There are 
two identified sigma receptor subtypes, sigma-1 receptors and sigma-2 receptors [9,10]. 
Sigma-1 receptors are upregulated with the onset of cancer cell proliferation [11]. Also, 
sigma-2 receptors are 10-fold more abundant in rapidly proliferating cancer cells than 
in quiescent cancer cells derived from mouse mammary adenocarcinoma in vitro and in 
vivo [12]. A 3- to 5-fold overexpression of sigma-2 receptors has been observed in low 
grade bovine bladder carcinomas, whereas a marked 25- to 44-fold overexpression is 
found in high-grade bovine bladder carcinomas [13]. These data are consistent with the 
participation of sigma receptors in cellular proliferation and indicates that sigma ligands 
may be useful diagnostic agents and radiotracers for cancer imaging. 
  Sigma ligands (sigma-1 antagonists and sigma-2 agonists) have strong anti-
cancer properties, but they exert only minor effects on non-cancerous tissue [14]. In 
addition, sigma ligands can repress or overcome therapy resistance in cancer cells and, 
thus,  enhance  the  anti-cancer  effect  of  chemotherapeutics  (reviewed  in  [15]).  This 
observation has resulted in several in vitro and in vivo studies with sigma ligands as anti-
cancer agents including clinical trials with rimcazole (Modern Biosciences), siramesine (H 
Lundbeck A/S), SR31747A (Sanofi-Aventis) and ANAVEX 1007 (Anavex Life Sciences).
  Sigma ligands can activate multiple cell death pathways dependent on the cancer 
type and ligand concentration. The mechanism by which a sigma ligand induces cytotoxicity 
is partially p53- and caspase-independent [16]. However, it involves disturbance of the 
cell cycle (particularly arrest of cancer cells in G1 phase) [17,18], changes in calcium 
homeostasis [19,20] and modulation of the ceramide/sphingolipid ratios [21]. The key 
pathway in these processes could be PI3K/Akt, since both downregulation of sigma-1 
receptors  and  treatment  with  sigma  ligands  (e.g.  IPAG,  rimcazole  and  haloperidol) 
affects Akt phosphorylation [14,22-25]. Furthermore, haloperidol was shown to inhibit 
proliferation of B16 and SK-MEL-28 melanotic melanoma cell lines [17]. Sigma receptors 
are, therefore, an appealing target for melanoma treatment.
  Previously, we have demonstrated a strong anti-cancer activity of the sigma-
ligand, rimcazole, in cultured human A375M amelanotic melanoma cells and rat C6 glioma 
[26,27]. In addition, our in vitro results showed that cytotoxic doses of sigma-ligands 
were  generally  associated  with  increased  uptake  of  2-deoxy-2-(18F)fluoro-D-glucose 
(18F-FDG) [27]. 
  Although sigma receptors are abundant in melanoma and the sigma ligands, 128
(submitted)
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rimcazole and haloperidol, showed superior activity towards melanoma cells in culture 
[19,26], the effect of rimcazole on the in vivo growth of a melanoma xenograft was never 
documented. Furthermore, while sigma ligands are currently being tested in clinical trials 
for cancer treatment, there is lack of a non-invasive technique, like positron emission 
tomography (PET), for monitoring of in vivo responses during sigma receptor targeted 
anti-cancer therapy. 
  18F-FDG  may  be  a  suitable  PET  probe  for  this  purpose,  for  the  following 
reasons:
  1.  18F-FDG, the most commonly used tracer in oncology, monitors the cellular metabolic 
rate of glucose, which is an indirect reflection of tumor growth. 18F-FDG uptake is 
mainly  determined  by  the  activity  of  glucose  transporters  (GLUTs)  and  the  first 
enzyme of the glycolytic pathway, hexokinase (HK). Overexpression and increased 
activity  of  GLUTs  and  HK  isozymes  is  a  characteristic  feature  of  rapidly  dividing 
cancer cells.
In cancer cells grown  2.  in vitro, 18F-FDG uptake shows strong changes which reflect 
sigma  ligand-induced  cancer  cell  death.  We  noticed  an  increased  rather  than  a 
decreased uptake 24h after treatment. Such a response is known in the literature 
as a “metabolic flare” and is frequently observed in tumors after hormonal drug 
administration. 
  In the current study we assessed the in vivo activity of rimcazole against human 
A375M melanoma subcutaneously xenografted in athymic nude mice, using 18F-FDG and 
microPET (FDG-PET). Tumor growth was monitored with calipers and FDG-PET scans were 
made on d0, d7 and d14 of rimcazole treatment to test whether the treatment-induced 
changes in tumor growth are accompanied by changes in glucose metabolism.
 
Material & Methods
Culture Media and Drugs
  DMEM  (high-glucose)  medium  was  purchased  from  Sigma.  Fetal  calf  serum 
(FCS) was obtained from Bodinco (Alkmaar, The Netherlands), trypsin was a product of 
Invitrogen (Breda, The Netherlands), and matrigel was from Becton Dickinson (Breda, 
The Netherlands). Water-soluble form of rimcazole (BW234U; 9-[3-(cis-3,5-Dimethyl-1-
piperazinyl)propyl]-9H-carbazole dihydrochloride) was purchased from Tocris Bioscience 
(Bristol, United Kingdom), diluted accordingly to ~ 4,7 mg/ml stock, aliquoted and frozen 
at -20˚C. Isoflurane was from Pharmachemie BV (Haarlem, The Netherlands). Anti-Ki-67 
antibody (ab9260) was from Chemicon/Milipore (Amsterdam, The Netherlands). Antibody 
for human sigma-1 receptor (OPRS1, polyclonal, ab89655) was from Abcam (Cambridge, 129
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UK). Secondary antibodies goat-anti-rabbit-peroxidase (GaRPO, P0448) and rabbit-anti-
goat-peroxidase (RaGPO, P0160) were from Dako (Glostrup, Denmark).
Radiopharmaceuticals
  Synthesis  and  quality  control  of  18F-FDG  were  performed  according  to  the 
standard procedures reported in the literature. 18F-FDG was prepared by an automated 
synthesis module, using the Hamacher method [28]. The specific radioactivity was always 
more  than  10  (usually  between  50  and  100)  TBq/mmol.  18F-FDG  was  sterile  and  its 
radiochemical purities were always greater than 95%.
Cell Culture
  The malignant human melanoma cell line A375M was purchased from the American 
Type Culture Collection (ATCC). A375M cells were cultured as monolayers in DMEM (high-
glucose) supplemented with 10% FCS at 37°C and incubated in a humidified atmosphere 
(5% CO2 in air). Cells were passaged 1:10 twice a week. For in vivo experiments, cells in 
exponential phase of growth were used. The A375 cell line, which is parental to A375M, 
was previously characterized for high sigma receptor content (sigma-1: Bmax = 34 fmol/
mg protein, sigma-2: Bmax = 3403 fmol/mg protein [29]).
Animal Model
  A375M tumor xenografts were established in athymic nude-nu mice (Hsd:Athymic 
Nude-Fox1nu; Harlan, The Netherlands, aged 6 weeks) by s.c. injection of 2 × 106 cells 
in 100 µl matrigel into the right shoulder of the animal. Animals were randomly assigned 
to treatment groups. In treated mice (n = 5), rimcazole (26 mg/kg of body weight,   
in ~ 150 µl water) was administered by daily i.p. injection from day 14 after tumor 
inoculation (when tumor size reached 0.041 ± 0.006 cm3) and was continued for the 
remaining 14 days (Fig. 1A). Control mice (n = 5) received i.p. water injections. Animal 
welfare, behavior and body weight were checked at daily intervals. At the same time, 
tumor  size  measurements  were  performed  using  digital  calipers  and  tumor  size  was 
calculated  using  the  formula  V  =  0.5234  x  [H]  x  [L]  x  [W],  where  H,  L  and  W  are 
respectively height, length and width. On d14 of treatment, mice were sacrificed, and 
tumors were excised and weighed. Experiments were performed by licensed investigators 
in compliance with the Law on Animal Experiments in The Netherlands. The protocol was 
approved by the Committee on Animal Ethics of the University of Groningen. Mice were 
maintained in IVC cages (2 mice per cage) under a regime of 12 h of light and 12 h of 
dark cycle and were fed standard laboratory chow ad libitum.130
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MicroPET Study
  All  mice  were  scanned  three  times  with  18F-FDG:  scan  1,  baseline  on 
d0; scan 2, treatment evaluation on d7; and scan 3, follow-up on d14 of treatment 
(Fig.  1A).  Before  each  scan,  mice  were  anesthetized  with  isoflurane  (induction  3%, 
maintenance  1.5%),  thereafter,  animal  weight  and  blood  glucose  levels  (One-Touch 
Ultra2  Blood  Glucose  Meter;  LifeScan  Inc.;  CA,  USA)  were  determined.  18F-FDG   
(8.74 ± 0.69 MBq, pH 6.6-7.0, volume < 0.1 ml) was injected through the penile vein. 
The camera (microPET Focus 220; CTI Siemens, Munich, Germany) was started 8 minutes 
after tracer injection. Two animals were scanned simultaneously in each scan session. 
Heating mats were used to maintain body temperature of the mice at 37˚C. A list-mode 
protocol was used (44 minutes acquisition time, whole body scan). Reconstructions were 
performed using microPET Manager 2.3.3.6. List-mode data were processed by a static 
reconstruction (94 slices with a slice thickness of 0.796 mm, and an in-plane image matrix   
of  128  x  128  pixels  of  size  0.47  x  0.47  mm3).  Emission  sinograms  were  iteratively 
reconstructed (OSEM2D) after being normalized, corrected for attenuation, and corrected 
for decay of radioactivity. A separate transmission scan (515 sec) with a Co-57 point 
source was acquired for attenuation correction of 511 keV photons by tissue.  
18F-FDG Uptake Analysis
  After  image  reconstruction,  Inveon  Research  Workplace  software  (Siemens, 
USA) was used to manually draw 3D regions of interest (ROIs) around the tumor. Necrotic 
areas of tumors, identified by histopathologic evaluation of hematoxylin and eosin-stained 
tissue section, were included in the ROI. The data is presented as the mean uptake   
in Bq/cc normalized to a blood glucose level of 7.8 mmol/L, body weight of 27 g and 
injected dose of 10 MBq, assuming a tissue density of 1 g/cm3.
Ex vivo Biodistribution
  Following  scan  3,  animals  were  terminated  via  cervical  dislocation  under 
anesthesia and a biodistribution study was performed (Fig. 1A). Blood was collected, and 
plasma and a cell fraction were obtained from the blood sample by short centrifugation 
(5 min at 1,000 x g). Several tissues (see Table 1) were excised and stored on ice. 
Radioactivity in tissue samples and in infusate was measured using a gamma counter 
(CompuGamma  CS  1282,  LKB-Wallac,  Turku,  Finland),  applying  a  decay  correction.   
All samples were weighed. The results were expressed as dimensionless standardized 
uptake values (SUVs) normalized to a blood glucose level of 7.8 mmol/L. The parameter 
SUV is defined as: [tissue activity concentration (MBq/g) * body weight (g) / injected 
dose (MBq)]. Tissue-to-plasma and tumor-to-muscle concentration ratios of radioactivity 
were also calculated.131
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Histology and Immunohistochemistry
  Liver samples were formalin-fixed for 24 h, embedded in paraffin, cut into 4 µm 
sections and stained with hematoxylin-eosin. Liver histopathology (hepatic tissue injury 
and inflammation) was evaluated by an independent researcher who was blinded to all 
data (Dr. Arjan Diepstra, Department of Pathology, University Medical Center Groningen, 
The Netherlands). 
  Tumor samples were rapidly frozen and stored at -80˚C until further analyses. 
For staining, tumors were cut into 5.5 µm sections and fixed in acetone. A two-step 
immunoperoxidase  technique  was  used.  Sections  were  stained  with  selected  primary 
antibodies (dilution 1:50, 45’, RT). Subsequently, endogenous peroxidase was blocked 
with H2O2, followed by staining with the secondary antibody (GaRPO, dilution 1:100, 30’, 
RT) and the tertiary antibody (RaGPO, dilution 1:100, 30’, RT). The reaction was developed 
using brown/red 3-Amino-9-Ethyl-Carbazole/H2O2. Sections were counterstained using 
Mayer’s  Hematoxylin  Solution  (Merck,  Darmstadt,  Germany).  A  negative  control  was 
obtained by omission of the primary antibody.
Statistics
  All results are expressed as mean ± SEM. Differences between groups were 
examined  both  by  two-tailed  unpaired  t-test  and  1-way  ANOVA,  followed  by  a  post 
hoc Tukey’s Multiple Comparison Test, if applicable. A P value < 0.05 was considered 
statistically significant.
Results
Sigma-1 receptors in established A375M xenografts
  All A375M melanoma xenografts maintained sigma-1 receptor expression after 
4 weeks of growth in athymic nude mice (Fig. 1B). Sigma-1 receptor staining was found 
generally in cytoplasmic compartment, but occasionally also a ring around the nucleus 
(possibly part of endoplasmic reticulum or nuclear membrane) was stained. Furthermore, 
we  detected  a  comparable  staining  in  control  tumors  and  rimcazole-treated  tumors 
suggesting that expression of sigma-1 receptors is preserved after two weeks of rimcazole 
treatment. Sigma-2 receptor expression was not evaluated because no antibodies exist 
for staining sigma-2 receptors.
   
Effects of rimcazole treatment on tumor growth
  In all studied mice, A375M tumor formed palpable masses 11-12 days after 
inoculation. Treatment of the control group (n = 5) and rimcazole group (n = 5) started 
on day 14 after inoculation, when the tumor reached a size of 0.041 ± 0.006 cm3. Tumor 
size at the beginning of treatment was not significantly different between control and 132
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rimcazole-treated group. The tumor growth curve obtained from caliper measurements 
indicated that rimcazole rapidly inhibited tumor growth (Fig. 2A). The significant reduction 
in tumor growth was observed already at the 4th day of treatment and onwards. On the 
last day of rimcazole treatment tumor volume from caliper measurements in rimcazole-
treated group was 4.8-fold (79%) smaller than in control group (P < 0.0001). These 
volumes corresponded well with tumor weight determined on the last day of treatment, 
which showed a > 4.4-fold (77%) reduction (from 0.436 ± 0.117 cm3 to 0.100 ± 0.026 
cm3, P < 0.03). Since sigma ligands have both tumoricidal and anti-proliferative activity, 
we used a proliferation marker, Ki-67, to check whether reduced tumor size by rimcazole 
is due to a growth inhibitory effect of this drug. Tumor samples derived from all rimcazole-
treated mice showed a decrease in nuclear expression of Ki-67 in comparison to control 
tumor slices (Fig. 2B).  
Adverse-effects of rimcazole treatment
  Aside from strongly retarded tumor growth, mice treated with 26 mg/kg rimcazole 
did not show any changes in behavior and appearance. However, one mouse from the 
rimcazole-treated group contracted diarrhea of unknown origin on day 6/7 of treatment, 
which persisted until the end of the experiment. None of the rimcazole-treated mice 
experienced treatment-related death. The body weight of both vehicle- and rimcazole-
Fig.1. Experimental design: A) study plan; B) sigma-1 receptors are present in human A375M 
melanoma grown for 4 weeks in athymic nude mice and sigma-1 receptor levels appear to be preserved 
after 14 days of rimcazole treatment.133
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treated group remained constant during the period of treatment (Fig. 3A). Blood glucose 
levels  in  the  control  group  (8.26  ±  0.24  mmol/L)  and  the  rimcazole-treated  group   
(7.83 ± 1.46 mmol/L) were not significantly different. 
  One of the organs with the highest sigma receptor expression is liver. If the 
amount of sigma receptors determines the cytotoxic effect of sigma ligands, liver could be 
especially susceptible to treatment-induced side-effects. Examination of the H&E-stained 
liver sections from the control and rimcazole-treated group revealed no obvious hepatic 
injury or inflammation, although a slight increase in hepatocyte mitosis was noticed in   
the rimcazole-treated group (Fig. 3B).
Effects of rimcazole treatment on tumor 18F-FDG uptake 
a) MicroPET scans
  18F-FDG  visualized  all  A375M  tumors.  The  tracer  showed  a  heterogeneous 
distribution in tumors, with low uptake in the necrotic regions. Necrotic center in the 
tumor was visible in PET images in 3 out of 5 control animals and in 1 out of 5 rimcazole-
treated  mice.  Generally  necrosis  was  found  in  A375M  tumors  bigger  than  250  mm3. 
The fraction of necrosis in tumors appeared to be related to tumor volume but was not 
proportional to changes of 18F-FDG-SUV (data not shown). Tumor volumes from manually 
Fig.2.  Rimcazole-induced  growth  inhibition  of  human  A375M  melanoma:  A)  tumor  size 
determined by caliper measurements in the control (n = 5, solid line) and rimcazole-treated (n = 5, 
dashed line) groups; B) decrease of Ki-67 expression in A375M melanoma determined by IHC staining 
after 14 days of rimcazole treatment. Asterisk indicates significant difference, P < 0.0001134
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drawn 3D ROIs corresponded to the volumes estimated from tumor weight or, in case 
of scan 1 and scan 2, caliper measurements. However, in one control animal tumor size 
was underestimated by caliper measurements because the tumor had grown into the 
underlying muscle tissue.
  On d7 (scan 2) of treatment, 18F-FDG uptake corrected for blood glucose levels 
showed an increase in 3 animals and a decrease in 2 animals from the rimcazole–treated 
group, whereas it was unchanged in 1 animal and decreased in 4 animals from the control 
group, all with respect to 18F-FDG uptake in scan 1 (before treatment). These increases or 
decreases were not related to changes in tumor volume. One of the two animals from the 
rimcazole-treated group showing a decrease of 18F-FDG uptake on day 7 was the mouse 
with diarrhea. When mean 18F-FDG uptake in control and rimcazole-treated groups on day 
7 and day 1 were compared, no statistically significant differences were noted. However, 
the ratio of mean 18F-FDG uptake in rimcazole-treated to control animals was significantly 
(2-fold) increased on d7 of treatment (from 0.68 ± 0.08 in scan 1 to 1.36 ± 0.19 in 
scan 2, P < 0.02) (Fig. 4B). The mean tumor uptake of 18F-FDG can be underestimated 
when the necrotic center, especially of a larger extent, is included in the analysis. On 
the contrary, the max uptake of 18F-FDG is not sensitive to inclusion or exclusion of the 
Fig.3. Lack of adverse effects after rimcazole treatment: A) body weights in the control (solid 
line)  and  rimcazole-treated  (dashed  line)  groups  were  not  significantly  different;  B)  no  hepatic 
injury or inflammation were detected by H&E staining of formalin-fixed liver sections after 14 days   
of rimcazole treatment135
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necrotic center from the analysis. Comparison of the max 18F-FDG uptake in control and 
rimcazole-treated groups gave similar results as comparison of the mean 18F-FDG uptake 
(data not shown). However, the increase in ratio of max 18F-FDG uptake in rimcazole-
treated to control animals on d7 of treatment was still significant (1.7-fold, P = 0.045).
Fig.4.  18F-FDG  uptake  at  different  time  points  after  rimcazole  treatment:  A)  transverse   
18F-FDG microPET images of a single control (upper row) and rimcazole-treated mouse (lower row).   
The position of the tumor is indicated by an arrow. B) a rimcazole-induced “metabolic flare” is manifested 
by a temporary increase of 18F-FDG uptake in the tumor at day 7 of treatment; C) 18F-FDG uptake 
calculated from manually drawn regions of interest in microPET images corresponds rather closely 
to  18F-FDG uptake measured in a biodistribution study. Asterisks indicate a significant difference,   
P < 0.05.136
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  On d14 (scan 3), 18F-FDG uptake corrected for blood glucose levels showed a 
decrease in 4 animals and a small increase in 1 animal from the rimcazole–treated group, 
whereas in the control group a decrease was noted in 4 animals and no change was seen 
in 1 animal (the same as in scan 2), all with respect to 18F-FDG uptake in scan 1. The 
decrease in  18F-FDG uptake was statistically significant in the control group but not in 
the rimcazole-treated group. The ratio of mean 18F-FDG uptake in rimcazole-treated to 
control animals at scan 3 was not changed compared to the ratio at scan 1 (Fig. 4B). 
  Tumor SUV values obtained from a PET scan and tumor SUV values obtained 
from  the  later  biodistribution  study  were  closely  correlated  (P  <  0.002,  R2  =  0.72)   
(Fig. 4C).
b) Biodistribution
  The biodistribution study which was performed on day 14 indicated that rimcazole 
treatment had little impact on  18F-FDG uptake in most tissues (Table 1). A small but 
significant increase of SUV was observed in liver and pancreas (P < 0.02 and P < 0.01, 
respectively) after correction for blood glucose level, and a small but not statistically 
significant decrease in SUV and tissue-to-plasma ratio was observed in muscle. Rimcazole 
treatment  tended  to  increase  the  tumor-to-muscle  uptake  ratio  of  18F-FDG  (from   137
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3.18 ± 0.79 to 5.50 ± 0.79, P = 0.07), as a consequence of the slightly decreased SUV 
in muscle after treatment.
 
Discussion
  In the present study, we assessed whether treatment-resistant human A375M 
melanoma  cells  subcutaneously  xenografted  in  athymic  nude  mice  are  sensitive  to 
rimcazole treatment. In addition, we investigated the in vivo changes of 18F-FDG uptake 
in tumor and non-tumor tissue at different time points of rimcazole treatment.
Anti-melanoma effects
  We observed that rimcazole (at 26 mg/kg) causes a 4.4- to 4.8-fold reduction 
of  human  A375M  melanoma  tumor  growth  compared  to  control  by  the  end  of  the   
(14 day) treatment (Fig. 2). This marked reduction of tumor size was, at least in part, 
due to a growth inhibitory effect of rimcazole as indicated by decreased staining of the 
proliferation marker Ki-67 in rimcazole-treated A375M tumors in comparison to vehicle-
treated control tumors (Fig. 2). A similar rimcazole effect has been observed in three 
mammary carcinomas (MDA-MB 468, MDA-MB 435, MCF-7), one lung cancer (HT1299) 
and one prostate cancer (PC3M) xenograft [14]. Similar inhibition of tumor growth as 
we observed in A375M tumors was seen in MCF-7 carcinomas (3-fold reduction of tumor 
growth after 14 days of treatment), whereas a stronger tumoricidal effect was noted   
in a H1299 cancer (> 10-fold reduction). However, the concentration of rimcazole used   
in these studies was higher (40 mg/kg) than the concentration used by us (26 mg/kg). 
  We noticed that A375M melanoma maintains its expression of sigma-1 receptors 
after being xenografted into athymic nude mice (Fig. 1B). No changes of sigma-1 receptor 
staining were seen between tumors treated with water and tumors treated with rimcazole. 
Sigma-2 receptor changes were not examined. Earlier communications have shown that 
repeated haloperidol treatment decreases sigma-1 receptor but not sigma-2 receptor 
binding without affecting sigma-1 receptor mRNA levels in guinea pig brain [30]. Previous 
data from our institution have shown that sigma-1 receptor binding and sigma-1 receptor 
densities are reduced (both by 26-27 %) within 1 or 2 days after in vivo treatment of rat 
gliomas with doxorubicin [31]. The observation that sigma receptor binding is maintained 
or only slightly decreased in melanomas during in vivo treatment with sigma ligands may 
have important implications for using such drugs in melanoma patients. In other words, 
the molecular target for sigma receptor ligand treatment is preserved and melanoma cells 
probably did not develop resistance within these treatment period.138
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Absence of adverse-effects
  During our daily monitoring of animal welfare no apparent adverse effects were 
noted in mice treated for 14 days with rimcazole (Fig. 3). This is consistent with the low 
toxicity of sigma ligands towards non-tumor tissue in concentrations toxic for cancer cells 
[14,29]. The only documented exception is lens epithelial cells, where sigma-1 receptor 
antagonists cause growth inhibition and pigment formation [22]. Rimcazole is known to 
be rapidly accumulated in tissues, particularly liver [14,32]. In a previous study it was 
reported that peak concentrations of the drug in the liver were 20 to 30 times higher and 
peak concentrations in tumors were 20 to 100 times higher than those in plasma [14]. 
Yet, we detected no signs of fibrosis or steatosis after histological examination of liver 
slices and we observed no loss of hepatic tissue but rather a slightly increased population 
of dividing hepatocytes after 14 days of rimcazole treatment. Thus, a rimcazole dose 
which strongly inhibited tumor growth did not result in any liver damage.  
18F-FDG uptake in melanomas
  Based on the documented effect of blood glucose levels on 18F-FDG uptake, we 
used a glucose normalization procedure to compare 18F-FDG data of individual animals 
and scans performed on different days. 
  We observed an increase of  18F-FDG uptake (metabolic flare) in 60% of the 
rimcazole-treated animals and none of the control animals after 7 days of treatment   
(see  the  PET  images  presented  in  Fig.  4A).  The  magnitude  of  the  increase  in  the 
rimcazole-treated group was variable, perhaps because scan 2 was always made after 
7 days whereas the timing of the flare may be different in different animals. We did 
not observe any correlation between the magnitude of the rimcazole-induced increase   
of 18F-FDG uptake and rimcazole-induced inhibition of tumor growth (data not shown).   
It  may  be  necessary  to  perform  18F-FDG  scans  earlier  after  rimcazole  treatment   
(e.g., after 1 or 2 rather than 7 days) to predict later reduction of tumor growth from the 
size of the metabolic flare. 
  Because of a large inter-individual variability in 18F-FDG uptake, the mean SUV 
of  18F-FDG in the control and rimcazole-treated groups was not significantly different. 
The  effect  of  drug  treatment  on  tumor  metabolism  is  better  visible  when  ratios  of   
18F-FDG uptake in treated and untreated animals are compared at different time points   
(Fig. 4B). After 7 days of treatment, this ratio was significantly increased when compared 
to the ratio before treatment. After 14 days, the ratio had returned to the pretreatment 
level (Fig. 4B). In an in vitro study from our institution, we observed a marked increase 
in the 18F-FDG uptake of glioma cells after 24 h of sigma ligand (haloperidol, rimcazole, 
(+)-pentazocine) treatment [27]. Apparently, rimcazole increases 18F-FDG uptake in the 
early stage of treatment both in vivo and in vitro, although the mechanisms underlying 139
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increased glucose consumption should still be examined. 
  A  “metabolic  flare”  of  18F-FDG  frequently  occurs  in  tumors  during  hormonal 
therapy or radiotherapy and was proposed to be an indicator of hormone responsiveness 
in  breast  cancer  [33,34].  This  effect  has  been  explained  by  the  assumption  that 
inflammatory processes occur or that the therapeutic drugs are partial agonists. Since 
the athymic mice which we used do not have functional T-lymphocytes, it is unlikely that 
the rimcazole-induced flare was due to an inflammatory process. Since rimcazole binds to 
both subtypes of sigma receptors, it may activate several downstream signaling cascades 
and act in some as a partial agonist. In cultured A375M cells, we previously observed   
a  marked  decrease  of  cellular  ATP  after  24  h  treatment  with  rimcazole  (unpublished 
results). Other groups have also reported decreases of ATP levels in neuroblastoma and 
melanoma cell lines treated with sigma ligands [17,20]. Tumor cells depleted of ATP may 
try to restore their initial energy levels by increasing the expression of GLUTs and/or 
glucose metabolism enzymes, like HK, which will result in increased uptake of 18F-FDG.
18F-FDG uptake in peripheral organs
  Our biodistribution data indicate increased SUV but not tissue/plasma ratios of 
18F-FDG in liver and pancreas after treatment with rimcazole (Table 1). Uptake of 18F-FDG 
in muscle and red blood cells (RBC) tended to decrease but this trend was not statistically 
significant. 
  Hepatocytes have high and pancreatic exocrine glandular and skeletal muscle 
cells have moderate sigma-1 receptor expression (www.proteinatlas.com). High affinity 
binding sites for the selective sigma-1 receptor ligand, (+)-pentazocine, are present in 
outer mitochondrial membranes of rat liver [35]. These binding sites have been called 
“sigma-1  like  receptors”,  because  they  are  pharmacologically  distinct  from  sigma-1 
receptors in the brain and show a higher affinity to typical sigma-1 ligands. 
  The  first  possible  explanation  for  increased  glucose  uptake  in  the  liver  is  a 
slightly  increased  mitotic  division  and,  therefore,  increased  energy  requirements  of 
hepatocytes (see above). Another possible mechanism is a stimulating effect of rimcazole   
on glycogenesis. Increased levels of blood glucose activate glycogen production in the 
liver. We did not observe any changes in blood glucose levels during rimcazole treatment, 
but blood glucose was measured just before each microPET scan and at least 16 h after the 
last rimcazole administration. If rimcazole causes a transient increase of blood glucose, 
our measurements would fail to detect this response. Such increases of plasma glucose 
have been reported in humans after treatment with the sigma ligand, haloperidol [36]. 
Two other sigma ligands, (+)-3-PPP ((+)-3-(3-Hydroxyphenyl)-N-(1-propyl)-piperidine) 
and DTG (1,3-di-o-tolylguanidine), have been shown to affect insulin secretory responses 
in rat islets of Langerhans in an imidazoline-independent but glucose-dependent manner. 140
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Insulin increases the uptake of glucose from the blood by liver and muscle (for production 
of glycogen) and by adipose tissue (for the production of fat). A third explanation for 
increased  glucose  uptake  may  thus  be  activation  of  hepatic  glycogenesis  by  insulin. 
Increased glucose uptake in the pancreas could be related to increased energy demand 
of this organ for insulin production. 
Conclusion
  Rimcazole strongly inhibited the growth of A375M melanoma in vivo. A transient 
increase of 18F-FDG uptake was seen on day 7 in most rimcazole-treated tumors but not 
in control tumors. This early increase may be related to tumor response and later growth 
inhibition. Pilot studies in melanoma patients may be facilitated by the fact that some 
sigma ligands (e.g., haloperidol) have already been registered for human use. In these 
studies, FDG-PET imaging may be applied for predicting early responses to sigma ligand 
treatment and the possibility of a metabolic flare should be considered.
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Abstract
Advanced melanoma is characterized by a pronounced resistance to therapy leading to a 
limited patient survival of ~6 - 9 months. Here, we report on a novel bifunctional therapeutic 
fusion protein, designated anti-MCSP:TRAIL, that is comprised of a melanoma-associated 
chondroitin sulfate proteoglycan (MCSP)-specific antibody fragment (scFv) fused to soluble 
human TRAIL. MCSP is a well-established target for melanoma immunotherapy and has 
recently been shown to provide important tumorigenic signals to melanoma cells. TRAIL 
is a highly promising tumoricidal cytokine with no or minimal toxicity towards normal 
cells. Anti-MCSP:TRAIL was designed to 1. selectively accrete at the cell surface of MCSP-
positive melanoma cells and inhibit MCSP tumorigenic signaling and 2. activate apoptotic 
TRAIL-signaling. Results: Treatment of a panel of MCSP-positive melanoma cell lines 
with anti-MCSP:TRAIL induced TRAIL-mediated apoptotic cell death within 16 h. Of note, 
treatment with anti-MCSP:TRAIL was also characterized by a rapid dephosphorylation of 
key proteins, such as FAK, implicated in MCSP-mediated malignant behavior. Importantly, 
anti-MCSP:TRAIL treatment already inhibited anchorage-independent growth by 50% at 
low picomolar concentrations, whereas > 100 fold higher concentrations of non-targeted 
TRAIL failed to reduce colony formation. Daily i.v. treatment with a low dose of anti-
MCSP:TRAIL  (0.14  mg/kg)  resulted  in  a  significant  growth  retardation  of  established 
A375M xenografts. Anti-MCSP:TRAIL activity was further synergized by co-treatment with 
rimcazole, a sigma ligand currently in clinical trials for the treatment of various cancers. 
Conclusions:  Anti-MCSP:TRAIL  has  promising  pre-clinical  anti-melanoma  activity  that 
appears to result from combined inhibition of tumorigenic MCSP-signaling and concordant 
activation of TRAIL-apoptotic signaling. Anti-MCSP:TRAIL alone, or in combination with 
rimcazole, may be of potential value for the treatment of malignant melanoma.
Keywords:  melanoma,  fusion  protein,  melanoma-associated  chondroitin  sulfate 
proteoglycan,  tumor  necrosis  factor-related  apoptosis  inducing  ligand,  synergy, 
rimcazole
  
Introduction
  Patients  diagnosed  with  localized  melanoma  have  a  10-year  survival  rate  of 
up to 95%. In contrast, the life expectancy of patients with metastasized melanoma is 
limited to only 6 - 9 months [1]. The poor survival of patients with advanced melanoma 
is largely attributable to resistance towards current treatment modalities such as chemo- 
and radiotherapy [2]. Therefore, the development of novel therapeutic approaches that 
can trigger melanoma-selective cell death appears warranted.
  One target molecule of potential relevance for the tumorigenicity of melanoma 
is the melanoma chondroitin sulfate proteoglycan (MCSP), also known as high molecular 
weight melanoma associated antigen (HMW-MAA). MCSP is highly expressed on the cell 
surface of both benign dysplastic nevi and on over 85% of malignant melanomas [3]. 147
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Importantly,  over-expression  of  MCSP  correlates  with  an  unfavorable  prognosis  [4]. 
Expression of MCSP on normal tissue is mainly restricted to cells of the melanocyte lineage, 
but has also been detected in basal cells of the epidermis and within the hair follicle, in 
pericytes, chondrocytes and smooth muscle cells [3]. Recent studies have revealed that 
MCSP expression may provide important tumorigenic signals to melanoma cells. MCSP 
signaling stimulates growth, motility, and tissue invasion by melanoma cells, e.g. by 
enhancing integrin function [5], activation of Focal Adhesion Kinase (FAK) [6], mitogenic 
ERK signaling [7] and matrix metalloproteinase 2 [8]. Furthermore, non-metastatic radial 
growth tumor cells acquired anchorage-independent growth characteristics upon ectopic 
expression of MCSP [6]. Of note, anti-MCSP antibody treatment can partly inhibit MCSP-
tumorigenic signaling in vitro, as evidenced by a pronounced inhibition of FAK [6].
  Thus, MCSP appears to be important for melanoma tumorigenicity and appears to 
be a promising target for both naked monoclonal antibody (mAb) as well as immunotoxin-
based strategies [9,10]. Notably, anti-MCSP mAbs proved to have beneficial effects on 
the clinical course of the disease of melanoma patients [3,11].
  In recent years, we have demonstrated that scFv antibody fragment-targeted 
delivery  of  the  immuno  cytokine  TRAIL  holds  particular  promise  for  tumor-selective 
induction of apoptosis in various cancer types. TRAIL (Tumor Necrosis Factor Related 
Apoptosis Inducing Ligand) is a highly promising anti-cancer agent with pronounced pro-
apoptotic activity towards various malignant cell types, including melanoma. Importantly, 
TRAIL essentially lacks activity towards normal cells [12]. Based on these characteristics, 
recombinant soluble TRAIL (sTRAIL) preparations have recently entered clinical trials, 
with promising preliminary reports on anti-tumor activity and safety [13].
  Antibody fragment-mediated targeting of TRAIL can further selectively enhance 
the anti-tumor activity of TRAIL towards various types of cancer, including carcinomas and 
Acute Myeloid Leukemia [12,14-20]. Briefly, genetic fusion of TRAIL to a scFv antibody 
fragment allows for the selective delivery of TRAIL to a pre-selected tumor-associated 
antigen at the tumor cell surface. The resulting high levels of tumor cell surface bound 
TRAIL  then  efficiently  activate  apoptotic  signaling  via  the  agonistic  TRAIL-receptors 
TRAIL-R1 and TRAIL-R2 in a mono- and/or bi/multicellular manner [14-18,20]. Of note, 
non-targeted sTRAIL has no intrinsic tumor-selective binding activity and is less efficient 
in cross-linking and activating TRAIL-R2 [21].
  Here we preclinically evaluated the anti-melanoma activity of MCSP-targeted 
delivery of TRAIL, using fusion protein anti-MCSP:TRAIL. Anti-MCSP:TRAIL was designed 
to selectively bind to MCSP at the cell surface of melanoma cells and simultaneously 
inhibit tumorigenic signaling by MCSP. Once bound to MCSP-expressing melanoma cells, 
the anti-MCSP:TRAIL fusion protein can activate apoptotic TRAIL-signaling. Since TRAIL 
resistance has been reported for melanoma [22] we further evaluated a combinatorial 148
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strategy in which anti-MCSP:TRAIL treatment was combined with rimcazole. Rimcazole 
is a sigma receptor ligand currently in clinical trials for various cancers that has shown 
potent single-agent anti-tumor activity towards glioma and breast cancer [23,24]. Sigma 
ligand-based therapy may also be of value for the treatment of melanoma since the two 
subtypes  of  sigma  receptors,  sigma-1  receptors  and  sigma-2  receptors,  are  strongly 
overexpressed in this tumor [25,26].
  MCSP targeting with anti-MCSP:TRAIL indeed appeared to inhibit MCSP-signaling 
and activated TRAIL-apoptotic signaling in melanoma cells in vitro and in vivo. Furthermore, 
TRAIL-apoptotic signalling in melanoma cells can be further increased by combinatorial 
treatment with rimcazole. The dual anti-melanoma activity of anti-MCSP:TRAIL alone, or 
in combination with rimcazole, may be of interest for treatment of melanoma.
Materials & Methods
Reagents
  MAb 9.2.27 is a murine IgG2a with high binding affinity for human MCSP [10]. 
TRAIL-neutralizing mAb 2E5 was purchased from Alexis (10P’s, Breda, The Netherlands). 
Caspase inhibitors zVAD-fmk and zLEHD-fmk were from Calbiochem (VWR International 
B.V., Amsterdam, The Netherlands) and dissolved at 10 mM in DMSO. Rimcazole (BW 239U) 
and (+)-pentazocine were from Sigma Aldrich (Sigma-Aldrich Chemie B.V. Zwijndrecht, 
Netherlands). Stock solutions of rimcazole (3.9 mM in ethanol) and (+)-pentazocine (10 
mM in 0.1 N hydrochloric acid) were freshly prepared for each experiment.
Cell lines 
  MCSP-positive/EpCAM-negative melanoma cell lines A375M, A2058 and SK-MEL-
28 were obtained from and characterized (STR profiling, karyotyping, isoenzyme analysis) 
by the American Tissue Culture Collection (ATCC). The MCSP-negative melanoma cell line 
M14 and transfectant cell line M14.MCSP were provided by Prof. Dr. G.H. Fey. Expression 
of MCSP was determined by flow cytometry using anti-MCSP mAb 9.2.27 and a FITC-
conjugated goat-anti-mouse mAb. A375M.FADD-DED cells were generated by transfection 
of parental A375M cells using Fugene (Roche BV, Woerden, The Netherlands). All cell lines 
were cultured at 37°C, in a humidified 5% CO2 atmosphere. A375M, A2058, SK-MEL-
28 and M14 cells were cultured in RPMI 1640 medium (Cambrex Bio Science, Verviers, 
France) supplemented with 10% fetal calf serum. M14.MCSP cells were cultured in RPMI 
1640 medium supplemented with 10% fetal calf serum and 400 μg/ml Geneticin. A375M.
FADD-DED cells were cultured in RPMI 1640 medium supplemented with 10% fetal calf 
serum and 500 μg/ml Geneticin.149
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Primary human hepatocytes (PHH) and melanocytes
  Cryopreserved  human  hepatocytes  and  melanocytes  (Tebu-bio  bv, 
Heerhugowaard,  The  Netherlands)  were  isolated  according  to  standard  protocol 
using hepatocyte isolation kit and melanocyte isolation kit, respectively (tebu-bio bv, 
Heerhugowaard, The Netherlands). For experiments, hepatocytes and melanocytes were 
seeded in a 48-well plate at a density of 0.5 × 106 cells/ml.
Construction of fusion protein anti-MCSP:TRAIL
  A scFv antibody fragment in the VH-VL format was derived from mAb 9.2.27 using 
standard antibody-phage display technology [10]. Fusion protein anti-MCSP:TRAIL was 
constructed by cloning the cDNA of antibody fragment MCSP in frame with soluble TRAIL 
into in-house constructed vector pEE14 using unique SfiI and NotI restriction enzyme sites, 
yielding plasmid pEE14-anti-MCSP:TRAIL. Fusion protein anti-MCSP:TRAIL was produced 
in CHO-K1 cells using previously described methods [14,16]. Culture medium containing 
anti-MCSP:TRAIL was cleared by centrifugation (10 000 x g, 10 min), filter sterilized, and 
stored at -80°C until further use. Fusion protein anti-MCSP:TRAIL was purified via the 
N-terminal Hemagglutinin (HA)-tag using anti-HA affinity chromatography. Fusion protein 
scFvC54:sTRAIL [14], for reasons of clarity hereafter renamed into anti-EpCAM:TRAIL, is 
a fusion protein that is essentially identical to anti-MSCP:TRAIL except that it contains an 
anti-EpCAM scFv instead of an anti-MSCP scFv.
Assessment of apoptosis
  MCSP-restricted induction of apoptosis by anti-MCSP:TRAIL was assessed on a 
panel of melanoma cell lines. Briefly, melanoma cells were pre-cultured in a 48-well plate 
at a concentration of 3 × 104 cells/well. Subsequently, cells were treated as indicated 
and apoptosis was assessed by: Loss of mitochondrial membrane potential (ψ);  ψ was 
analyzed by DiOC6 staining (Eugene, The Netherlands) as previously described [16]. 
After 16 h treatment, cells were harvested and incubated for 20 min with DiOC6 (0.1 μM) 
at 37°C, harvested (1000 x g, 5 min.), resuspended in PBS, and assessed for staining 
by  flow  cytometry.  Caspase-8,  caspase-9  and  caspase-3/-7  activity;  caspase  activity 
was assessed using the Caspase-Glo 8, 9 and 3/7 Assay according to manufacturer’s 
instructions  (Promega  Benelux  BV,  Leiden,  The  Netherlands).  The  assay  is  based  on 
the cleavage of non-luminescent substrates by activated caspases into a luminescent 
product. Luminescence was quantified using a Victor3 multi-label plate reader (Perkin 
Elmer, Groningen, The Netherlands)
Soft agar colony forming assay
  Soft agar colony forming assays were performed in 24-well plates pre-coated 150
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with 0.5 ml solidified 0.4% agarose in RPMI 1640 medium. Cells were resuspended at   
a density of 1 × 104 cells/well in 0.6% agarose in RPMI 1640 medium supplemented with 
20% fetal calf serum and layered on the solidified 0.4% agarose in a 24-well plate. Tumor 
cell containing agarose was allowed to solidify for 10 minutes at 4°C before addition of 
1 ml of RPMI 1640 medium supplemented with 20% fetal calf serum. Cells were treated 
as indicated and subsequently cultured at 37°C, in a humidified 5% CO2 atmosphere. 
Colony formation was assessed 21 days after start of treatment. Assays were performed 
in quadruplicate. Number of colonies was quantified and percentage of colony growth 
was calculated with the formula: Percentage of colony growth = (number of colonies in 
experimental condition)/(number of colonies in medium control) × 100%. For A375M 
cells, the number of colonies in untreated samples ranged from 30 ± 5 to 262 ± 35 
between individual experiments.
Proteome Profiler array
  The effect of MCSP targeting on protein tyrosine kinase activity was assessed 
by the Human Phospho-Kinase Array Kit (R&D Systems) according to the manufacturer’s 
recommendations. Briefly, per condition 1 × 107 cells were treated for 0, 30, 60, or 240 
min. at 37°C as indicated. Lysate (500 μg/condition) was added to the NC-membranes 
containing  spotted  Phospho-Kinase  (PK)  antibodies.  Subsequently,  secondary  Biotin-
conjugated anti-Kinase antibodies and Horseradish Peroxidase-conjugated Streptavidin 
were added to detect the presence of phosphorylated kinases. Between incubation steps, 
membranes  were rigorously washed. Blots were developed by standard  chemoluminescence 
(Roche). Luminescent signals were quantified using the IVIS Spectrum bioluminescent 
imager  (Caliper  Biosciences)  as  photons/sec/sr/cm2.  After  background  luminescence 
subtraction,  the  relative  kinase  activity  in  treated  conditions  was  calculated  by  the 
formula: (PK activity experimental condition/PK activity medium control) × 100%.
A375M xenograft mouse model
  Experiments  involving  animals  were  performed  in  accordance  with  the 
experimental  protocol  approved  by  the  Committee  for  Research  and  Animal  Ethics 
of the UMCG. Six week old healthy male athymic mice (n = 8) were purchased from 
Harlan  (Harlan  Netherlands  B.V.,  Horst,  The  Netherlands).  Mice  were  housed  in  IVC 
cages  and  fed  ad  libitum.  Subsequently,  mice  were  subcutaneously  inoculated  with   
2 × 106 A375M cells suspended in 100 μl matrigel. Tumor growth was monitored daily by 
electronic caliper measurements. After reaching tumor size of ~ 50 ± 6 mm3, mice were 
randomly assigned into two groups with a sample size of 4. Mice received daily i.v. saline 
injections or anti-MCSP:TRAIL injections (0.14 mg/kg). After two weeks of treatment, 
mice were sacrificed by cervical dislocation. Tumor size was calculated by the formula:   151
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V = 0,5234 × H × L × W [mm3]. Tumor size was expressed as the percentage of maximum 
tumor size in Sham-treated mice.
Liver histopathology
  Formalin-fixed liver samples were embedded in paraffin, sectioned into 5 μm 
thickness and stained with hematoxylin-eosin and microscopically inspected for hepatic 
tissue damage and inflammation.
Combination treatment with anti-MCSP:TRAIL and σ-ligands
  Cells were plated at 3.0 × 104 cells/well in a 48-well plate and allowed to adhere 
overnight. Cells were concurrently treated for 24 h with anti-MCSP:TRAIL with or without 
rimcazole (15 μM), and (+)-pentazocine (200 nM). Synergy was assessed by calculating the 
cooperativity index (CI) in which the sum of apoptosis induced by single-agent treatment 
is divided by apoptosis induced by combination treatment. When CI was less than 1, 
treatment was considered synergistic; when CI equaled 1, treatment was considered 
additive; when CI was greater than 1, treatment was considered antagonistic.
Statistical analysis
  Data reported are mean values ± standard error of the mean of at least three 
independent experiments. Statistical analysis was performed by one-way ANOVA followed 
by Tukey-Kramer post test or by two-sided unpaired Student’s t-test. P < 0.05 was defined 
as a statistically significant difference.
Results and Discussion
MCSP-restricted induction of apoptosis by anti-MCSP:TRAIL
  We  and  others  have  previously  demonstrated  that  selective  delivery  of  the 
cytokine TRAIL by genetic fusion to an appropriate tumor-selective scFv antibody fragment 
significantly enhances the anti-tumor activity of TRAIL towards the corresponding type 
of cancer [14-20]. Here, we adapted this targeted approach to malignant melanoma by 
exploiting an anti-MCSP scFv antibody fragment that was derived from the well-established 
monoclonal  antibody  (mAb)  9.2.27.  The  resultant  fusion  protein,  anti-MCSP:TRAIL, 
was equipped to selectively accrete at the cell surface of MCSP-positive cells only and 
subsequently trigger TRAIL-mediated apoptosis.
  Indeed, treatment of MCSP-transfected M14 melanoma cells (M14.MCSP) with 
anti-MCSP:TRAIL resulted in dose-dependent activation of apoptosis within 16 h, whereas 
parental  MCSP-negative  M14  cells  were  resistant  to  treatment  with  anti-MCSP:TRAIL   
(Fig. 1A). Similarly, treatment of a series of MCSP-positive cell lines (A375M, A2058 and 152
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Fig.1. MCSP-restricted induction of apoptosis by anti-MCSP:TRAIL: A) M14 and M14.MCSP 
cells were treated with increasing concentrations of anti-MCSP:TRAIL for 16 h and apoptosis was 
assessed by Δψ; B) MCSP-negative cell line M14 and MCSP-positive cell lines M14. MCSP, SK-MEL-28, 
A2058 and A375M were treated with 500 ng/ml anti-MCSP:TRAIL for 16 h and apoptosis was assessed 
by Δψ; C) A375M, A2058 and SK-MEL-28 cells were treated with equimolar concentrations of anti-
MCSP:TRAIL, anti-EpCAM:TRAIL, anti-MCSP mAb or anti-EpCAM:TRAIL + anti-MCSP mAb for 16 h 
and apoptosis was assessed by Δψ; D) A2058 cells were treated with 500 ng/mL anti-MCSP:TRAIL 
in the absence or presence of parental MCSP-blocking mAb 9.2.27, TRAIL-neutralizing mAb 2E5 or 
pan-caspase inhibitor zVAD-fmk for 16 h and apoptosis was assessed by Δψ; E) A375M and A375M.
FADD-DED cells were treated with anti-MCSP:TRAIL or rhTRAIL for 16 h and apoptosis was assessed 
by Δψ; F) A375M cells were incubated with anti-TRAIL-R1 (thin line) or anti-TRAIL-R2 (thick line) mAb 
and expression of TRAIL-R1 and TRAIL-R2 was analyzed by flow cytometry. Shaded area indicates the 
fluorescence signal when cells were incubated with fluorescent-labeled secondary antibody alone.153
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SK-MEL-28) with anti-MCSP:TRAIL resulted in a marked induction of apoptosis (Fig. 1B). 
In a control experiment we treated the same series of melanoma cells with fusion protein 
anti-EpCAM:TRAIL, a fusion protein that is essentially identical to anti-MCSP:TRAIL except 
that it contains an anti-EpCAM scFv instead of an anti-MCSP scFv antibody fragment [14]. 
EpCAM is a well established carcinoma-associated cell surface target antigen that is not 
expressed on melanoma cells. Indeed, no signs of apoptosis were observed when A375M, 
A2058 or SK-MEL-28 cells were treated with anti-EpCAM:TRAIL (Fig. 1C and Fig. 2A).
  Treatment of MCSP-positive A375M, A2058 or SK-MEL-28 cells with the parental 
anti-MCSP  antibody  mAb  9.2.27  failed  to  induce  any  signs  of  apoptosis  (Fig.  1C). 
Importantly, also co-treatment with MAb 9.2.27 and anti-EpCAM:TRAIL did not induce 
any significant signs of apoptosis (Fig. 1C). Thus, treatment of MCSP-positive melanoma 
cells with fusion protein anti-MCSP:TRAIL efficiently activates apoptosis that is MCSP-
restricted and that is superior to combined treatment with TRAIL and the parental anti-
MCSP mAb 9.2.27.
  Induction of apoptosis by anti-MCSP:TRAIL was abrogated when treatment was 
performed in the presence of the parental mAb 9.2.27 (Fig. 1D). Thus, anti-MCSP:TRAIL 
activity is strictly dependent on binding to cell surface-expressed MCSP on malignant cells. 
Furthermore, addition of the TRAIL-neutralizing mAb 2E5 fully abrogated the apoptotic 
effect of anti-MCSP:TRAIL (Fig. 1D), indicating that induction of apoptosis is dependent 
on  interaction  of  TRAIL  with  its  agonistic  TRAIL-receptors.  In  addition,  induction  of 
apoptosis was inhibited when treatment is performed in the presence of pan-caspase-
inhibitor zVAD-fmk (Fig. 1D), further suggesting involvement of TRAIL-mediated apoptotic 
signaling. Indeed, treatment of melanoma cells with anti-MCSP:TRAIL was characterized 
by time-dependent activation of initiator caspase-8 (Fig. 2B) as well as effector caspases 
3 and 7 (Fig. 2C).
  To further confirm that TRAIL-signaling is involved, the mutant cell line A375M.
FADD-DED that ectopically overexpresses a dominant negative mutant of the adaptor 
protein FADD, was produced. FADD is a pivotal adaptor protein in TRAIL-receptor signaling. 
The mutant FADD protein lacks the so-called DED domain, which results in a general and 
strong resistance against TRAIL-mediated apoptosis. Indeed, TRAIL-mediated apoptotic 
signaling was fully halted in A375M.FADD-DED cells, as is evidenced by the fact that these 
cells  were  fully  resistant  to  ubiquitously  active  recombinant  human  TRAIL  (rhTRAIL) 
(Fig. 1E). Likewise, A375M.FADD-DED cells were also fully resistant to treatment with 
anti-MCSP:TRAIL (Fig. 1E). Taken together, these data clearly demonstrate that the pro-
apoptotic activity of anti-MCSP:TRAIL is TRAIL-mediated.
  Previously, we and others have shown that upon binding to the respective target 
antigen, scFv:TRAIL fusion proteins can efficiently activate TRAIL-R2, whereas untargeted 
sTRAIL preparations have a markedly reduced capacity to activate TRAIL-R2 signaling. 154
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Fig.2.  A)  A2058  cells  were  treated  with  increasing  concentrations  of  anti-MCSP:TRAIL  or  anti-
EpCAM:TRAIL  for  16  h  and  apoptosis  was  assessed  by  Δψ;  B)  A375M  cells  were  treated  with   
500 ng/ mL anti-MCSP:TRAIL for the time-points indicated and caspase-8 activation was assessed;   
C) A2058 cells were treated with 500 ng/mL anti-MCSP:TRAIL in the absence or presence of parental 
MCSP-blocking mAb 9.2.27 or TRAIL-neutralizing mAb 2E5 and caspase-3/-7 activation was assessed; 
D) MCSP-restricted binding of anti-MCSP:TRAIL to melanocytes was assessed. Specific binding was 
demonstrated by pre-incubating melanocytes with mAb 9.2.27 followed by incubation with anti-MCSP: 
TRAIL. Binding of anti-MCSP:TRAIL was assessed by flow cytometry using a PE-conjugated anti-TRAIL 
mAb; E) A2058 and A375M cells were treated with increasing concentrations of anti-MCSP:TRAIL for 
16 h and apoptosis was assessed by Δψ.155
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Indeed A375M cells, that solely express TRAIL-R2 at the cell surface (Fig. 1F) are sensitive 
to treatment with anti-MCSP:TRAIL (Fig. 1B, Fig. 2E), indicating that anti-MCSP:TRAIL 
can potently activate TRAIL-R2 signaling in MCSP-positive melanoma cells. This feature 
may be of special relevance for melanoma since TRAIL-R2 is the most prevalent agonistic 
TRAIL-receptor expressed on melanoma cells [27].
Potent inhibition of anchorage-independent growth by anti-MCSP:TRAIL
  The MCSP antibody fragment used in this study was derived from mAb 9.2.27. 
In earlier studies, mAb 9.2.27 partly inhibited MCSP-tumorigenic signaling in vitro, as 
evidenced by inhibition of FAK [9]. Since ectopic expression of MCSP was also recently 
shown  to  induce  anchorage-independent  growth  capacity,  anti-MCSP:TRAIL  was 
evaluated for its effect on anchorage-independent growth of melanoma cells. In a soft 
agar assay, treatment of the MCSP-positive cell lines A375M and A2058 cells with anti-
MCSP:TRAIL abrogated colony outgrowth in a dose-dependent manner (Fig. 3A). Of note, 
anti-MCSP:TRAIL reduced colony formation by 50% already at very low concentrations 
(0.1 ng/ml and 1 ng/ml for A375M and A2058 cells, respectively). Induction of apoptosis 
by anti-MCSP:TRAIL at these concentrations in adherent growth conditions was marginal 
(see Fig. 2E for dose-response curves of apoptosis induction). In contrast, treatment 
with  similar  concentrations  of  anti-EpCAM:TRAIL  or  with  anti-MCSP  mAb  9.2.27  only 
marginally reduced colony formation (Fig. 3B). Importantly, also combinatorial treatment 
with equimolar concentrations of anti-EpCAM:TRAIL and mAb 9.2.27 failed to significantly 
inhibit colony outgrowth of A375M cells at the highest concentrations tested (Fig. 3B). 
Furthermore, rhTRAIL failed to significantly reduce colony outgrowth (Fig. 3C). Thus, 
anti-MCSP:TRAIL uniquely and efficiently prevents colony outgrowth.
  Treatment of A375M cells with anti-MCSP:TRAIL in the presence of the TRAIL-
neutralizing mAb 2E5 largely blocked the effect of anti-MCSP:TRAIL on colony outgrowth 
(Fig.  3D).  Similarly,  treatment  of  cells  with  anti-MCSP:TRAIL  in  the  presence  of  the 
parental anti-MCSP mAb 9.2.27 inhibited anti-MCSP:TRAIL activity, although the number 
of colonies still remained significantly lower than medium control (Fig. 3D). Of note, 
co-incubation  with  pan-caspase  inhibitor  zVAD-fmk  abrogated  the  inhibitory  effect  of 
anti-MCSP:TRAIL on colony outgrowth (Fig. 3D), suggesting that apoptotic signaling is 
required for the inhibitory effect of anti-MCSP:TRAIL.
  To further evaluate whether TRAIL-induced caspase-signaling was required for 
the inhibitory effect of anti-MCSP:TRAIL on colony outgrowth, TRAIL-resistant A375M.
FADD-DED  cells  were  treated  with  anti-MCSP:TRAIL.  Importantly,  colony  formation 
of  A375M.FADD-DED  cells  was  inhibited  by  anti-MCSP:TRAIL  treatment  although   
~50- to 100-fold higher concentrations were required to obtain the same magnitude of 
inhibition as observed for parental A375M cells (Fig. 3E). Of note, treatment of A375M.156
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Fig.3. Inhibition of anchorage-independent growth by anti-MCSP:TRAIL: A) A375M and A2058 
cells were treated with increasing concentrations of anti-MCSP:TRAIL for 21 days and colony formation 
was  assessed;  B)  A375M  cells  were  treated  with  increasing  concentrations  of  anti-MCSP:TRAIL,   
anti-EpCAM:TRAIL, anti-MCSP mAb or anti-EpCAM:TRAIL+anti-MCSP mAb for 21 days and colony 
formation  was  assessed;  C)  A375M  cells  were  treated  with  rhTRAIL,  anti-EpCAM:TRAIL  or  anti-
MCSP:TRAIL  for  21  days  and  colony  formation  was  assessed;  D)  A375M  cells  were  treated  with   
100 ng/ml anti-MCSP:TRAIL in the absence or presence of TRAIL-neutralizing mAb 2E5, parental   
anti-MCSP  mAb  9.2.27  or  pancaspase  inhibitor  zVAD-fmk  for  21  days  and  colony  formation  was 
assessed;  E)  A375M  and  A375M.FADD-DED  cells  were  treated  with  increasing  concentrations  of 
anti-MCSP:TRAIL for 21 days and colony formation was assessed; F) A375M.FADD-DED cells were 
treated  with  increasing  concentrations  of  anti-MCSP:TRAIL,  anti-EpCAM:TRAIL,  anti-MCSP  mAb   
or anti-EpCAM:TRAIL+anti-MCSP mAb for 21 days and colony formation was assessed.157
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FADD-DED cells with anti-EpCAM:TRAIL did not inhibit colony formation (Fig. 3F), nor did 
combination treatment of anti-EpCAM:TRAIL and mAb 9.2.27 (Fig. 3F). In contrast, mAb 
9.2.27 alone did significantly inhibit colony outgrowth in this cell line, although to a lesser 
extent than anti-MCSP:TRAIL (Fig. 3F). Together, these experimental data suggest that 
the simultaneous interaction of anti-MCSP:TRAIL with MCSP and TRAIL-receptors uniquely 
blocks anchorage-independent growth of melanoma cells at low concentrations.
Anti-MCSP:TRAIL dephosphorylates proteins involved in cell proliferation and apoptosis 
resistance
  The efficacy of anti-MCSP:TRAIL on inhibition of colony formation by melanoma 
cells  in  3D-culture  suggests  that  antibody  fragment-dependent  sensitization  of  cells 
to concurrent TRAIL-signaling may contribute to its therapeutic effect. Previously, we 
generated  proof  of  concept  data  for  such  dual  therapeutic  signaling  with  scFv:TRAIL 
fusion  proteins,  using  an  scFv:TRAIL  fusion  protein  that  targeted  the  Epidermal 
Growth Factor Receptor [16,19]. Here, the EGFR-inhibitory antibody fragment blocked 
mitogenic EGFR-signaling and synergized TRAIL apoptotic signaling [16,19]. To assess 
whether the MCSP-specific antibody fragment might contribute to the anti-tumor activity   
of  anti-MCSP:TRAIL,  a  focused  set  of  48  cellular  phosphoproteins  was  examined  for 
the level of phosphorylation after treatment with anti-MCSP:TRAIL (Fig. 4A and 4B),   
anti-MCSP mAb 9.2.27 (Fig. 4C) and rhTRAIL (Fig. 4D). Interestingly, although A375M cells 
were treated with anti-MCSP:TRAIL in adherent growth conditions in view of experimental 
Table 1. Kinases downregulated by anti-MCSP:TRAIL, the percentage of inhibition after 1 h treatment 
with anti-MCSP:TRAIL and their role in oncology158
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Fig.4.  Anti-MCSP:TRAIL  triggers dephosphorylation of cellular proteins.  A375M  cells  were 
treated with anti-MCSP:TRAIL, anti-MCSP mAb 9.2.27, rhTRAIL or left untreated for 1 h. Whole cell 
lysates were analyzed for phosphorylation of 48 cellular kinases: A) Phosphorylation of 28 kinases in 
untreated cells (left panel) or anti-MCSP:TRAIL-treated cells (right panel) are depicted. Images are 
representative of three independent experiments. B-D) Changes in the phosphorylation of 21 kinases 
after treatment with: B) anti-MCSP:TRAIL, C) anti-MCSP mAb 9.2.27 or D) rhTRAIL are expressed as 
a percentage of the phosphorylation measured in untreated cells. E) A375M cells were treated with 
anti-MCSP:TRAIL for 0, 30, 60 or 240 min. Whole cell lysates were analyzed for phosphorylation of 48 
cellular kinases. Changes in phosphorylation of the different kinase groups as indicated in panel B are 
depicted. *, P < 0.05; **, P < 0.001; ***, P < 0.0001.159
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limitations with 3D-cultures, significant dephosphorylation of various proteins involved 
in cell survival and proliferation was detected after 1 h of treatment (Fig. 4A, 4B and 
Table  1).  This  dephosphorylation  induced  by  anti-MCSP:TRAIL  was  detectable  within   
30 minutes and increased for up to 4 h after start of treatment (Fig. 4E). Treatment with 
mAb 9.2.27 and rhTRAIL also triggered dephosphorylation of proteins at 1 h of treatment, 
but to a lesser extent and in a smaller panel (Fig. 4C and 4D, respectively).
  First  and  foremost,  the  previously  reported  down-stream  target  of  MCSP, 
FAK, was dephosphorylated by a factor 2 compared to medium control. The parental 
anti-MCSP mAb 9.2.27 has been shown to prevent association of MCSP with integrins, 
thereby preventing activation of FAK [6]. Thus, although not determined here for anti-
MCSP:TRAIL, a similar inhibition of MCSP/integrin interaction by the mAb 9.2.27-derived 
antibody fragment may be responsible for the inhibitory effect of anti-MCSP:TRAIL on 
FAK. Intriguingly, cross-linking of MCSP by bead-coated mAb 9.2.27 has also been used 
to achieve activation of MCSP-signaling [6]. The different outcome of treatment with 
soluble vs. coated mAb suggests that the extent of cross-linking of MCSP by the antibody 
determines the activation or inhibition, respectively, of downstream signaling. It will be 
interesting to evaluate in future studies whether the three MCSP reading heads in trimeric 
anti-MCSP:TRAIL are perhaps better suited for inhibition of MCSP-signaling.
  The  activity  of  ERK1/2,  another  established  downstream  effector  of  MCSP 
signaling [6], was not affected after 1 h of treatment with anti-MCSP:TRAIL. One possible 
reason for this finding is a perhaps delayed effect of anti-MCSP:TRAIL on ERK1/2 signaling 
at later and not examined time-points. In addition, it has been shown that MCSP enhances 
FAK and Erk1/2 signaling by distinct mechanisms [6]. It is therefore also conceivable that 
FAK is dephosphorylated while Erk1/2 is not a target of inhibition by anti-MCSP:TRAIL.
  In addition to the established MCSP-target FAK, a panel of other proteins was 
dephosphorylated upon anti-MCSP:TRAIL treatment, including the kinase Fyn, and the Src 
kinases Src, Hck, Lyn and Yes. The relative impact of these respective proteins on MCSP 
tumorigenic signaling is currently being evaluated in extended ongoing studies using 
e.g. constitutively active and/or dominant negative mutants as well as small inhibitory 
RNA-mediated silencing of the individual components. Importantly, the above-mentioned 
experiments  need  to  be  performed  not  only  in  2D,  but  also  in  3D-cultures,  in  order 
to reliably determine the relative importance of the here identified proteins for MCSP-
dependent anchorage-independent growth of melanoma cells.
  Perhaps counter intuitively, the proto-oncogene Beta-Catenin (β-Catenin) was 
also  dephosphorylated  by  treatment  with  anti-MCSP:TRAIL,  as  well  as  by  treatment 
with mAb 9.2.27 and rhTRAIL (Fig. 4B, 4C and 4D, respectively). Dephosphorylation of 
β-Catenin does not inactivate β-Catenin but actually prevents proteasomal degradation 
and increases cellular levels of β-Catenin. In turn, this leads to activation of pro-oncogenic 160
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Fig.5.  Anti-tumor  activity  of  anti-MCSP:TRAIL  towards  A375M  xenografts:  A)  mice  were 
inoculated with A375M tumor cells at day 0 and developed xenografts of ~ 50 mm3 after 12 days. 
Starting at day 12, mice were injected daily with saline (n = 4) or anti-MCSP:TRAIL (0.14 mg/kg,   
n = 4) and tumor size was measured daily using electronic caliper measurements; B) tumor size   
at day 23; C) MCSP-positive melanocytes and MCSPnegative leukocytes and hepatocytes were treated 
with 500 ng/ml anti-MCSP:TRAIL for 16 h and apoptosis was assessed by Δψ; D) melanocytes were 
treated with 4 μg/mL anti-MCSP:TRAIL for up to 14 days and apoptosis was assessed by Δψ at time 
points indicated; E-F) liver pathology of mice carrying A375M xenografts was examined for E) Sham-
treated mice and F) anti-MCSP:TRAIL-treated mice.161
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gene transcription [28]. However, the exact role of β-Catenin-induced gene transcription 
in melanoma is still a matter of debate. Based on mouse models with activating mutations 
in β-Catenin, an oncogenic role of β-Catenin in melanoma was proposed [29]. On the other 
hand, others have shown that β-Catenin induces a transcriptional profile in melanoma 
cells that is reminiscent of normal melanocyte differentiation [30]. This transcriptional 
profile is moreover associated with increased patient survival and is lost upon malignant 
progression [30].
  Taken together, anti-MCSP:TRAIL dephosphorylates a panel of established MCSP 
targets as well as newly identified proteins (see Table 1 for overview). Thus, the kinase 
array data support a dual anti-melanoma activity by anti-MCSP:TRAIL that partly relies 
on inhibition of tumorigenic signaling by the anti-MCSP antibody fragment.
Anti-tumor activity of low dose anti-MCSP:TRAIL towards A375M xenografts
  To further characterize the anti-melanoma activity of anti-MCSP:TRAIL, A375M 
cells were xenografted subcutaneously in nude mice and allowed to form small tumors 
(~ 50 mm3). Subsequently, mice were treated daily by intra-peritoneal injection with 
a  low  dose  of  anti-MCSP:TRAIL  (~  0.14  mg/kg)  or  with  saline.  Of  note,  anti-MCSP 
mAb 9.2.27 and therefore anti-MCSP:TRAIL do not cross-react with mouse MCSP [3]. 
Compared to sham-treated mice, tumor size of the anti-MCSP:TRAIL-treated mice was 
strongly retarded in time (Fig. 5A), with a 50% reduction in tumor size at the end of the 
experiment (Fig. 5B). Of note, earlier animal studies with A375M cells and non-targeted 
rhTRAIL were performed at > 300 times higher concentrations (50 mg/kg) compared to 
the here employed treatment regimen with anti-MCSP:TRAIL [31]. Thus, in analogy to the 
low dose required for therapeutic activity in colony formation assays, anti-MCSP:TRAIL 
already has potent in vivo anti-melanoma activity at a very low dose.
Anti-MCSP:TRAIL lacks apoptotic activity towards normal cells
  Earlier studies have shown that tumor targeted delivery of TRAIL augments the 
tumor-specific activity of TRAIL, while not affecting the absence of toxicity on normal human 
cell types. Indeed, although anti-MCSP:TRAIL strongly bound to MCSP on normal human 
melanocytes (Fig. 2D), no apoptosis was induced in melanocytes even when treatment 
was performed with 4 μg/ml anti-MCSP:TRAIL (Fig. 5C). Also extended treatment (up to 
8 days) of melanocytes with 4 μg/ml anti-MCSP:TRAIL did not yield significant increases 
in apoptosis compared to medium control (Fig. 5D). Similarly, normal human MCSP-
negative hepatocytes were fully resistant to treatment with anti-MCSP:TRAIL (Fig. 5C). 
Hepatocytes have previously been shown to be one of the most vulnerable normal cell 
types to possible TRAIL-related toxicity [32]. Importantly, also in nude mice carrying 
A375M xenografts treatment with anti-MCSP:TRAIL had no deleterious effect on liver 162
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Fig.6.  Synergistic  induction  of  apoptosis  by  anti-MCSP:TRAIL  and  rimcazole:  A)  A375M 
cells were treated with increasing concentrations of anti-MCSP:TRAIL in the presence or absence of 
rimcazole for 16 h and apoptosis was assessed by Δψ; B) A375M cells were treated with rimcazole 
(15 μM), anti-MCSP:TRAIL (100 ng/ml) or both for 16 h, apoptosis was assessed by Δψ and the 
cooperativity index (CI) was calculated as indicated in the materials and methods section; C) A375M 
cells were treated with rimcazole (15 μM), anti-MCSP:TRAIL (100 ng/mL) or both in the presence or 
absence of pentacozine (200 nM) for 16 h and apoptosis was assessed by Δψ; D) Hepatocytes were 
treated with, rimcazole (15 μM), anti-MCSP:TRAIL (100 ng/ml) or both for 16 h and apoptosis was 
assessed by Δψ. KillerFasL (100 ng/ml)was used as a positive control for hepatocyte toxicity.
morphology, with morphology of liver sections comparable to the morphology of liver 
sections of Sham-treated mice (Fig. 5E and 5F). The here obtained data regarding the 
absence of activity of anti-MCSP:TRAIL towards normal cell types are in line with the large 
body of evidence in literature on the preclinical safety profile of sTRAIL. Indeed, ongoing 
clinical trials with rhTRAIL confirm the relative safety of TRAIL treatment with no serious 
adverse effects and no dose-limiting toxicity reported to date.163
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Synergistic induction of apoptosis by anti-MCSP:TRAIL and sigma ligands
  Since resistance of melanoma cells towards sTRAIL has previously been reported 
[22] a combinatorial strategy was evaluated of anti-MCSP:TRAIL with rimcazole, a sigma 
ligand in clinical trials for various cancers. Sigma receptors are expressed in the central 
nervous, immune, endocrine, and reproductive systems, but also in peripheral organs like 
kidney, liver and gastrointestinal tract. Although the precise function of these receptors 
remains unknown, both sigma-1 and sigma-2 receptors are strongly overexpressed in 
rapidly proliferating cells such as melanoma and may be exploited as possible targets for 
melanoma therapy [26]. Treatment of A375M cells with the sigma-1/sigma-2 antagonist 
rimcazole synergistically enhanced induction of apoptosis by anti-MCSP:TRAIL (Fig. 6A 
and 6B). Of note, treatment in the presence of the sigma-1 agonist (+)-pentazocine did 
Fig.7. Activity of caspases: A) caspase-8 and B) caspase-9 was assessed in A375M cells after 
incubation with anti-MCSP:TRAIL in the presence or absence of rimcazole (15 μM) for 1, 2, 3, 4, 5, 6 
or 16 h; C) A375M cells were treated for 16 h with 100 ng/mL of anti-MCSP:TRAIL and/or rimcazole 
(15 μM) in the presence or absence of zVAD-FMK (20 μM) or zLEHD-FMK and apoptosis was assessed 
by Δψ.164
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7 Fig.8. Schematic representation of the anti-melanoma activity of anti-MCSP:TRAIL: A) direct 
or indirect MCSP-mediated signaling involves (integrin-dependent) FAK and Src phosphorylation and 
maintains phosphorylation of downstream transcription factors and apoptotic modulators. MCSP thus 
contributes to pro-survival and metastatic signals;  B) binding  of anti-MCSP:TRAIL inhibits  MCSP-
mediated  signaling  and  concomitant  activation  of  pro-metastatic/-survival  signals  and  thereby 
sensitizes cells to apoptosis induction via binding of the TRAIL moiety to TRAILR.
not abrogate synergy, suggesting that rimcazole synergizes with anti-MCSP:TRAIL activity 
via sigma-2 receptors (Fig. 6C). Rimcazole did not upregulate TRAIL-R1 or TRAIL-R2 
expression (data not shown), but augmented the activation of initiator caspase-8 and 
initiator  caspase-9  upon  anti-MCSP:TRAIL  treatment  (Fig.  7A  and  7B,  respectively). 
Moreover,  inhibition  of  either  initiator  caspase  abrogated  cytotoxic  activity  (Fig.  7C). 
Thus,  rimcazole  appears  to  synergize  the  activity  of  anti-MCSP:TRAIL  by  promoting 
caspase-8 activation. Of note, anti-MCSP:TRAIL in combination with rimcazole lacked 
apoptotic activity towards hepatocytes (Fig. 6D), suggesting that this combination retains 
the favorable toxicity profile associated with TRAIL and rimcazole alone.
Conclusions
  We  provide  evidence  that  anti-MCSP:TRAIL,  a  TRAIL  fusion  protein  targeted 165
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to melanoma-expressed MCSP, inhibits MCSP tumorigenic signaling and simultaneously 
induces TRAIL apoptotic signaling. Consequently, fusion protein anti-MCSP:TRAIL potently 
inhibits outgrowth of melanoma cells both in vitro and in vivo and this effect can be further 
enhanced  with  the  cytotoxic  agent  rimcazole.  Based  on  the  above,  we  postulate  the 
following working model for anti-MCSP:TRAIL (see also Fig. 8A and 8B); anti-MCSP:TRAIL 
binds to MCSP and inhibits MCSP-signaling, which includes inhibition of src-kinases and 
FAK, the STAT transcription factors, and various anti-apoptotic modulators such as p53, 
TOR, JNK. Concurrently, interaction of the sTRAIL domain with its agonistic receptors 
TRAIL-R1 and TRAIL-R2 triggers potent induction of apoptosis. Notably, TRAIL/TRAIL-R 
interaction also triggers dephosphorylation of the STAT family, which may contribute to 
sensitization of cells to apoptosis [33,34]. Thus, melanoma cells are eliminated on the 
one hand by MCSP-mediated sensitization of melanoma cells to apoptosis and on the 
other hand by the concurrent activation of TRAIL-apoptotic signaling. Taken together, 
anti-MCSP:TRAIL is a novel immunotherapeutic agent that, either alone or in combination 
with rimcazole, may be of potential value for treatment of advanced melanoma.
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Abstract
Sub-toxic amounts of sigma ligands enhance apoptosis in A375M melanoma cells induced 
by  sTRAIL  (a  tumor-selective  pro-apoptotic  protein).  Although  we  have  previously 
established  a  caspase-dependent  mechanism  of  synergy,  the  precise  mechanism   
of interaction remained elusive. In this study, we asked whether early metabolic responses 
to treatment, monitored with radioactively labeled thymidine and glucose analogs (18F-FLT 
and 18F-FDG) in cancer and non-cancer cells, reflect enhanced apoptotic signaling and can 
provide insight into underlying molecular events. Sigma ligands and anti-MCSP:TRAIL 
synergistically  eliminated  A375M  and  A2058  (human  metastatic  melanomas)  but  not 
HUVEC (human umbilical vein endothelial) cells. PI staining followed by FACS analyses 
showed that sigma ligand-treated A375M cells increased in G1/G0-phase and decreased 
in S-phase fraction in a dose-dependent manner. Addition of anti-MCSP:TRAIL abrogated 
both effects and increased the apoptotic cell fraction, as demonstrated by analysis of   
the cell cycle and the 18F-FLT uptake. Cellular ATP levels quantified by bioluminescence 
additively decreased and  18F-FDG uptake synergistically increased after co-treatment. 
18F-FLT and 18F-FDG uptake studies demonstrate that a combination of sigma ligands with 
anti-MCSP:TRAIL changes cell cycle distribution and strongly depletes cellular energy 
levels in cancer cells. However, 18F-FDG uptake is not a direct reflection of synergy and 
changes of 18F-FLT uptake are too small to be easily quantified in vivo. Therefore, the 
mechanism of cooperation should be always considered when selecting a tracer for pre- 
and clinical studies.
Keywords:  sigma  receptor  ligands,  TRAIL,  enhanced  apoptotic  signaling,  cell  cycle, 
18F-FDG, 18F-FLT
Introduction
  Melanoma is the most deadly dermatologic malignancy and is responsible for 80% 
of deaths from skin cancer. This high mortality is due to its high metastatic potential. Only 
during the early stages of malignant melanoma, surgical resection is a viable treatment 
option. However, metastatic melanoma does not respond to current therapies [1]. 
  A promising compound for the safe elimination of melanoma cells is the immune 
effector molecule, Tumor Necrosis Factor Related Apoptosis Inducing Ligand (TRAIL) [2]. 
TRAIL selectively forces superfluous and potentially dangerous cells, such as cancer cells, 
to undergo programmed cell death, or apoptosis, with minimal or no activity towards 
normal  cells  [3].  The  effectiveness  and  safety  of  TRAIL  receptor  ligand  preparations 
(rhApo2L/TRAIL), alone or in combination with other anti-cancer agents, was already 
evaluated  in  human  subjects.  Interestingly,  recombinant  soluble  TRAIL  (sTRAIL)  has 
shown tumoricidal activity towards melanoma cell lines resistant to therapy with other 
cytokine-based therapeutics and promises to be the most effective cytokine for treatment 173
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of melanoma [4]. 
  Previously,  we  genetically  fused  sTRAIL  to  an  antibody  fragment  (scFv) 
directed against the human melanoma chondroitin sulfate proteoglycan (MCSP) [5]. The 
resulting anti-MCSP:TRAIL fusion protein selectively binds to and induces apoptosis in   
MCSP-positive cancer cells, with no toxicity towards normal cells [5].
  However,  many  tumor  cell  lines  and  almost  all  primary  tumor  cells  are   
TRAIL-resistant and require sensitization for sTRAIL-induced apoptosis [3]. The reason for 
this resistance is not completely clear, but alterations in cancer cell death pathways likely 
play a pivotal role. Therefore, a combination of two anti-cancer agents with different cellular 
targets, but intercalating mechanisms of action, is warranted to establish sensitization. 
Previously, we have demonstrated that promising compounds for combination treatment 
with anti-MCSP:TRAIL are sigma ligands, e.g. rimcazole [5] or haloperidol (unpublished 
results).
  Sigma receptors are strongly over-expressed in rapidly proliferating cells, like 
cancer cells [6,7]. Recent studies have confirmed that sigma receptors play a pivotal 
role in regulating growth of both cultured cancer cells and in vivo tumors [8]. More 
importantly, in vitro and/or in vivo treatment with sigma ligands is very effective in killing 
a variety of cancer cells like melanoma, ovarian, colon, prostate cancer and leukemia 
cells [9]. Many sigma ligands are used in clinical practice (haloperidol for treatment of 
psychosis, fluvoxamine and opipramol for handling depression, donepezil and memantine 
for treatment of Alzheimer’s disease, noscapine and dextromethorphan for suppression of 
cough). In addition, rimcazole was tested as an antipsychotic with reduced extrapyramidal 
side-effects, but it proved to lack the expected efficacy in schizophrenic patients. Currently 
rimcazole  is  being  re-tested  in  clinical  trials  and  re-profiled  for  treatment  of  cancer 
(Modern Biosciences). Sigma receptors are therefore relevant targets in the development 
of novel anti-cancer drugs [10]. Although the exact mechanism of action remains to be 
elucidated, the ability of sigma ligands to eliminate cancer cells is known to involve both 
caspase-dependent and caspase-independent mechanisms [11]. Moreover, sigma ligands 
(e.g. haloperidol or PB28) decrease expression and/or activity of p-glycoprotein (P-gp), 
a drug efflux pump implicated in multidrug resistance (MDR) [8]. Recent data show that 
sigma ligands can potentiate the action of several well known chemotherapeutic agents 
(e.g. haloperidol: doxorubicin, vinblastin, epirubicin and actinomycin D) [12,13]. Despite 
the broad utility, the dose of sigma ligands required for elimination of most adherent 
cancer cell lines is relatively high (20 -100 μM), a consequence of the fact that high sigma 
receptor occupancy is required for cell killing [14]. In combination therapy (as opposed to 
single agent therapy), lower (sub-toxic) doses of sigma ligands might be used. 
  Previously, we have shown that: 1. the cooperation between sTRAIL and sigma 
ligand, rimcazole, occurs exclusively in cancer cells, but not in normal cells like primary 174 Cell cycle inhibition by sigma ligands enhances apoptosis by TRAIL
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human  hepatocytes,  and  is  based  on  increased  caspase-8  and  caspase-9  activation, 
2. TRAIL-1 and TRAIL-2 receptor expression is not altered by rimcazole or haloperidol 
treatment,  3.  the  sigma-2  subpopulation  participates  in  the  cytotoxicity,  and  4.  the 
maximum  synergistic  effect  between  anti-MCSP:TRAIL  and  sigma  ligands  appears  to 
occur at a sub-toxic dose of sigma ligands [5,14]. Although we and others speculated 
that binding of sigma-2 receptors by sigma ligands induces dose-dependent sensitization 
to apoptotic stimuli by repressing anti-apoptotic processes [5,15], the precise mechanism 
underlying the synergy remained unknown. 
  Here, we used  18F-labeled metabolic tracers,  18F-FLT (3’-deoxy-3’-fluorothymidine, 
measures thymidine kinase 1 activity) [16] and 18F-FDG (fluorodeoxyglucose, measures 
glucose transport and/or metabolism) [17], to examine the manner in which a low dose 
of sigma ligand enhances sTRAIL-induced cancer cell death. Since tumors consist not only 
of tumor cells but to a large extension also of inflammatory tissue, in vivo assessment of 
the early metabolic responses of tumor cells to combination treatment can be difficult. 
Therefore, we selected an in vitro system to gain insight into the melanoma cell metabolism 
after sigma ligand and sTRAIL treatment, and for studying the mechanisms underlying 
synergy of this drug combination. 
Materials & Methods
Culture Media and Drugs
  DMEM (high-glucose) medium was purchased from Sigma. Fetal calf serum (FCS) 
was obtained from Bodinco, and trypsin was a product of Invitrogen. The pan-caspase 
inhibitor N-benzyloxycarbonyl-valyl-alanyl-aspartyl-fluoromethylketone (zVAD-fmk) was 
from Calbiochem, dissolved at 10 mM in DMSO and used at a final concentration of   
10 μM. Rimcazole, haloperidol, α-tocopherol and trypan blue [0.4% solution in phosphate-
buffered saline] were purchased from Sigma. Rimcazole and haloperidol stocks (3.9 mM 
and 4.8 mM) were prepared in ethanol with slight heating. α-tocopherol was dissolved 
in ethanol to 200 mg/ml and further in FSC to a stock concentration of 50 mg/ml. The 
synthesis and further production of anti-MCSP:TRAIL in CHO-K1 cells have been described 
previously [5].
Radiopharmaceuticals
  18F-FLT  and  18F-FDG  were  prepared  by  standard  procedures  reported  in  the 
literature [18]. 18F-FLT was prepared according to Machulla et al. [19]. The specific activity 
of the final product was >10 TBq/mmol. 18F-FDG was synthesized according to Hamacher 
et al. [20) by an automated synthesis module [21]. The specific radioactivity was always 
more than 10 (usually between 50 and 100) TBq/mmol. All radiopharmaceuticals were 
sterile and their radiochemical purities were greater than 95%.175
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Cell Culture
  The malignant human melanoma cell lines A375M and A2058 (MCSP-positive) 
were purchased from and characterized (STR profiling, karyotyping, isoenzyme analysis) 
by  the  American  Type  Culture  Collection  (ATCC).  A375M  and  A2058  were  previously 
characterized for MCSP expression [5,22] and sigma receptor content [9,23]. Melanoma 
cell lines were cultured at 37°C, in a humidified 5% CO2 atmosphere, in DMEM (high-
glucose) supplemented with 10% FCS. Before each experiment, the cells were seeded 
in 12-well plates (Costar). An equal number of cells was dispensed in each well and was 
supplied with 1.0 ml of complete cell culture medium. Human umbilical vein endothelial 
cells (HUVEC) were isolated as previously described [24]. HUVEC cells were used before 
culture passage number four and were grown in 6-well plates to 60% confluency before 
each experiment.
Uptake Studies
  Drug treatment was performed 24 h after seeding cells in 12-well plates when 
confluency  had  reached  40  to  45%.  Based  on  our  previous  results,  cellular  uptake 
of metabolic PET tracers was determined after 20-24 h incubation with sigma ligand   
(15 μM rimcazole, 38 μM haloperidol) and/or 100 ng/ml anti-MCSP:TRAIL [5,14]. For 
experiments involving α-tocopherol, A375M cells were incubated for 24 h with 48 μM 
haloperidol and/or 200 μg/ml α-tocopherol. Experiments were performed in 3-5 repeats 
for HUVEC and 6-16 repeats for A375M cells. At time zero, a PET tracer (2 MBq of 18F-FDG 
or 18F-FLT, in < 25 µl of saline) was added to each well. After 45 min of incubation the 
medium was quickly removed and the monolayers were washed 3 times with warm PBS. 
Cells were then treated for < 5 minutes with 0.2 ml of trypsin. When the monolayer had 
detached from the bottom of the well, 1 ml of complete cell culture medium was applied 
to stop the proteolytic action. Cell aggregates were resolved by repeated pipetting of the 
cell suspension. Radioactivity was assessed using a gamma counter (Compugamma 1282 
CS; LKB-Wallac). 
  A  sample  of  the  suspension  was  mixed  with  trypan  blue  solution  (1:1  v/v)   
and used for cell  counting. Cell  numbers were manually determined, using a phase-
contrast microscope (Olympus), a Bürker bright-line chamber (depth 0.1 mm; 0.0025 
mm2 squares), and a hand-tally counter. Uptake of radioactivity was normalized to the 
number of viable cells. Less than 3% of administered  18F-FDG or 7% of administered 
18F-FLT was taken up by the cells under these conditions. 
 
Scoring of Cell Number Decrease after Treatment
  Cytotoxicity experiments were performed in parallel with uptake studies. After 
assessment of tracer uptake with a gamma counter, a sample of the cell suspension was 176 Cell cycle inhibition by sigma ligands enhances apoptosis by TRAIL
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mixed with trypan blue solution (1:1 v/v) and used for cell counting (see above). 
  Additive or synergistic apoptotic effects were determined using the cooperativity 
index (CI). CI was calculated by the following formula: the sum of the effects induced by 
both single-agent treatments divided by the effect induced by combination treatment. 
When CI ≤ 0.9, treatment was termed synergistic; when 0.9 < CI ≤ 1.1, treatment was 
termed additive; when CI > 1.1, treatment was termed antagonistic.
ATP Assay
  Cellular ATP was measured with a kit based on firefly (Photinus pyralis) luciferase 
(ATPlite Luminescence ATP Detection Assay System; Perkin-Elmer). The bioluminescence 
was quantified using a Lumicount microplate luminometer (Packard Instruments Co.). A 
reaction blank and a standard curve with 9 concentrations of ATP were run in parallel. The 
assay was linear over a large range of ATP concentrations (10–7 to 10–4 mol/L) and of cell 
numbers in the assay. Cell samples were diluted to ensure that the concentration of ATP 
was within the range of the calibration curve.
Western Blot Analysis
  A375M cells were plated in two T75 flasks and used for control experiment or 
rimcazole (15 µM, 24 h) treatment. Similarly to the tracer uptake studies, floating dead 
cells were removed by PBS washing. Remaining attached cells were lysed and centrifuged 
14.000 rcf (10 min, 4°C). Nuclear fraction (pellet) was discarded. All supernatants were 
collected, analyzed for protein content by Bradford assay, boiled for 5 min and frozen 
in -80°C until use. Cellular proteins (30 µg) were size fractioned on a 7.5% SDS-PAGE 
(Biorad, Veenendaal, The Netherlands) and transferred onto activated PVDF membranes 
(Milipore, Etten-Leur, The Netherlands). Primary antibody: polyclonal anti-HKII antibody 
(diluted 1:200, Abcam) or monoclonal anti-GAPDH antibody (diluted 1:10000, Abcam); 
and  secondary  antibody:  horseradish  peroxidase-conjugated  goat  anti-rabbit  or  anti-
mouse antibodies (diluted 1:1500, DAKO, Glostrup, Denmark) were used for detection by 
chemiluminescence (BM Chemiluminescence blotting kit, Roche Biochemicals, Mannheim, 
Germany). Quantification of the band intensity was performed using ImageJ software 
(version 1.43; NIH, USA). For determination of the expression levels of HK-II, the band 
intensity of HK-II was divided by the band intensity of GAPDH. The HK-II expression after 
rimcazole treatment was expressed as percent of control.
Propidium Iodide (PI) Staining and Flow Cytometric Analysis
  A375M cells were plated at 3.0 × 104 cells/well in a 48-well plate containing 
0.25 ml of culture medium and allowed to adhere overnight. Subsequently, cell medium 
was  exchanged  and  the  cells  were  concurrently  treated  with  sigma  ligands  and/or 177
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anti-MCSP:TRAIL in a total volume of 0.25 ml. After about 20h of incubation, the cells 
were washed with 0.25 ml of warm PBS, incubated in 0.1 ml trypsin and re-suspended   
in 0.2 ml of culture medium. Supernatants and trypsinized cells were collected into 2 ml 
tube and centrifuged (1800 rpm, 3 min.). The cell pellet was subsequently re-suspended 
in 1 ml PBS and fixed for 15 min on ice in 2.5 ml ethanol (final concentration approx. 
70% v/v). Fixed cells were washed three times in PBS, where each washing step was 
followed by centrifugation (1500 rpm, 5 min), and stained with PI solution containing: 50 
μg/ml PI, 0.01 mg/ml RNase A and 0.05% Triton X-100 in PBS (40 min, 37ºC). Cellular 
DNA content was determined with a FACSCalibur (Becton Dickinson). Data were plotted 
using CellQuest software (Becton Dickinson); at least 5,000 events were analyzed for 
each sample.
Statistics
  Results are expressed as mean ± SEM. Statistical analyses were performed using 
SPSS 14.0 software and differences between groups were examined using 1-way ANOVA. 
When a significance of P < 0.05 was found, a post-hoc test for multiple comparisons was 
used (Bonferroni, P < 0.05). Significant changes are indicated with an asterisk.
Results
Synergistic Decrease in Melanoma Cell Number
  Co-treatment of A375M and A2058 cells with sub-toxic doses of sigma ligands, 
rimcazole  or  haloperidol,  and  anti-MCSP:TRAIL  for  24h  resulted  in  a  greater  loss  of 
viable cells than mono-treatment (P < 0.001) (Fig. 1). More importantly, the loss of 
viable cells after drug combination indicated synergy in A375M cells (Fig. 1A) and strong 
additive effect in A2058 cells (Fig. 1B). The cooperativity index (CI) for co-treatment of 
A375M cells with anti-MCSP:TRAIL and rimcazole was 0.77 compared to 0.51 for anti-
MCSP:TRAIL and haloperidol. The cooperativity index (CI) for co-treatment of A2058 cells 
with anti-MCSP:TRAIL and rimcazole was 0.94.
Cell Cycle Arrest 
  Morphological changes, like dispersed cell localization and decrease in number 
of cell-cell contacts, in A375M cells following treatment with 15 µM rimcazole or 38 µM 
haloperidol appeared indicative of cell cycle arrest in addition to a loss of cell viability. 
Therefore, we examined the inhibition of A375M cell proliferation after administration of 
haloperidol. The inhibition of proliferation was dose-dependent (Fig. 2A) and occurred 
even at low concentrations of haloperidol that did not result in any loss of cell viability 
after  24  h.  Furthermore,  we  studied  the  distribution  of  A375M  cells  among  different 
phases of the cell cycle following treatment with 15 µM rimcazole or 38 µM haloperidol in 178 Cell cycle inhibition by sigma ligands enhances apoptosis by TRAIL
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the presence or absence of 100 ng/ml anti-MCSP:TRAIL. As expected, mono-treatment 
with anti-MCSP:TRAIL did not alter the cell cycle distribution  (Fig. 2B). In contrast, 
treatment  with  rimcazole  or  haloperidol  increased  the  fraction  of  G1/G0  cells  by   
12 to 16%. Co-treatment with anti-MCSP:TRAIL and rimcazole or haloperidol restored the 
percentage of G0/G1 cells to the control value (Fig. 2B). Treatment of A375M cells with 
sigma ligands and anti-MCSP:TRAIL in the presence of 10 μM of pan-caspase inhibitor 
zVAD-fmk abrogated the synergistic loss of viable cells (Figs. 2C and 2D), but did not 
affect cell death induced by sigma ligands alone [5]. In addition, analysis of the fraction 
of cells in G0/G1 phase demonstrated that addition of zVAD-fmk to anti-MCSP:TRAIL with 
haloperidol prevents restoration of the control values for the fraction of G0/G1 cells (Fig. 
2E, right bar).
Changes in Metabolic Tracer Uptake
  18F-FLT: Treatment of A375M with anti-MCSP:TRAIL did not alter 18F-FLT uptake 
per viable cell compared to control (Fig. 3A). However, treatment with both rimcazole 
and haloperidol resulted in a decrease of 18F-FLT uptake per viable cell to 27.5 ± 2.1% 
and 30.4 ± 1.1% of the control value, respectively. Furthermore, co-treatment of A375M 
cells with anti-MCSP:TRAIL and rimcazole or haloperidol increased 18F-FLT uptake up to   
37.7 ± 1.0% (P < 0.001) and  41.1 ± 2.3% (P < 0.05) in comparison to treatment with 
these sigma ligands alone. Interestingly, changes in  18F-FLT uptake after sigma ligand 
treatment and co-treatment closely monitored changes in the fraction of S-phase cells 
determined by PI staining (P < 0.05) (Fig. 3B). 
Fig. 1. Co-treatment reduces the number of A) A375M cells; B) A2780 cells. 
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Fig. 2. Effect of treatment on cell proliferation: A) dose-dependent increase of G0/G1 fraction 
of A375M cells by haloperidol; B) synergy between sigma ligands and anti-MCSP:TRAIL depends on 
the G0/G1 stage of the cell cycle (sub-G0/G1 indicates the apoptotic cells); C) zVAD-fmk abrogates 
potentiating of anti-MCSP:TRAIL signaling by rimcazole; D) zVAD-fmk abrogates potentiating of anti-
MCSP:TRAIL signaling by haloperidol; E) zVAD-fmk inhibits anti-MCSP:TRAIL-induced killing of cells 
arrested in G0/G1. 
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Fig. 3. Changes in: A) cellular  18F-FLT uptake; B) fraction of cells in S-phase; C) cellular  18F-FDG 
uptake after co-treatment of A375M with sigma ligands and anti-MCSP:TRAIL or D) mono-treatment 
of A375M cells with anti-MCSP:TRAIL; E) cellular 18F-FDG uptake after co-treatment of A2058 with 
rimcazole and anti-MCSP:TRAIL.
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  18F-FDG: Incubation of A375M cells with rimcazole and haloperidol resulted in a 
significant increase of 18F-FDG uptake per viable cell (by 66.9 ± 5.8% and 26.9 ± 2.5%, 
respectively). In contrast, treatment with a sub-toxic concentration of anti-MCSP:TRAIL 
did not alter the uptake of 18F-FDG (Fig. 3C). The synergistic decrease in viable A375M 
cells  was  reflected  by  a  synergistic  increase  of  18F-FDG  uptake  by  121  ±  5.8%  and   
49.9 ± 3.7% (P << 0.05) with CI values of 0.55 and 0.54 for co-treatment with rimcazole 
Fig.  4.  ZVAD-fmk  does  not  block  the  increase  of  18F-FDG  uptake  after  co-treatment  with   
anti-MCSP:TRAIL and A) rimcazole, B) haloperidol. α-tocopherol C) reduces increase of 18F-FDG uptake 
and D) increases viability in A375M cells after haloperidol treatment.
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or  haloperidol,  respectively.  Interestingly,  incubation  with  increasing  concentrations 
of anti-MCSP:TRAIL induces a dose-dependent decrease in  18F-FDG uptake (Fig. 3D).   
ZVAD-fmk did not significantly block the synergistic increase of 18F-FDG uptake (Figs. 4A 
and 4B). Interestingly, α-tocopherol blocked the increase of  18F-FDG uptake in A375M 
cells treated with a high dose of haloperidol by 28% (P < 0.001) (Fig. 4C) and increased 
the survival of these cells by 12 % (P < 0.05) (Fig. 4D). Similarly, in A2058 cells rimcazole 
treatment increased 18F-FDG uptake per viable cell by 73 ± 2.9%, anti-MCSP:TRAIL did 
not alter the uptake of 18F-FDG and co-treatment with rimcazole and anti-MCSP:TRAIL 
resulted in a synergistic increase of 18F-FDG uptake by 136 ± 14.7% (P < 0.001) with CI 
value of 0.65 (Fig. 3E).
Changes of cellular ATP levels
  The large increase of glucose consumption after co-treatment could indicate 
changes in cellular energy levels. Therefore, we determined ATP content in A375M cells 
after drug treatment. Incubation with anti-MCSP:TRAIL, haloperidol or rimcazole for 24h 
decreased the amount of ATP per cell to 62.5 ± 2.8%, 54.6 ± 0.7% and 46 ± 6.3% of 
control, respectively. Furthermore, co-treatment with haloperidol or rimcazole resulted 
in further dramatic decrease of cellular ATP content to 11.1 ± 1.2% and 7.7 ± 1.5% of 
control, respectively (Fig. 5A). However, drug-induced ATP depletion displayed no synergy 
(CIs ≈ 1).
Fig. 5. Changes in A) cellular ATP content after single-agent and co-treatment, B) cellular HEX-II 
expression after rimcazole treatment.
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Changes hexokinase-II expression
  Decrease of cellular ATP by sigma ligands may activate a survival cascade in   
the cell and increase the expression of hexokinase-II (HK-II), a first enzyme on a glycolytic 
pathway of  18F-FDG. Incubation of A375M cells with rimcazole for 24 h increased the 
expression of HK-II by 28-55% (Fig. 5B). 
Synergy does not affect HUVEC Cells
  To determine the effect of co-treatment in untransformed cells, we used healthy 
human  umbilical  vein  endothelial  cells  (HUVEC).  Doses  of  sigma  ligands  and  anti-
MCSP:TRAIL which resulted in elimination of A375M cells did not affect the viability of 
HUVEC (Fig. 6A). The combination of rimcazole and anti-MCSP:TRAIL did not significantly 
decrease the number of HUVEC cells (P > 0.05).
  In contrast to A375M cells, HUVEC cells treated with haloperidol or co-treated 
with haloperidol and anti-MCSP:TRAIL did not respond with increased  18F-FDG uptake 
(Fig. 6B). However, moderate, but significant, (29.8 ± 6.3% (P < 0.01) and 50.8 ± 8%   
(P < 0.001)) increases in 18F-FDG uptake were observed after both single agent treatment 
with rimcazole and co-treatment with rimcazole and anti-MCSP:TRAIL, respectively. The 
increases of 18F-FDG uptake in HUVEC cells were more than two fold smaller than those 
observed in A375M melanoma.
Fig. 6. Responses of HUVEC to single-agent and combination treatment: A) surviving cells, B) 
18F-FDG uptake.
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Discussion
  Previously, we have observed that sigma ligands strongly enhance apoptosis 
triggered by the newly developed melanoma-targeted anticancer agent, anti-MCSP:TRAIL. 
As it is of interest to get further insight into the mechanism of action of this promising 
drug combination, we employed metabolic tracers,  18F-FLT and  18F-FDG, in an in vitro 
assay and showed that combination of sigma ligands with anti-MCSP:TRAIL changes cell 
cycle distribution and strongly depletes cellular energy levels in cancer cells.
Cell cycle
  Previously, Azzariti et al. reported that the sigma ligand, PB28, inhibits breast 
cancer cell proliferation by increasing the G1 population by ~ 20% in a dose- and time-
independent manner [25]. Here we show that the sigma ligand, haloperidol, similarly 
inhibits proliferation of A375M melanoma cells by simultaneously increasing G0/G1-phase 
and decreasing S-phase population, but in a dose-dependent manner (Fig. 2A). The same 
effect was observed after rimcazole treatment (data not published). Co-treatment with 
anti-MCSP:TRAIL and rimcazole or haloperidol eliminated this arrested population by a 
mechanism which  involves    caspases, since  the  elimination  is  inhibited  by  zVAD-fmk   
(Fig. 2, C-E). 
  These findings are consistent with earlier work by Jin et al. [26] demonstrating 
increased susceptibility of H460 lung cancer and SW480 colon cancer cells to TRAIL-
mediated apoptosis when cells were arrested in G0/G1. Their data suggest no changes in 
the levels of Bcl-2, Bcl-XL, FADD, DcR2, FLIP, IAPs or alteration in TRAIL-1 and TRAIL-2 
receptor expression. Similarly, we observed no changes in TRAIL receptor expression 
level [5]. Therefore, synergy between sigma ligands and anti-MCSP:TRAIL likely relies on 
molecular changes that occur in cells arrested during the cell cycle. However, the precise 
mechanism of interaction needs further investigation.
18F-FLT
  The first metabolic PET tracer which we used to monitor effects of single agent 
and combination treatment on tumor cell metabolism was the nucleoside 18F-FLT. Uptake 
of 18F-FLT into tumor cells is related to the activity of the principal enzyme in the salvage 
pathway of DNA synthesis, thymidine kinase 1 (TK1). After being taken up by the cell, 
18F-FLT is phosphorylated by TK1 into  18F-FLT-monophosphate, which is trapped in the 
cell. This activity is a biomarker of cell proliferation, as it is very low in the G0 and early 
G1 phase and reaches a maximum in the late G1 and S-phase of the cell cycle [27].   
In our experiments, 18F-FLT uptake per viable cell showed a strong decline after treatment 
of A375M cells with rimcazole and haloperidol (Fig. 3A), in accordance with the observed 185
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cell cycle arrest at G0/G1 and a decrease mainly of the S-phase population (Figs. 2B, 
and 3B). Co-treatment with anti-MCSP:TRAIL attenuated this decrease (Fig. 3A), due 
to preferential elimination of G0/G1-arrested cells and a resulting slight increase of the 
S-phase fraction of the remaining cell population. Thus, the uptake of 18F-FLT reflected 
changes of the S-phase fraction of A375M cells after combination treatment (Figs. 3A 
and 3B).
18F-FDG
  The second tracer which we employed was the glucose analog  18F-FDG. The 
uptake  of  18F-FDG  depends  on  the  activity  and  expression  of  glucose  transporters 
(GLUTs) and the enzymes performing the first step in glycolysis, hexokinases (HKs). 
18F-FDG uptake is used to indirectly assess population doubling time and cell viability. 
Measurement  of  changes  in  the  tumor  uptake  of  18F-FDG  is  considered  a  promising 
technique to monitor treatment response in various forms of cancer [28-30]. Previously, 
we have reported that sigma ligands increase glucose uptake in rat C6 glioma cell line 
after 16-20 h treatment despite their anticancer properties [14]. Treatment of A375M 
and A2058 melanoma cells with sigma ligand also resulted in increases of cellular 18F-FDG 
uptake (Fig. 3C). In contrast, incubation of A375M cells with increasing anti-MCSP:TRAIL 
concentrations decreased the uptake of glucose (Fig. 3D). Finally, the synergistic decrease 
of cell numbers which was observed after co-treatment was accompanied by a significant 
and synergistic increase in 18F-FDG uptake per viable cell in A375M and A2058 (Figs. 3C 
and 3E), but not in HUVEC (Fig. 6B). The increase in 18F-FDG uptake after sigma ligand 
treatment was related at least partially to increased hexokinase II (HK-II) expression 
(Fig. 5B). However, the involvement also of glucose transporting systems (e.g. GLUT-1, 
GLUT-3) in the increase of 18F-FDG uptake cannot be excluded. 
  Incubation with zVAD-fmk did not abrogate the increase of 18F-FDG uptake after 
combination treatment (Figs. 4A and 4B) in contrast to the increase of apoptosis (Figs. 
2C and 2D). Thus, although synergistic changes of 18F-FDG uptake were observed after 
the combination treatment, 18F-FDG uptake was no direct reflection of cell killing by the 
tested drug combinations. 
  In contrast, α-tocopherol partially prevented increase of  18F-FDG uptake and 
decrease of viability in A375M cells triggered by a high dose of haloperidol (Figs. 4C 
and  4D).  α-tocopherol  is  the  major  lipophilic  chain  breaking  antioxidant  which  can 
regulate also protein expression, ROS and other free radical production and mitochondrial 
function. Oxidative stress and cellular ATP depletion have been reported to affect glucose 
uptake [31,32]. ROS production and early (24 h) ATP depletion have been shown in   
SK-MEL-28  melanoma  after  treatment  with  sigma  ligands  (haloperidol  >  ifenprodil 
tartrate >> carbetapentane citrate) [33]. We have observed a decrease of cellular ATP in 186 Cell cycle inhibition by sigma ligands enhances apoptosis by TRAIL
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A375M melanoma following rimcazole or haloperidol treatment and a marked decrease 
in ATP after 24 h of co-treatment with sigma ligand and anti-MCSP:TRAIL. Such a strong 
decrease  in  cellular  ATP  (i.e.  exceeding  50%)  indicates  excessive  mitochondrial  DNA 
damage and damage to respiratory complexes [34], as could be expected following a 
substantial induction of apoptosis. Because cells try to compensate for any loss of ATP, 
glucose uptake will be strongly increased if cellular ATP levels show a significant decline. 
Furthermore, a reduction of cellular ATP results in a reduction of the levels of cyclin 
D1  and  cell  cycle  arrest,  as  was  demonstrated  after  oligomycin-induced  inhibition  of 
mitochondrial ATPase [35]. Thus, cell cycle arrest and the observed increases of 18F-FDG 
uptake may have a common origin.
Conclusion
  Addition  of  anti-MCSP:TRAIL  to  rimcazole-  and  haloperidol-treated  A375M 
cells  preferentially  eliminates  cells  arrested  in  G0/G1  by  these  sigma  ligands.  By 
this  mechanism,  sub-toxic  doses  of  sigma  ligands  can  potentiate  caspase  activation   
and the anti-tumor effects of recombinant sTRAIL, which may offer important therapeutic 
advantages: reduced sTRAIL dosing, limited side effects in patients undergoing cancer 
therapy, and increased chances of therapeutic success. 
   The uptake of  18F-FDG and  18F-FLT is differently affected after co-treatment. 
18F-FLT reflects the fraction of cells in S-phase and, therefore, the impact of combination 
therapy on tumor cell cycling. Synergistic changes of 18F-FDG uptake after the combination 
treatment paralleled the synergistic induction of apoptosis. However, 18F-FDG uptake was 
no direct reflection of treatment-induced apoptosis, since the increases of 18F-FDG uptake 
were based on a caspase-independent mechanism. 187
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Introduction
  Ovarian carcinoma (OC) remains the leading cause of gynecologic cancer deaths 
and its long-term survival rate has not improved in recent years [1,2]. Furthermore, while 
OC is highly responsive to platinum-based therapy after initial cytoreductive surgery, 
there  is  a  very  high  risk  (approx.  75%)  for  recurrences  of  refractory  disease  [3,4]. 
This is because OC acquires drug resistance [4,5]. Therefore, development and clinical 
implementation of novel targets for treatment and/or repression of drug resistance in 
advanced OC may improve disease-free survival.
  Sigma ligands possess low toxicity towards normal cells, while they activate unique 
(caspase- and p53-independent) mechanisms of cancer cell death that slow down cancer 
cell proliferation and overcome therapy resistance (Chapter 2 and Chapter 8, [6-15]). 
Furthermore, sigma ligands can enhance the anti-cancer activity of various conventional 
chemotherapeutic agents [7,8,12] and novel tumor-selective, pro-apoptotic therapeutics 
(see Chapter 7-8 for anti-MCSP:TRAIL). As such, sigma ligands may be highly suitable, 
alone or in drug combination, for improving treatment outcome of refractory OC. In this 
chapter, we present preliminary data indicating that sigma ligand-based approaches may 
be of value for the treatment of OC and we discuss plans for future experiments.
Materials & Methods
Culture Medium and Reagents
  RPMI 1640 medium was from Cambrex Bio Science (Verviers, France). DiOC6 
was purchased from Eugene (The Netherlands). Primary anti-human sigma-1 receptor 
antibody (ab89655) was from Abcam. Secondary PE-labeled goat anti-rabbit antibody was 
from Southern Biotech. Rimcazole (BW 239U) and haloperidol were from Sigma Aldrich 
(Sigma-Aldrich  Chemie  B.V.  Zwijndrecht,  Netherlands).  Stock  solutions  of  rimcazole   
(3.9 mM in ethanol) and haloperidol (4.8 mM in ethanol) were freshly prepared for each 
experiment.
ScFv425:sTRAIL production
  ScFv425:sTRAIL was produced as described previously [16]. Briefly, the high 
affinity  antibody  fragment  scFv425  (Vh-(G4S)3-Vl  format)  (provided  by  Merck),  was 
directionally inserted in the first multiple cloning site of vector pEE14, using the unique 
SfiI and NotI restriction enzyme sites. A PCR-truncated 593-bp DNA fragment encoding 
the extracellular domain of human TRAIL (sTRAIL) was cloned in-frame in the second 
multiple  cloning  site  using  restriction  enzymes  XhoI  and  HindIII,  yielding  plasmid 
pEE14-scFv425:sTRAIL. Expression plasmid pEE14-scFv425:sTRAIL was transfected into 193
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Chinese hamster ovary K1 (CHO-K1) cells using FuGENE 6 reagent (Roche Diagnostics) 
according to the manufacturer’s instructions. Successfully transfected cells were selected 
by the glutamine synthetase system. Single cell sorting using the MoFlo high speed cell 
sorter (Cytomation, Fort Collins, CO) established clone 100F1, stably secreting 2.4 μg/ml 
scFv425:sTRAIL into the culture medium.
Culture of ovarian cancer cell lines and primary ovarian cancer
  OVCAR-3  and  SKOV-3  were  obtained  from  the  American  Tissue  Culture 
Collection (ATCC). Both cell lines were cultured as monolayer at 37°C, in a humidified 
5% CO2 atmosphere and in RPMI 1640 medium supplemented with 10% fetal calf serum 
(FCS). Before each experiment cells were plated in 48-well plate in 250 µl of medium 
supplemented with 10% FCS.
  Primary ovarian cancer cells were isolated from tumor masses or ascites using 
a mechanical separation method followed by purification with Cancer Cell Isolation Kit 
(Panomics). Isolated cancer cells (viability >60 %) were used within 5 days after isolation. 
In this period, primary ovarian cancer cells were maintained at 37°C, in a humidified 5% 
CO2 atmosphere and in RPMI 1640 medium (Cambrex Bio Science, Verviers, France) 
supplemented with 10% fetal calf serum (FCS)
FACS staining of sigma-1 receptors
  Staining of sigma-1 receptors was performed in human ovarian cancer cells in 
the exponential phase of growth. First, the dead floating cells were removed from culture 
by 2x washing with PBS. Adherent cells were detached with trypsin and counted. For 
permeabilization (Fix and Perm kit, Invitrogen), 600 000 cells were used for each sample. 
After permeabilization, cancer cells were incubated (30 min, in darkness at 4˚C) with 
a primary rabbit antibody recognizing an internal domain of human sigma-1 receptor 
(dilution 1:1000) and washed 3x by resuspension in cold PBS and repeated centrifugation 
(5 min, 900 rpm). Afterwards, cells were incubated (30 min, in darkness at 4˚C) with the 
secondary PE-labeled goat anti-rabbit antibody (dilution 1:100) and washed as above. 
Two negative controls were taken along for each condition (one, unstained cells; second, 
cells incubated only with the secondary but not primary antibody). Mean fluorescence 
intensity (MFI) was quantified by FACS (Accuri C6 Flow Cytometer, BD) and corrected for 
background and non-specific binding.
Combination Treatment with Sigma Ligands and scFv425:sTRAIL 
  Combination treatment with sigma ligands and scFv425:sTRAIL was assessed 
in ovarian cancer cells pre-cultured in a 48-well plate at a concentration of 3 × 104 
cells/well. On the next day, cells were treated as indicated and apoptosis was assessed 194 Treatment of ovarian carcinoma with sigma ligands
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by DiOC6 staining measuring changes of mitochondrial membrane potential (∆ψ). After 
24 h treatment, cells were harvested and incubated for 20 min with DiOC6 (0.1 μM) at 
37°C, centrifuged (1000 x g, 5 min), re-suspended in PBS, and assessed for staining by 
flow cytometry (Accuri C6 Flow Cytometer, BD). Experiment was repeated three times in 
OVCAR-3 and SKOV-3. 
  Primary ovarian cancer cells were incubated (24 h) with: 1. scFv425:sTRAIL 
(300  ng/ml),  2.  rimcazole  (23  µM)  or  3.  rimcazole  +  scFv425:sTRAIL.  Two  methods 
for measurement of cytotoxicity were used: 1. trypan blue staining followed by manual 
counting of the dead and viable cells in the Bürker chamber, and 2. DiOC6 staining for 
decrease of mitochondrial membrane potential during the onset of apoptosis assessed by 
FACS (Accuri C6 Flow Cytometer, BD). Experiments were approved by the local Medical 
Ethics Committee and patients/healthy volunteers signed for informed consent.
  Synergy was assessed by calculating the cooperativity index (CI) in which the 
sum of apoptosis induced by single-agent treatment is divided by apoptosis induced by 
combination treatment. When CI was less than 1, treatment was considered synergistic; 
when CI equalled 1, treatment was considered additive; when CI was greater than 1, 
treatment was considered antagonistic.
Preliminary results
Identification of sigma-1 receptors in OC
  Only  limited  data  (immunohistochemical  staining,  www.proteinatlas.com)   
is  available  on  the  expression  levels  of  sigma-1  receptors  in  OC.  We  performed  a 
fluorescent staining and flow cytometry (FACS) analysis to compare sigma-1 receptor 
levels in four ovarian cancer cell lines (SKOV-3, OVCAR-3, A2780, A2780/CP70) and in 
one short culture of primary ovarian carcinoma (POC) derived from a patient. The analysis 
indicated that sigma-1 receptors are present at high levels in ovarian cancer cell lines and   
Table 1. Sigma-1 receptor staining in ovarian cancer
Sigma-1 receptors [MFI] 
SKOV-3  0 
OVCAR-3  2.70 x 10
6 
A2780  2.34 x 10
6 
A2780/CP70  4.13 x 10
6 
POC  4.27 x 10
6 195
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in  primary  ovarian  carcinoma  (Table  1).  The  order  of  the  mean  fluorescent  intensity 
(MFI) for the total sigma-1 receptor pool is: POC ≈ A2780/CP70 > A2780 ≈ OVCAR-3. 
Sigma-1 receptors were not detected in SKOV-3. The observed difference in MFI between 
a drug-sensitive OC cell line (A2780) and a cisplatin-resistant variant of this cell line   
(A2780/CP70) may suggests that sigma-1 receptor expression is different in treatment-
sensitive and -resistant OC cells. 
Sigma ligands enhance TRAIL-induced apoptosis in OC cell lines and in short cultures of 
POC
  Combined  administration  of  a  sigma-1/-2  ligand,  rimcazole  or  haloperidol,   
and  an  EGFR-targeted  TRAIL  fusion  protein  (scFv425:sTRAIL)  resulted  in  synergistic 
induction of apoptosis in OVCAR-3 and SKOV-3 cell lines (Fig. 1A-B). 
  In the next pilot study we evaluated the anti-cancer activity of combination 
treatment  with  the  sigma  ligand,  rimcazole,  and  EGFR-targeted  scFv425:sTRAIL   
or EpCAM-targeted scFvC54:sTRAIL, on POC cells derived from six POC patients. Patients 
were  divided  into  two  groups,  responders  and  non-responders,  based  on  the  effect   
of combination treatment. 
  POC  cells  from  four  out  of  six  patients  (67%)  responded  synergistically 
to  combination  treatment  with  rimcazole  and  the  EGFR-selective  fusion  protein 
scFv425:sTRAIL (Fig. 2A). Treatment for 24h with rimcazole, scFv425:sTRAIL or their 
combination resulted in induction of apoptosis in 17%, 27%, and 69% of short cultures 
Fig.1.  Synergistic  enhancement  of  TRAIL-induced  apoptosis  by  sigma  ligands  in 
ovarian  cancer  cell  lines:  A)  OVCAR-3,  and  B)  SKOV-3.  Data  are  expressed  as  mean 
±  SEM.  Differences  between  groups  were  examined  using  1-way  ANOVA.  Significant   
differences (P < 0.05) were found between monotreatment and co-treatment conditions. 
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of POC, respectively. A CI = 0.6 indicated synergism.
  POC cells from two out of six patients (33%) showed no synergistic enhancement 
of apoptosis (Fig. 2B). However, single-agent treatment with rimcazole induced already 
apoptosis  in  ~  68%  of  cancer  cells  derived  from  samples  of  these  two  patients.   
In these cells, scFv425:sTRAIL had a minimal effect on cell viability. Thus, cell death   
in  combination  treatment  was  comparable  to  cell  death  in  treatment  with  rimcazole 
alone. These preliminary results indicate that both groups of patients might benefit from   
the rimcazole and scFv425:sTRAIL combination.
Conclusion
  The data presented in this chapter are limited to two cell lines and six patient-
derived POC. However, the strong apoptotic effect of the combination treatment with 
sigma ligand and TRAIL fusion protein in these cells encourages us to further evaluate 
this treatment in a greater number of OC cell lines and POC samples. 
  Rimcazole in combination with TRAIL preparations (particularly those currently 
under clinical and pre-clinical investigation) may be of potential value for the treatment 
of refractory ovarian carcinoma. This  aspect will  be explored  in  greater detail  in  the 
proposed project. 
Fig.2. Synergistic enhancement of TRAIL-induced apoptosis by sigma ligands in patient-
derived  POC:  A)  samples  responding  to  drug  combination,  B)  samples  already  responding   
to rimcazole only. 
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Perspectives
  Our preliminary results indicate that it may be worthwile to perform a more 
detailed pre-clinical evaluation of sigma ligands for their suitability in the treatment of OC 
and other types of cancer. In the first part of such a project, one or two candidate sigma 
ligands may be identified for further evaluation regarding the treatment of refractory OC. 
Also, investigators could assess the phenotype(s) of OC patients that would be eligible 
for sigma ligand therapy. In the second part of the project, optimal treatment schemes 
(sequential- or co-administration or dosing of a sigma ligand with a conventional anti-
cancer drug or TRAIL) can be determined, in order to overcome therapy resistance in 
OC.
  To this end:
1. Anti-cancer activity of a small panel of selected sigma ligands should be evaluated 
using chemo-sensitive vs. chemo-resistant OC cell lines and patient-derived OC cells
2. Anti-cancer activity of sigma ligands should be correlated to the respective sigma 
receptor  expression  levels  in  an  elaborate  panel  of  chemo-sensitive  and  chemo-
resistant OC cell lines and in patient-derived short-term cell cultures of OC. Sigma 
receptor expression must be determined in different phases of the cell cycle and after 
(pre-)treatment with various anti-cancer drugs.
3. MicroPET imaging with a suitable sigma ligand will be applied to evaluate sigma levels 
in vivo in xenograft tumor models of OC at various stages of disease.
4.  Based  on  the  outcome  of  the  experiments  described  above,  optimal  combination 
treatment schemes (sequential or co-administration and dosing of sigma ligands with 
various conventional anti-cancer drugs) should be identified and evaluated for their 
efficacy and toxicity in established i.p. and s.c. xenografted mouse models of OC.
  Finally,  data  obtained  from  this  project  will  show  if  sigma  ligands  alone   
or in combination with various anti-cancer drugs (in particular, cisplatin and paclitaxel) can 
be applied to overcome drug resistance in OC. These results may significantly accelerate   
the testing of sigma ligands in a pilot clinical study in a small number of OC patients   
(e.g. undergoing peritoneal cavity wash). 198 Treatment of ovarian carcinoma with sigma ligands
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  The heterogeneous biology of cancer compels development of novel targeted 
therapeutics  and  suitable,  personalized  imaging  methods  (Chapter  1).  This  thesis 
describes  the  use  of  sigma  ligands  as  new  cancer-targeting  therapeutics  and  cancer 
imaging tools. 
  Sigma  receptors  are  a  class  of  transmembrane  proteins  present  in  plasma, 
endoplasmic reticulum, mitochondrial and lysosomal membranes [1,2]. Initial research 
on sigma receptors was focused on the brain rather than on tumors [3], since several 
clinically used neuroleptic drugs were found to have high affinity towards sigma receptors. 
Overexpression  of  sigma  receptors  in  tumor  tissue  and  anti-tumor  activity  of  sigma 
ligands were later reported [4-6] (Chapter 2). 
  Sigma receptors are more abundant in cancer tissue than in corresponding normal 
tissue [6]. Also, they have higher expression in high-grade vs. low-grade carcinomas 
[7]. This suggests that radiolabeled sigma ligands may be used for tumor detection and 
staging. Two studies aimed at evaluation of radiolabeled sigma ligand for cancer detection 
are described in the initial part of this thesis (Chapter 3-4). 
  Sigma  ligands  inhibit  cancer  cell  proliferation  and  induce  cancer  cell  death 
[8]. Furthermore, sigma ligands are capable of killing cancer cells with a drug-resistant 
phenotype and they enhance the oncolytic activity of chemotherapeutics [9,10]. Five 
studies aimed at evaluation of sigma ligands for cancer treatment are described in the 
second part of this thesis (Chapter 5-9). 
Evaluation of Sigma Ligand, 11C-SA4503, for Tumor Imaging
  Several issues must be considered when developing and evaluating a radioligand 
for tumor imaging using PET.  These issues will be discussed here in a context of the 
sigma-1  ligand,  1-(3,4-dimethoxyphenethyl)-4-(3-phenylpropyl)piperazine  (SA4503), 
which was used in the research described in this thesis. 
1. Ligand must be amenable to labeling. 
  A compound amenable to labeling with a positron emitter (11C,  18F) must be 
selected. The labeling should also be possible by a rapid synthetic procedure, because   
half-lives  of  PET  radionuclides  are  short  (see  Table  1  in  Chapter  1).  Successful 
radiochemistry with PET isotopes  11C and  18F was reported for sigma ligand, SA4503   
and its derivatives [11]. Whereas,  18F-derivatives of SA4503 displayed similar affinity 
to  sigma-1  and  sigma-2  receptors,  11C-SA4503  was  selective  for  sigma-1  receptors. 
11C-SA4503 was already used in human volunteers and is the most widely employed 
sigma ligand for PET. Labeling of SA4503 with 11C is reliable (uses our routine, automated 
synthesis method with 11C-methyl iodide as a building block) and results in a product with 
sufficient yield, high specific radioactivity and radiochemical purity (Table 1A) [12,13]. 201
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2. Small molecular size. Lipophilicity. Charge. 
  The blood-brain barrier (BBB) is a complex membranous structure that protects 
brain and spinal cord from potentially harmful substances present in the circulating blood, 
whereas it allows access of the essential substances such as glucose and oxygen [14]. 
The BBB may create a problem in visualization and treatment of brain tumors by limiting 
the uptake of radiopharmaceuticals and therapeutic drugs  [14,15], even though some 
brain tumors can disrupt the BBB and allow entry of a broader range of compounds 
into the brain. Problems remain because the changes in permeability of the BBB are 
usually local and nonhomogenous [16]. Therefore, the BBB must be considered when 
developing a tracer for imaging of brain tumors. Compounds that pass the BBB must 
be small (molecular mass smaller than 600 Da), moderately lipophilic (logP between +2   
and  +3,  as  higher  lipophilicity  promotes  nonspecific  binding  of  the  compound)  and 
optimally charged (pKa between 7.4 and 8.3) [17-19]. 11C-SA4503, due to its small-size, 
favorable lipophilicity and optimal charge (Table 1B), is capable of reaching intracellular 
binding sites by penetrating biological membranes, and entering the brain by passive 
diffusion across the BBB [20](Chapter 3-4).
  Furthermore, these features allow fast distribution of the compound throughout 
the body. An in vitro study with  11C-SA4503 has shown that this tracer binds rapidly   
to  tumor  cells,  whereas  in  vivo  experiments  indicated  a  rapid  blood  clearance  and 
distribution to target tissues (Table 1B) [13]. Importantly, a rapid uptake in C6 tumors was 
followed by minimal washout, whereas no detectable washout occurred from spontaneous 
pituitary tumors in rats within 60 min after tracer injection (Chapter 3-4). 
3. High affinity for target. High density of target in tumor.
  For good visualization of the receptors by PET, the ratio of specifically bound (B) 
ligand and free background radioactivity (F) must be sufficient (B/F ≥ 4). An elevated 
B/F ratio results from a high affinity of the ligand (low dissociation constant, Kd, of the 
ligand-receptor  complex)  and  a  high  density  of  the  receptor  (Bmax)  in  target  tissue 
[21].  11C-SA4503  shows  high  affinity  to  sigma  receptors  [22,23]  (Table  1C).  Also, 
sigma-1 receptors are present in tumors in sufficiently high densities for PET imaging   
(~ 170 fmol/mg protein in s.c. grown C6 glioma, ~ 1700 fmol/mg protein in AH109A 
hepatoma) [24,25]. With B/F ratio >> 10, 11C-SA4503 should be potentially able to image 
sigma-1 receptors in cancer.
4. Specificity for target. Overexpression of target in tumor.
  The quality of tumor imaging is dependent on the specificity of a radioligand for 
its target. Binding to non-target proteins should preferably occur with affinities at least 
50-fold lower than the affinity of the probe for its target. Moreover, the target protein 202 Summary
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should be more highly expressed in tumor than in non-tumor tissue in order to obtain a 
low background signal. 
  a) off-target affinity: 11C-SA4503 showed a high affinity to sigma-1 receptors, 
but negligible affinity to many other neuroreceptors, transporters and enzymes (Table 
1C)  [22].  The  compound  displayed  ~100-times  lower  affinity  to  sigma-2  receptors,   
α1-adrenergic, dopamine D2, serotonin (5-HT)1A, 5-HT2, histamine H1, and muscarinic 
M1 and M2 receptors, and no affinity at all to another 29 receptors, ion channels, and 
second messenger systems [22]. Brain uptake of 11C-SA4503 is not affected by the activity 
of the drug-efflux pump, P-glycoprotein (P-gp), present in BBB and in some tumors with 
acquired drug resistance [20]. Therefore, 11C-SA4503 will not be actively removed from 
P-gp expressing cells.
  b) uptake in healthy, non-tumor tissues: The highest in vivo uptake of  11C-SA4503 
was noticed in rat organs, such as liver, pancreas, kidney, bone marrow, lung, intestines, 
spleen and brain (Table 1C and Chapter 3) [13]. The absorbed dose of radiation in 
liver, pancreas and kidneys (the organs with highest 11C-SA4503 accumulation) was low 
enough to allow clinical use [12]. Specific binding of 11C-SA4503 to sigma receptors was 
observed in rat brain, intestines, kidneys and liver [13].
  Other  semi-quantitative  indices  allowing  a  comparison  of  tumor  activity  to 
“background  activity”  are  tumor-to-muscle  and  tumor-to-plasma  ratios.  The  higher 
these values are the better a tumor is visualized.  11C-SA4503 showed better tumor-to-
muscle ratios than 11C-choline, 11C-methionine or 18F-FLT, but lower ratios than 18F-FDG, 
whereas the tumor-to-plasma ratio of 11C-SA4503 was the highest of all tested tracers   
(Fig. 1., Table 1D and Chapter 3) [13,26,27]. 
  c)  uptake  in  tumor:  Sigma-1  receptors  were  shown  to  be  overexpressed  in 
tumor tissue in comparison to the tissue of its origin (see Table 3 in Chapter 2, for 
pituitary gland and pituitary tumor see Chapter 4) [28]. Indeed, high specific binding 
of 11C-SA4503 was also found in subcutaneous C6 glioma xenografts [13]. However in 
previous studies, a higher 11C-SA4503 uptake was observed in rat brain than in C6 tumors 
grown subcutaneously [13,27]. If the amount of 11C-SA4503 binding in spontaneous brain 
tumors or intracranial tumors is similar to  11C-SA4503 uptake in C6 glioma, tumor-to-
brain ratios of radioactivity will be low (< 1) in  11C-SA4503-PET. This would limit the 
applicability  of  11C-SA4503  for  tumor  detection  in  close  proximity  to  sigma  receptor-
rich organs like brain. However, microPET scanning with 11C-SA4503 proved capable of 
detecting spontaneous rat pituitary adenomas with a size smaller than 10 mm3. Tumor-
to-brain uptake ratios were approximately 5.7, whereas tumor-to-plasma uptake ratios 
were > 100 (Chapter 4 and Table 1D). Accumulation of 11C-SA4503 in these pituitary 
tumors appears partially due to increased sigma-1 receptor expression. We also noticed 
that the presence of a pituitary tumor affects the distribution of 11C-SA4503 in many other 203
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tissues. This may be a consequence of a decreased rate of blood flow and altered tracer 
distribution throughout the body. Since the distribution volume of 11C-SA4503 is highly 
sensitive to changes of blood flow, kinetic modeling may be necessary for quantification 
of sigma receptors.
  d) uptake in inflammatory tissue: Inflammatory cells may cause a false-positive 
diagnosis  of  neoplasm,  especially  in  FDG-PET  scans  [27].  Moreover,  chemotherapy 
can trigger inflammation in and around tumors. This inflammation may obscure tumor 
responses to chemotherapy, since these responses are evaluated by measuring decreases 
Fig.1. Comparison of  11C-SA4503 to other oncologic PET tracers: A) standard uptake value 
(SUV); B) tumor-to-plasma ratio (T/P), C) tumor-to-muscle ratio (T/M), D) selectivity index (tumor-
to-inflammation ratio corrected for the uptake in non-inflamed muscle). For graphs A-C, data are 
expressed as mean ± SEM. For graph D, deviation could not be given, because of indifferent uptake 
in inflamed and non-inflamed contralateral muscle in some animals. The original data were adapted 
from previous publication [27].
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of metabolic activity in the tumor region. Decreases of metabolism in tumor cells may be 
off-set by active metabolism in infiltrating non-tumor cells (e.g. neutrophils, macrophages, 
fibroblasts and lymphocytes) [29]. In the model of acute, sterile muscle inflammation   
11C-SA4503  demonstrated  a  much  better  selectivity  for  tumor  over  inflammatory 
tissue than other commonly used oncologic PET tracers, such as  11C-choline,  18F-FDG   
or 11C-methionine (Table 1D) [27]. The tumor selectivity of 11C-SA4503 was comparable 
to 18F-FLT, a tracer which monitors the activity of thymidine kinase 1, an enzyme involved 
in cell proliferation. This shows that  11C-SA4503 may be used for selective detection 
of tumors, although more study is needed for examining 11C-SA4503 uptake in chronic 
inflammation (see future perspectives in Chapter 11).
5. Effect of the endogenous competitor.
  Endogenous  sigma  (ant)agonists  could  compete  with  11C-SA4503 for  binding 
to  sigma  receptors  in  tumors,  thus  changes  of  the  levels  of  such  compounds  could 
affect  the  tumor-to-muscle  and  tumor-to-plasma  ratios  of  this  radioligand  and  affect 
the interpretation  of PET  data. Competition  of an endogenous antagonist for binding 
to sigma-1 receptors was considered and its possible impact on  11C-SA4503 PET was 
studied in Chapter 3. Steroid hormones (particularly progesterone and testosterone) 
were proposed to bind sigma receptors. However, identification of steroid hormones as 
endogenous  sigma  receptor  ligands  remained  uncertain  since  the  examined  steroids 
showed a rather low affinity [30]. We demonstrated that in vitro and in vivo binding 
of  11C-SA4503 to rat C6 glioma cells is sensitive to modifications in steroid hormone 
levels (Table 1E). We calculated that at least 16% of the sigma receptor population in C6 
tumors may normally be occupied by endogenous steroids. Decreasing the endogenous 
steroid  levels  resulted  in  increased  tumor-to-muscle  and  tumor-to-plasma  ratios  of   
11C-SA4503 (from 5 to 7 and from 10 to 15, respectively). An IC50 value (concentration 
of drug inhibiting 11C-SA4503 binding by 50%) of 33 nM was measured for the strongest 
competitor, progesterone. This level can be exceeded in human blood during the luteal 
phase of the menstrual cycle. Also, chemotherapy in oncology patients is sometimes 
accompanied  by  hormonal  changes,  which  may  affect  11C-SA4503  uptake.  Therefore, 
correction of the PET data for the levels of progesterone in blood may be necessary   
in 11C-SA4503 PET. 
6. Metabolism in plasma and in target.
  The ideal radioligand should show little metabolism during a few half-lives of the 
PET nuclide, i.e. the time window available for acquisition of tumor images. In case of 
11C-SA4503, only a small amount of metabolites was detected in rat brain 30 min after 
tracer injection. However in plasma,. 20% to 50% of total radioactivity at this time point 205
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represented metabolites (Table 1F) [12,33]. Since most radioactive metabolites derived 
from SA34503 are hydrophilic, they do not pass the BBB and do not significantly affect 
brain imaging. Hydrophilic metabolites will also be taken up less easily in tumor tissue 
than the moderately lipophilic parent ligand. However, to the best of our knowledge, 
the ratio of parent compound and metabolites in implanted tumors after injection of   
Table 1. Characteristic features of 11C-SA4503
 
11C-SA4503   References 
Synthesis Time  45 min  [13] 
Yield  ~ 9-11%  [13,27] 
Specific Radioactivity  ~ 11-22 TBq/mmol  [13,27] 
A) Labeling 
Radiochemical Purity  > 95%  [13,27] 
Molecular Size  368.51 Da   
Lipophilicity (LogP)  + 2.52  [31] 
Charge (pKa)  8.2  [32] 
In vitro Equilibrium (37˚C)  ~ 20 min  [13] 
In vivo Blood Clearance  > 80% at 20 min after injection  Chapter 3 
Plateau of TAC in Brain and Tumor  in 10 min after injection  Chapter 3 
Crossing Cell Membrane & BBB  yes  [20] 
B) Distribution 
Washout from C6/Pituitary Tumor  < 4.5%/no at 60 min after injection  Chapter 3-4 
Affinity to Sigma-1 Receptors [nM]  IC50=17.4 or Ki=4.6   [22,23] 
Affinity to Sigma-2 Receptors [nM]  IC50=1784 or Ki=63.1   [22,23] 
Selectivity Sigma-1/-2 receptor   100-fold or 14-fold  [22,23] 
Off-target Affinity  low (rat brain)  [12] 
P-gp Modulation  no  [20] 
C) Binding 
Specific Binding  brain, intestine, kidney, liver, C6 tumor  [13] 
Tumor-to-Muscle Ratio  ~5 (C6 glioma)  [27] 
Tumor-to-Plasma Ratio  ~10 (C6 glioma), ~100 (pituitary tumor)  [27], Chapter 4 
Tumor-to-Inflammation Selectivity  ~10 (C6 glioma)  [27] 
D) Selectivity 
Tumor-to-Tissue of Origin Ratio  ~ 3 (pituitary tumor/pituitary gland)  Chapter 4 
Steroid Hormones  progesterone (IC50 = 33 nM)  Chapter 3  E) Endogenous    
     Competitor  In vivo Occupancy in C6 Tumor  > 16% of sigma receptors  Chapter 3 
Rat Plasma   20-50% (30 min)  [12,33] 
F) 
11C-Metabolites 
Rat Brain  < 7% (30 min)  [12,33] 
Tumor Detection  glioma, pituitary  tumor  Chapter 3-4 
Disease-Free Survival (?)  progesterone receptor and Bcl-2 status   ? 
Early Cancer Responses  to doxorubicin treatment  [24,26] 
G) Applications 
Sigma Receptor Occupancy  dose of therapeutic sigma ligand  Chapter 5 
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11C-SA4503 has never been examined (see future perspectives in Chapter 12).
7. Relation of target expression or affinity state to response of cancer to treatment.
  An in vitro study in C6 cells treated with chemotherapeutic agents showed that 
the uptake of  18F-FLT and  11C-SA4503 was more rapidly altered than uptake of other 
tested PET tracers (Table 1G) [26]. In vivo doxorubicin treatment of C6 xenografts had   
no inhibitory effect on tumor growth at 48h, but it reduced  11C-SA4503 uptake in the 
tumor (as a result of downregulation of sigma-1 receptors) and 18F-FDG uptake (indicating 
inhibition of metabolism) [24]. Changes of the tumor uptake of PET tracers (11C-SA4503 
and 18F-FDG) preceded morphological changes. Radiolabeled sigma ligands may therefore 
be applied for monitoring early responses to chemotherapy. 
  In conclusion, the main challenge of nuclear medicine is to visualize tumors and 
to monitor therapeutic responses as early as possible. The data provided in this thesis 
indicate that radiopharmaceuticals for sigma receptors may be used for tumor detection, 
tumor staging, and evaluation of anti-tumor therapy. In addition, radioligands for sigma 
receptors can be used for monitoring the dose-dependent occupancy of sigma receptors 
in tumors by non-radioactive sigma ligands (see next paragraph).
Evaluation of Sigma Ligands for Cancer Treatment
  Sigma ligands have shown promising anti-tumor activity in pre-clinical studies 
[8-10].  Antagonists  at  sigma-1  receptors  and  agonists  at  sigma-2  receptors  induce 
changes in cancer cell proliferation and release an internal “brake” in cancer cells on 
the apoptotic machinery (see Chapter 1-2). The anti-tumor activity of sigma ligands is 
associated with a minimal toxicity towards normal cells and tissues (see Chapter 6 for 
hepatocytes and Chapter 8 for human umbilical vein epithelial cells), with epithelial lens 
cells as the only known exception [34]. This observation has led to several in vitro and 
in vivo studies in which sigma ligands were evaluated as potential anti-cancer agents, 
including  clinical  trials  with  rimcazole  (Modern  Biosciences),  siramesine  (H  Lundbeck 
A/S), and SR31747A (Sanofi-Aventis). 
  Sigma ligands must be applied in micromolar doses to trigger cell death in cancer 
cells, i.e. at significantly higher concentrations than reported Kd values for their in vitro 
binding to sigma-1 receptors [35,36]. By performing competition studies with 11C-SA4503 
in intact cells, we showed that occupancy of the sigma-1 population is not related to 
the cytotoxic effect, but almost complete occupancy of the sigma-2 receptor population 
is required for rapid cell death (Chapter 5) These data suggest that determination of 
sigma-2 receptor levels in tumors and sigma-2 receptor occupancy by therapeutic drugs 
may be important for assessment of the therapeutic dose of sigma ligands.
  Treatment  of  cancer  cells  with  sigma  ligands  induces  changes  of  cellular 207
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metabolism. We examined early metabolic changes following sigma ligand administration 
in order to predict which PET tracer is most suitable for evaluation of tumor responses 
to  therapy.  Results,  presented  in  Chapter  5  and  Chapter  8,  suggest  that  the  best 
tracers for monitoring such changes are 18F-FLT and 18F-FDG. Uptake of 18F-FLT is mainly 
determined by the activity of thymidine kinase 1, which is highest in S-phase and very 
low  in  G0/G1.  Treatment  of  glioma  and  melanoma  cells  with  sigma  ligands  strongly 
decreased the uptake of 18F-FLT (Chapters 5 and Chapter 8). Moreover, it changed the 
distribution of cells through different phases of the cell cycle. The population of cells in 
S-phase (dividing) was decreased and the fraction of non-dividing cells (G0/G1-phase) 
was increased (Chapter 8). Uptake of 18F-FDG is dependent on the activity of proteins 
involved in glucose transport and metabolism, such as glucose transporters (GLUTs) and 
hexokinases (HKs) [37]. A decreased 18F-FDG uptake in tumors is normally considered to 
reflect a positive response to treatment, although a transient increase (“metabolic flare”) 
may be initially observed [38,39]. Since we studied predominantly early changes right 
after the onset of treatment with sigma ligands, we observed a strongly increased 18F-FDG 
uptake in tumor cells in vitro (Chapter 5 and Chapter 8) and a moderately increased 
18F-FDG uptake in implanted tumors in vivo (Chapter 6). This “metabolic flare” appears 
to be a response to stress, i.e. increased energy consumption because the cells attempt 
to repair damage to cellular components induced by the treatment. Increased uptake of 
18F-FDG in dying cancer cells was not related to the activity of caspases but it was related 
to oxidation of cellular lipids (Chapter 8). 18F-FLT and 18F-FDG-PET can provide insight 
into  the  molecular  events  underlying  successful  chemotherapy  (inhibition  of  the  cell 
cycle, decrease in cellular ATP levels). However, synergistic effects of chemotherapeutic 
agents on cancer cell death should rather be assessed by a tracer measuring apoptosis,   
e.g. radiolabeled Annexin A5 or a caspase-3 ligand.
  Cancer cell death induced by sigma ligands can be independent of the p53 protein 
status of tumors and also be independent of caspase activation [9](Chapter 7). Therefore, 
sigma ligands may be suitable for treatment of a wide variety of tumors, including those 
resistant  to  any  treatment  which  depends  on  p53  or  caspase  downstream  signaling.   
A regulatory effect of sigma receptors on ceramide levels, calcium homeostasis, reactive 
oxygen species, lysosomal cathepsins and/or the activity of Akt kinase is supposed to 
underlie the anti-cancer activity of sigma ligands (see Chapter 2). Activation of such   
a large variety of death pathways may help overcome therapy resistance in cancer.
  Sigma ligands are capable of potentiating the anti-cancer effects of conventional 
chemotherapeutics  or  small  inhibitory  molecules  in  a  broad  spectrum  of  human 
malignancies. For instance, the sigma ligands CB64D and CD184 synergized the anti-
tumor  activity  of  doxorubicin  and  actinomycin  D  in  both  MCF-7  and  drug-resistant   
MCF-7/Adr  breast  cancer  cells.  Likewise,  the  sigma  ligand  haloperidol  significantly 208 Summary
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enhanced  the  anti-tumor  activity  of  a  tyrosine  kinase  inhibitor  (Gleevec,  also  known   
as  imatinib)  towards  SK-MEL-28  melanoma  cells  [40].  Sigma  ligands  may  kill  both 
sensitive and drug-resistant tumor cells when used in a proper drug combination [41]. We 
showed that sigma ligands synergistically potentiate the tumor-selective pro-apoptotic 
activity of TRAIL (Chapter 7-9). Combination of sigma ligands and TRAIL displayed robust 
anti-cancer  effects,  both  in  established  human  melanoma  cell  lines  (Chapter  7  and 
Chapter 8) and in short term cultures of primary human ovarian carcinoma (Chapter 
9). In primary samples of ovarian carcinoma patients, two groups of responses could be 
discriminated. In the first group, cancer cells responded very well to a combination of 
sigma ligand and TRAIL. In the other group, cancer cells were already strongly responsive 
to  treatment  with  sigma  ligand  alone,  and  combination  treatment  did  not  result   
in a greater anti-cancer effect. Thus, the final outcome of combination treatment in the 
two groups was comparable. 
  We  conclude  that  sigma  ligands  may  be  valuable  chemotherapeutic  agents; 
both  when  applied  alone  or  in  combination  with  conventional  chemotherapy,  TRAIL,   
or novel small inhibitory molecules; and can improve the treatment outcome of refractory 
cancers.
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  This thesis was focused on the evaluation of sigma ligands for cancer imaging 
and cancer treatment. In Chapter 3, we confirmed that steroid hormones (particularly 
progesterone) can bind in vivo to sigma-1 receptors in the brain and tumor, and may be 
the endogenous competitors to the sigma-1 ligand, 11C-SA4503. In Chapter 4, we showed 
that spontaneous pituitary tumors can be clearly visualized with  11C-SA4503, despite   
a high physiologic expression of sigma-1 receptors in the normal brain. In Chapter 5, 
we concluded that almost complete occupancy of sigma-2 receptors is associated with 
anti-cancer effects. In Chapter 6, we demonstrated strong antitumor action of rimcazole 
(sigma-1/-2 ligand) against metastatic melanoma xenografts in the absence of acute 
side-effects. In Chapters 7-9, we reported a robust synergistic killing of various cancer 
cell lines and patient-derived primary ovarian cancer cells by combining sigma ligands 
and TRAIL preparations. In the following paragraphs, we identify some areas for further 
study and we discuss our findings in the context of new discoveries in the sigma receptor 
field.
Is tumor imaging influenced by 11C-SA4503 metabolites?
  We observed differences in the washout kinetics of  11C from brain and tumor   
in 11C-SA4503 PET (Chapter 3-4). During a 60 minute scan, the decay-corrected activity 
in the brain showed a significant decline, whereas activity in the tumor was maintained 
at the initial level. A similar observation was made by other investigators, who used 
different tumor models and/or different radioligands [1-5]. 
  One  possible  explanation  for  differences  in  washout  kinetics  of  11C-SA4503   
in  the  brain  and  tumors  is  that  11C-SA4503  uptake  may  be  affected  by  competition 
with  endogenous  sigma-1  ligands  (neurosteroid  hormones,  N,N-dimethyltryptamine,   
or some other endogenous ligand) in a brain, but not in tumor (Chapter 3, [6]). Second 
possible explanation for the difference in kinetics is that sigma-1 receptors in tumors 
and the brain have different affinity states. Due to a higher ratio of kon/koff, the ligand-
receptor complex may remain assembled for a longer period of time in the tumor than 
in the brain [7,8]. This property of tumoral receptors would be very desirable for tumor 
imaging. However, third possible mechanism underlying the kinetic differences is that 
11C-SA4503, after crossing cellular membranes, is metabolized to hydrophilic radioactive 
metabolites which are then trapped inside the cell. Since tumor cells have an increased 
metabolic activity in comparison to non-tumor cells, trapping may preclude washout from 
tumors but not from brain. If significant intracellular metabolism of the tracer occurs,   
it may be difficult to quantify sigma-1 receptors in tumors by kinetic modeling. The ratio   
of parent compound and metabolites in tumors after injection of 11C-SA4503 has never 
been  examined.  Future  experiments  are  required  to  establish  or  refute  mechanisms 
1, 2 and 3, and to prove that it is possible to quantify sigma-1 receptors in tumors   215
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with 11C-SA4503 and PET. 
Can sigma ligands distinguish tumor from chronic inflammation?
  Significant uptake of a PET tracer in inflammatory cells may be a cause of false-
positive  tumor  diagnosis  and  may  complicate  the  interpretation  of  tumor  responses   
to treatment (Chapter 10). Based on their time course, inflammatory processes can   
be divided, into acute and chronic inflammations. Acute inflammation is mediated mainly 
by granulocytes, chronic inflammation by monocytes and lymphocytes. 
  In  a  model  of  acute,  sterile  muscle  inflammation,  11C-SA4503  demonstrated   
a much better selectivity for tumor over inflammatory tissue than the metabolic PET tracers, 
such as 18F-FDG, 11C-choline, or 11C-methionine, and a similar selectivity as the nucleoside 
18F-FLT.  Proliferation  markers  like  18F-FLT  show  little  uptake  in  acute  inflammation,   
but  they  can  accumulate  in  chronic  inflammation,  because  of  infiltrations  of  rapidly 
dividing  lymphocytes,  macrophages  and/or  fibroblasts  [9-13].  Thus,  the  selectivity   
of  18F-FLT  for  tumor  over  acute  inflammation  is  much  better  than  its  selectivity  for 
tumor  over  chronic  inflammation.  The  uptake  of  11C-SA4503  in  chronic  inflammation   
has not yet been examined. Future experiments are required to determine if tumors can 
be distinguished from chronic inflammations by 11C-SA4503-PET.
  Since ligands for sigma-2 receptors have been reported to be better proliferation 
markers than sigma-1 receptor ligands, the tumor selectivity of such ligands should be 
examined in animal models of acute and chronic inflammation. Such studies have not 
been reported in the literature.
Are  non-subtype-selective  ligands  better  for  tumor  detection  than  sigma-1 
ligands?
  Sigma  receptors  are  potential  biomarkers  for  tumor  imaging.  Both  sigma-1 
and (particularly) sigma-2 receptors are overexpressed in tumors [14-19]. Radioligands 
which bind to both sigma receptor subtypes may therefore be accumulated more in tumor 
tissue than sigma-1-subtype-selective tracers, and higher tumor-to-background ratios 
may be achieved by using such compounds for PET imaging [1,19]. Imaging of breast 
tumors showed that better tumor visualization was achieved with a radioligand which 
is selective for the sigma-2 subtype than a non-selective or selective for the sigma-1 
subtype [20,21]. Future studies should investigate the suitability and benefits from using 
non-subtype-selective (e.g. 18F-FESA5845) or sigma-2 subtype-selective (e.g. 125I-RHM-4) 
sigma ligands for tumor detection with PET and SPECT.216 Conclusions and perspectives
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Which sigma receptor subtype is a better biomarker for monitoring of therapy 
responses?
  In  several  studies,  sigma-1  receptor  expression  and  the  binding  of  sigma-1 
agonists  (e.g.  11C-SA4503)  have  been  reported  to  be  not  closely  related  to  cellular 
proliferation [22,23]. Other studies reported that sigma-1 receptors are involved in cellular 
proliferation. In these studies, sigma-1 antagonist treatment and silencing of sigma-1 
receptor subtype reduced proliferation of cancer cells [14,24-26]. Also, alterations in 
cell cycle had an effect on the uptake of the radioligand (125I-PAB) selective for sigma-1 
subtype [27]. This last result must be interpreted with caution because melanin pigment, 
in  addition  to  sigma-1  receptors,  interacts  with  125I-PAB  [28].  Furthermore,  sigma-1 
receptor RNA levels did not determine the susceptibility to rimcazole in NCI60 cell line 
panel [26]. Other study examined the prognostic value of sigma-1 receptor expression 
in breast cancer [22]. This study showed that sigma-1 receptor levels were related to 
progesterone  receptor  positivity,  Bcl-2  expression  and  poorer  disease-free  survival, 
but were not related to tumor size, histological grade or the expression of the Ki-67 
proliferative  marker,  in  95  human  breast  cancer  patients.  Based  on  these  conflicting 
reports regarding relation of sigma-1 receptor expression to cellular proliferation, the 
expression and function of sigma-1 receptors in various types of malignancy should be 
re-examined and correlated to the proliferative status of cancer and prognosis. 
  In  contrast  to  the  conflicting  findings  regarding  sigma-1  receptors,  sigma-2 
receptor  expression  and  the  binding  of  non-subtype-selective  (e.g.  18F-FE-SA5845  or 
18F-FE-SA4503) or sigma-2-selective ligands (e.g. fluorescently labeled SW120, PB28) was 
found to be related to cellular proliferation [23,24,29-31]. Therefore, sigma-2 receptor 
expression is proposed to be a biomarker of cellular proliferation and sigma-2 selective 
ligands may be useful for assessing the proliferative status of tumors and evaluating 
tumor responses to chemotherapy [32-36]. Furthermore, there are several reasons why 
sigma-2 ligands appear to be better candidates for tumor imaging than sigma-1 ligands: 
1. Sigma-2 receptor is more commonly expressed in cancer and sigma-2 receptor levels 
in cancer are generally much higher than those of the sigma-1 subtype [18]; 2. Sigma-2 
receptors densities correlate to histopathologic grade of human urinary bladder carcinomas 
[15]; 3. Sigma-2 receptor density is related to cellular proliferation [33]; 4. In cancer 
cells responsive to treatment with tamoxifen, decrease in sigma-2 densities correlates to 
Ki-67, IdU labeling indexes and AgNOR scores [32]; 5. In general, signaling is considered 
to be pro-survival downstream sigma-1 receptor and pro-apoptotic downstream sigma-2 
receptor. Therefore, evaluation of the early responses to anti-cancer therapy may be more 
rapid and easily quantifiable while using radioactive sigma-2 ligand (and not sigma-1 
ligand)  for  PET  or  SPECT.  Assuming  a  pro-survival  function  of  sigma-1  receptors  in 
tumors, an early increase in the tumor uptake of sigma-1 ligands may be observed after 217
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the onset of an effective treatment (reflecting activation of survival pathways), which 
is later followed by a decrease when cells start to die. In contrast, a sudden decrease   
in the tumor uptake of sigma-2 ligands may be expected (reflecting inhibition of cellular 
proliferation). In conclusion, sigma-2 ligands appear to be better candidates for imaging 
of tumor responses to anti-cancer therapy than sigma-1 ligands.
What  would  increase  the  importance  of  sigma-2  receptors  as  a  target  in 
oncology?
  Sigma-2 ligands with high subtype selectivity have only been explored for tumor 
imaging by three research institutions (Washington University School of Medicine, St.Louis, 
USA, Wake-Forest University School of Medicine, Winston-Salem, USA, and University   
of Bari, Bari, Italy). These institutions developed their own sigma-2-selective radioligands. 
SM-21 is to date the only available non-radioactive sigma-2 antagonist. Unfortunately, 
SM-21 is only ~14-fold selective for sigma-2 over sigma-1 receptor subtype and binds 
with  similar  affinity  also  to  dopamine  D2  and  5-HT2  receptors  [37].  Studies  on  the 
biology of sigma-2 receptors and the development of sigma-2 ligands for PET imaging 
would be greatly facilitated if better sigma-2 ligands than SM-21 became commercially 
available. Synthetic efforts should be directed towards the development of novel sigma-2 
(ant)agonists  with  improved  affinity  and  selectivity.  Novel  sigma-2  ligands  could  be 
derived from e.g. 1. benzomorphan-7-one; 2. 3-(ώ-aminoalkyl)-1H-indole; 3. tropane;   
or 4. piperazine [38]. These scaffolds were previously used in synthesis of ligands with 
high affinity and selectivity towards sigma-2 receptors. 
Do PET scans of sigma-2 receptor densities allow prognosis of the therapeutic 
outcome?
  Sigma-2  receptor  levels  and  occupancy  may  determine  the  anti-tumor 
effect of sigma-2 ligands (Chapter 5) and/or their adjuvant action in chemotherapy.   
If a selective  sigma-2 tracer for  PET  becomes available,  a study  correlating sigma-2 
receptor levels to anti-cancer activity of sigma-2 ligands could be performed in cancer cells 
with drug-sensitive and -resistant phenotypes, as a continuation of the work described 
in Chapter 9. The results of such a study may enable identification of the phenotypes 
of cancer patients that are eligible for sigma-2 ligand-based therapy, and may provide 
data about the drug dose necessary for optimal cancer killing. Furthermore, sigma-2 
receptor expression is probably different in different stages of cancer progression. Thus, 
the novel study could also indicate when the treatment with sigma-2 ligands will have 
the strongest effect. Sigma receptor levels and oncolytic activity of sigma ligands should 
be  determined  in  patient-derived  primary  samples  of  carcinoma  of  different  stages.   
A parallel study in experimental animals could assess sigma-2 expression during different 218 Conclusions and perspectives
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stages of carcinogenesis with microPET. Results of these studies could indicate if PET 
scans of sigma-2 receptor expression allow prognosis of the therapeutic outcome.
Imaging  of  which  sigma  receptor  subtype  is  worthwhile  testing  in  oncology 
patients?
  a) sigma-1 receptor
  11C-SA4503  has  already  been  successfully  employed  for  imaging  sigma-1 
receptors  in  healthy  volunteers  and  patients  with  Alzheimer’s  or  Parkinson’s  disease 
[23,39-42]. In these human studies, high uptake was seen in the liver, followed by lung 
and brain. Low uptake was seen in kidneys, extremities and the abdominal region. A small 
pilot study with 11C-SA4503 has been performed in four untreated patients with non-small 
cell lung cancer which were also scanned with 18F-FDG. In contrast to 18F-FDG, 11C-SA4503 
was found to be not suitable for staging of non-small cell lung cancer. 11C-SA4503-PET 
did not detect all lesions. Several local metastases, bone or brain metastases were visible 
with  18F-FDG but not with the sigma-1 ligand. Tumors frequently showed up as cold 
spots in 11C-SA4503 scans, and a weak accumulation of radioactivity was observed only 
at the tumor rim. In a few cases,  11C-SA4503 was showing complementary hot spots 
to those observed in the  18F-FDG scan. Despite these negative results, the feasibility 
of  11C-SA4503  PET  for  imaging  of  hormone-responsive  tumors  could  be  examined   
(e.g., ovarian carcinoma or breast cancer), since sigma-1 receptor levels in such tumors 
have been reported to be related to hormone receptor positivity [22].
  b) sigma-2 receptor
  Sigma-2  ligands  or  non-subtype-selective  sigma  ligands  seem  to  be  more 
promising for tumor imaging than sigma-1 ligands, because the expression of sigma-2 
receptors is considered to be related to cellular proliferation. However, no human PET 
study with a selective sigma-2 ligand has been performed thus far. In order to make 
such a study possible, toxicity and mutagenicity data for a newly developed sigma-2 
ligand should be collected. If no adverse toxicity or mutagenicity is observed, pilot studies   
in healthy volunteers and small groups of cancer patients are a logical continuation of the 
research of the St. Louis group.
Has the sigma-2 receptor really been identified? 
  The sigma-1 receptor gene of several mammalian species has been cloned and 
is known to be encoded in band p13 of human chromosome 9. However, the existence 
of  the  sigma-2  receptor  has  only  been  proven  by  pharmacological  methods.  This 
makes the sigma-2 receptor a somewhat enigmatic protein which is not easily studied.   
The possibility of the sigma-2 receptor being a histone binding protein was once considered 
[15], but evidence to confirm this hypothesis is lacking. In July 2011, the progesterone 219
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receptor membrane component 1 (PGRMC1) protein complex was tentatively identified 
as the putative sigma-2 receptor [43]. Although these data seem very convincing, they 
need to be confirmed by other research institutions. It is important to perform functional 
experiments in which changes of PGRMC1 expression and sigma-2 ligand binding are 
monitored in parallel, e.g. after chemotherapeutic treatment. Some doubt may be raised 
by the fact that PGRMC1 is localized in the plasma membrane, cytoplasm and nuclear 
spindle, whereas confocal microscopy with fluorescent sigma-2 ligands has not shown any 
accumulation of these compounds in the nucleus [43,44]. With respect to the evaluation 
of sigma-2 intrinsic activity, Colabufo et al. suggested that sigma-2 ligands which inhibit 
electrically evoked contractions in guinea pig bladder and ileum might be considered 
sigma-2 agonists [45]. However, the use of guinea pig bladder instead of tumor cells   
to distinguish between sigma-2 agonistic and antagonistic ligands limits the use of this 
assay  in  oncology.  Furthermore,  whereas  sigma-2  agonists  display  oncolytic  activity, 
PGRMC1 plays an essential role in promoting the in vitro survival of normal and cancer 
cells [44]. A better definition and assay for determination of agonistic or antagonistic 
action at sigma-2 receptors are urgently required. 
What is the precise role of sigma-2 receptors in cancer cell proliferation?
  Sigma-2  ligands  were  shown  to  affect  transition  of  cell  through  the  phases   
of cell cycle. Since the majority of sigma-2 selective ligands (with exception of PB28)   
do not show any accumulation in the nucleus, sigma-2 receptors may influence cell cycle 
regulatory proteins in the cytoplasm (e.g. Akt kinase), or proteins capable of crossing   
the membrane between cytoplasm and nucleus (e.g. cyclin-dependent kinases and cyclins), 
rather than directly affecting nuclear proteins (such as p21, p27 or p53). Future studies 
should examine the function of sigma-2 receptors in control of the cell cycle, particularly 
because sigma-2 receptors were found to be biomarkers of cellular proliferation. 
Conclusion
  Sigma receptors are an interesting target for tumor imaging and treatment. 
However,  based  on  our  own  data  (presented  in  Chapter  5  and  Chapter  7)  and  data 
from other institutions, sigma-2 ligands are more promising for treatment and imaging   
of cancer than ligands for the sigma-1 receptor. Sigma-2 receptors, in contrast to sigma-1 
receptors, are thought to be markers of cellular proliferation.220 Conclusions and perspectives
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Achtergrond
  Wereldwijd sterven er ongeveer acht miljoen mensen per jaar aan kanker. Hoewel 
er al aanzienlijke vooruitgang is geboekt met het vaststellen en behandelen van kanker 
zal dit aantal nog steeds verder toenemen. Het is dan ook niet verrassend dat er intensief 
gezocht wordt naar nieuwe mogelijkheden om kanker sneller vast te stellen en beter te 
behandelen. Het vergaren van kennis over het ontstaan en groei van kankercellen speelt 
hierbij een belangrijke rol. 
  Kanker is een complexe ziekte die ontstaat als normale lichaamscellen “ontsporen”. 
Hierbij gaat een lichaamscel zich steeds meer geïsoleerd gedragen zonder dat daarbij een 
gezonde interactie met de rest van het lichaam wordt gewaarborgd. Helaas is vrijwel 
elke lichaamscel in principe in staat om een kankercel te vormen. Hierdoor verschillen 
kankercellen aanzienlijk van patiënt tot patiënt en zelfs kankercellen van één enkele 
patiënt zijn vaak verschillend van elkaar. Als gevolg hiervan manifesteren verschillende 
kankers zich dikwijls met verschillende symptomen. Bij alle vormen van kanker kunnen 
echter vier stadia van ontwikkeling worden onderscheiden, namelijk: initiatie, promotie, 
progressie en conversie (zie ook Figuur 1).
  Tijdens al deze stadia veranderen kankercellen steeds meer ten opzichte van 
het  celtype  waaruit  ze  oorspronkelijk  zijn  ontstaan.  Deze  veranderingen  beschermen 
de kankercel tegen de afweermechanismen van het lichaam, en stellen de cel ook in 
staat om onbeperkt te blijven doorgroeien. Bekende voorbeelden hiervan zijn: 1. het 
vermogen van kankercellen om hun eigen groei te blijven stimuleren 2. de ongevoeligheid 
van kankercellen voor geprogrammeerde celdood (apoptose) en 3. het vermogen van   
een kankercel om zich ongelimiteerd te blijven delen in twee identieke dochtercellen. 
Vanwege deze veranderingen is een kankercel in het voordeel ten opzichte van normale 
cellen, maar wordt daarvan ook beter te onderscheiden.
  Bijvoorbeeld: bij normale groei van cellen bindt een groeifactor aan een receptor. 
Door deze binding wordt de groei van de cel gestimuleerd. Om maximaal gebruik te 
maken van groeifactoren verhogen kankercellen dikwijls de hoeveelheid receptoren die zij 
bezitten (verhoogde expressie). Hierdoor wordt de groei van kankercellen gestimuleerd, 
maar ontstaat er ook een onderscheid met normale cellen die minder receptoren bezitten 
hetgeen de mogelijkheid tot mogelijke behandeling biedt. Eén van de receptoren die 
verhoogd tot expressie komt op kankercellen is de zogenaamde sigma receptor.
  Sigma  receptoren  zijn  eiwitten  die  voorkomen  in  de  wanden  van  cel 
compartimenten zoals het endoplasmatisch reticulum, de mitochondriën, de lysosomen en 
tevens het plasmalemma (de buitenwand van de cel). Omdat sigma receptoren meer tot 
expressie komen in kankercellen dan in normale cellen, kunnen deze receptoren wellicht 
gebruikt worden om kanker op te sporen. Dit zou bijvoorbeeld kunnen met behulp van 227
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Fig. 1. Verschillende fasen van de ontwikkeling van kanker. Het ontstaan van tumoren wordt 
geïnitieerd door verscheidene mutaties in de cel. Verdere ontwikkeling van kanker wordt bevorderd 
als de gemuteerde cel vervolgens ontsnapt aan de verdedigingsmechanismen van het lichaam en 
zich  abnormaal  door  blijft  delen.  Hierdoor  ontstaan  verdere  mutaties  of  zogeheten  epigenetische 
modificaties. Tijdens de voortgang van de vorming van een tumor ondergaan kankercellen verschillende 
rondes van adaptatie, proliferatie en selectie. Hierdoor blijven uiteindelijk resistente en invasieve 
tumorcellen over die een grote overlevingskans hebben en vaak uitzaaien naar andere locaties.
Adapted from Pearson Education, Inc 2009
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chemische stoffen (liganden) die binden aan sigma receptoren. Daarnaast is gebleken dat 
zulke liganden kankercellen kunnen doden (zie hoofdstuk 2 voor een overzicht van het 
onderzoek naar sigma liganden).
  In dit proefschrift werden dan ook mogelijke toepassingen van sigma liganden 
getest zowel bij de diagnose als de behandeling van kanker.
Vaststellen van kanker
  Helaas treedt er na de behandeling van kanker meestal geen genezing op. Dit 
komt onder andere doordat de effectiviteit van de behandeling afhankelijk is van een 
groot aantal factoren, waaronder 1. een snelle diagnose, 2. het precies vaststellen van de 
locatie van zowel primaire tumoren als metastasen, en 3. de effectiviteit van de gebruikte 
geneesmiddelen.  Bij het verbeteren van de huidige therapieën voor het behandelen van 
kanker is een snelle diagnose dan ook van groot belang.
  Diagnose  van  kanker  kan  geschieden  door  middel  van  invasieve  en  niet-
invasieve methoden. Bij invasieve methoden kan men denken aan het nemen van een 
biopsie of aan lichamelijk onderzoek tijdens een exploratieve operatie. Deze methoden 
zijn echter beperkt tot het vaststellen van een tumor waarvan de locatie bekend is en 
zijn veel minder geschikt voor het opsporen van metastasen. Daarnaast is het lastig om 
met deze methoden de omvang en eigenschappen van de tumor vast te stellen. Onder 
niet-invasieve methoden vallen: 1. het afnemen van bloedmonsters om de eventueel 
verhoogde concentratie van circulerende eiwitten bij mensen met kanker te bepalen, 
2.  Anatomische  beeldvorming  van  tumoren  door  middel  van  echografie,  computed 
tomography (CT) en magnetic resonance imaging (MRI), 3. moleculaire beeldvorming 
met behulp van single photon emissie computer tomografie (SPECT) of positron emmisie 
tomografie (PET). PET is een aantrekkelijke methode omdat hierbij, in tegenstelling tot 
bloedmonsters, echografie, CT en MRI, zowel informatie over de locatie als de activiteit 
van de tumor wordt verkregen.
  PET is een erg gevoelige nucleaire diagnostische techniek waarbij gebruik wordt 
gemaakt van radioactieve isotopen met positron verval (zie ook Figuur 2). Positronen 
zijn subatomaire deeltjes met dezelfde massa als een elektron, maar in tegenstelling tot 
negatief geladen elektronen hebben positronen een positieve lading. Wanneer na verval 
een positron en een elektron met elkaar in contact komen treedt er een proces op dat 
annihilatie heet. Hierbij worden er twee fotonen uitgezonden die opgevangen kunnen 
worden door een PET camera. Doordat de fotonen (gammastraling) altijd onder een hoek 
van 180 graden ten opzichte van elkaar worden uitgezonden kan hiermee de locatie van 
het vervallen isotoop in het lichaam bepaald worden. Door isotopen, zoals fluor-18, te 
koppelen aan biologische moleculen zoals suikers kan het suikerverbruik in het lichaam met 
behulp van PET in kaart gebracht worden. Doordat kankercellen gemiddeld meer energie 229
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en daarmee meer suiker verbruiken dan gezonde cellen, hoopt 18F-fluorodesoxyglucose 
(18F-FDG) zich meer op in kankercellen dan in normale cellen en kan de tumor in kaart 
worden gebracht. Omdat moleculen zoals 18F-FDG gebruikt worden om het gedrag van de 
normale suiker in het lichaam te volgen worden deze tracers genoemd.
  Omdat alle cellen in het lichaam suiker verbranden is het gebruik van 18F-FDG 
niet de meest specifieke manier om tumorcellen te onderscheiden van normale cellen. 
Daarom is er veel aandacht voor het ontwikkelen van nieuwe moleculen die zich selectief 
ophopen in tumorcellen, maar niet in normale cellen. Een overzicht van zulke moleculen 
is weergegeven in tabel 1. Omdat sigma receptoren dikwijls hoger tot expressie komen 
in kankercellen dan in normale cellen is er in dit proefschrift gekeken naar het gebruik 
van sigma receptor liganden bij de diagnose van kanker. Voor dit doel beschikten wij 
Fig. 2. Positron emission tomography: A) de positron-emmisie isotopen die het meest gebruikt 
worden bij PET.; B) Schematische weergave van de werking van PET.
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over het sigma ligand 1-(3,4-dimethoxyphenethyl)-4-(3-phenylpropyl)piperazine dat met 
koolstof-11 radioactief was gemerkt (11C-SA4503).
  In  het  eerste  deel  van  dit  proefschrift  werd  met  behulp  van  microPET  in 
proefdieren  onderzocht  of  11C-SA4503  kan  worden  gebruikt  voor  het  opsporen  van 
tumoren. Een mogelijk probleem bij het gebruik van 11C-SA4503 voor tumordiagnose is 
competitie van lichaamseigen moleculen met de radioactieve stof voor binding aan de 
sigma receptoren. Uit de literatuur is bekend dat steroïdhormonen aan deze receptoren 
kunnen binden. Daarom hebben wij onderzocht of er in vitro (reageerbuis) en in vivo (in 
proefdieren) competitie optreedt tussen steroïden en 11C-SA4503 voor binding aan sigma 
receptoren in tumorcellen (hoofdstuk 3). Zowel het verhogen als het verlagen van de 
steroïdconcentratie had een significant effect op de binding van 11C-SA4503. Competitie 
van  progesteron  met  11C-SA4503  voor  binding  aan  sigma  receptoren  kan  wellicht 
verklaren waarom er tijdens PET studies met sigma liganden in patiënten soms variabele 
uitkomsten worden verkregen. Tijdens in vitro experimenten bleek dat de binding niet 
alleen wordt beïnvloed door progesteron maar ook door het mannelijk geslachtshormoon 
testosteron en door afbraakproducten van deze steroïden.
  Sigma  receptoren  komen  eveneens  hoog  tot  expressie  in het  centrale  zenuwstelsel. 
Hierdoor zou er in het brein sprake kunnen zijn van een hoog achtergrondsignaal zodat 
hersentumoren  met  een  radioactief  sigma  ligand  moeilijk  zichtbaar  gemaakt  kunnen 
worden. Daarom hebben wij onderzocht of  11C-SA4503 gebruikt kan worden bij het opsporen 
van tumoren van de hypofyse. Wistar ratten (veel gebruikte proefdieren) ontwikkelen op 
Tabel 1. Voorbeelden van PET tracers die gebruikt worden bij kankerpatiënten.
   
   
   
   
   
   
   
   
   
 
   
   
 
 
   
   
   
 
   
   
   
 
   
   
   
   
   
   
   
       
       
Eiwit dat de tracer in kaart brengt
glucose transporters (GLUTs) & hexokinases (HKs)       
thymidine kinase-1 (TK-1)                                       
aminozuur transporters                                           
choline kinases      
phosphatidylserine op het celoppervlak                         
oestrogen receptoren (ERs)                              
somatostatine receptor 2 (SST2Rs) 
intracellulaire reductases
androgeen receptoren (ARs) 
humane epidermale groei factor receptor 2 (Her2/neu) 
vasculaire endotheliale groei factor A (VEGF-A)                                         
epidermale groei factor receptor (EGFR, Her1)
Oncologische PET tracer
18
18
18F-fluoroethyltyrosine (FET)
11C-methionine (MET)
11C/   F-choline analogen
18F-annexine A5
18F-fluoroestradiol (FES)
18F-L-dihydroxyphenylalanine (DOPA)
18F-5-fluorouracil (5-FU)
18F/   Ga-octreotide analogen
18
18
89Zr-trastuzumab
F-fluoromisonidazole (FMISO)
F-fluorine androgeen analogen
89
89
Zr-bevacizumab
Zr-cetuximab
F-fluorodesoxyglucose (FDG)
F-fluoro-L-thymidine (FLT)
thymidylate synthase           
aminozuur transporters                             
grote aminozuur transporter (LAT), aminozuur 
 cellulair energie verbruik
 proliferatie
 aminozuur transport
 phospholipid metabolism
 aminozuur transport
 apoptose
 endocrine metabole activiteit
 proliferatie
 angiogenese
 endocrine metabole activiteit
 endocrine metabole activiteit
 hypoxia
 endocrine metabole activiteit
 proliferatie, overleving, differentiatie
 evasie & metastase
Geassocieerd biochemisch proces
18
64
~ 90% scans
decarboxylase (AADC), monoamine oxidase (MAO)231
C
h
a
p
t
e
r
 
1
2
latere leeftijd spontaan hormoonproducerende adenomas, een bepaald type tumor van 
de hypofyse. Of zulke tumoren (die ook bij mensen kunnen optreden) sigma receptoren 
tot expressie brengen was nog nooit onderzocht. In hoofdstuk 4 worden microPET scans 
van bejaarde ratten (28 tot 36 maanden) beschreven. De opname van 11C-SA4503 in de 
gezonde hypofyse is daarbij vergeleken met de opname in hypofysetumoren. Tevens werd 
onderzocht of tumoren van de hypofyse invloed hebben op de opname van 11C-SA4503 in 
het brein, de schildklier en andere organen. 11C-SA4503 werd aanzienlijk meer opgenomen 
in tumoren van de hypofyse dan in gezond hypofyseweefsel. Met behulp van dit sigma 
ligand en PET konden hypofysetumoren uitstekend worden afgebeeld. Farmacokinetische 
analyse maakte duidelijk dat de verhoogde traceropname in de tumoren het gevolg is 
van een toename van het aantal sigma receptoren in de tumorcellen. In het brein van 
tumordragende ratten werd eveneens een geringe verhoging van de opname van  11C-
SA4503 waargenomen. Deze verhoging kon niet worden toegeschreven aan een verhoogd 
aantal sigma receptoren, maar is waarschijnlijk het gevolg van een verandering van de 
doorbloeding.
Behandeling van kanker
  Behandeling van allerlei typen kankercellen met sigma liganden zorgt ervoor dat 
de kankercellen geremd worden in hun groei dan wel dood gaan. Op basis hiervan worden 
sigma liganden beschouwd als mogelijke nieuwe geneesmiddelen voor de behandeling 
van kanker. In het tweede gedeelte van dit proefschrift is de tumorremmende werking 
van  sigma  liganden  onderzocht,  zowel  in  monotherapie  als  tijdens  gecombineerde 
behandeling met Tumor Necrosis Factor Related Apoptosis Inducing Ligand (TRAIL).
  Sigma liganden zijn giftig voor kankercellen, maar niet voor de meeste normale 
cellen. Er zijn echter relatief hoge concentraties van zulke stoffen vereist om tumorcellen 
dood te maken (20-100 µM). Dit zou kunnen komen doordat sigma liganden barrières 
(membranen)  moeten  passeren  voordat  ze  aan  sigma  receptoren  kunnen  binden,  of 
doordat een relatief grote fractie van de sigma receptoren bezet moet zijn voordat het 
gewenste  effect  optreedt.  In  hoofdstuk  5  hebben  wij  onderzocht  wat  de  werkelijke 
reden  is.  De  bezetting  van  sigma  receptoren  in  tumorcellen  door  geneesmiddelen 
werd  bepaald  met  behulp  van  radioaktieve  technieken  en  gecorreleerd  aan  de  mate 
van de celdood. Wij vonden dat een bijna volledige bezetting van de sigma receptoren 
noodzakelijk was voor het therapeutische effect. Met behulp van 11C-SA4503 en PET is het 
wellicht mogelijk om de expressieniveaus en de bezettingsgraad van sigma receptoren 
in kankerpatiënten te bepalen. Zo zouden patiënten kunnen worden geselecteerd voor 
therapie met sigma liganden, en zou de optimale hoogte van de therapeutische dosis 
kunnen  worden  vastgesteld.  Verder  onderzoek  is  nodig  om  te  bepalen  welke  tracer 
voor andere fysiologische processen het meest geschikt is om veranderingen van de 232 Nederlandse samenvatting
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stofwisseling in tumorcellen na behandeling met sigma liganden zichtbaar te maken. 
  Tijdens  onze  in  vitro  experimenten  namen  wij  waar  dat  de  tumorcellen  een 
verhoogd glucose metabolisme hadden dat voorafging aan de uiteindelijke celdood. Dit 
effect staat bekend als een “metabolic flare”. Het is tijdelijk van aard en treedt ook op 
bij de behandeling van tumorcellen met hormonen. Omdat effecten die in vitro worden 
waargenomen niet altijd ook in vivo optreden hebben wij in levende proefdieren onderzocht 
of behandeling van tumoren met sigma liganden ook gepaard gaat met een “metabolic 
flare” (hoofdstuk 6). Hiertoe zijn muizen onderhuids ingespoten met melanoma cellen 
(A375M) en nadat deze cellen tumoren hadden gevormd werden de muizen behandeld met 
het sigma ligand rimcazol. De reactie van de tumorcellen op behandeling met rimcazol is 
gevolgd met behulp van 18F-FDG en microPET. Behandeling van melanomen met rimcazol 
veroorzaakte een sterke (4-voudige) remming van de tumor groei en de opname van 18F-
FDG nam in eerste instantie toe. Sigma liganden hebben dus ook invloed op het glucose 
metabolisme van tumoren in vivo en ook in levende proefdieren is er sprake van een 
“metabolic flare”.
  Bij de meeste patienten met een melanoom vormen er zich door het lichaam 
metastasen. Gemetastaseerde melanomen zijn dikwijls ongevoelig voor de standaard 
geneesmiddelen  die  bij  de  behandeling  van  kanker  worden  gebruikt.  Uit  preklinisch 
onderzoek is gebleken dat behandeling met zogenaamde cytokinen (zoals interferon-
gamma en TRAIL) daarentegen erg veelbelovend is. In het UMCG is een nieuw geneesmiddel 
ontwikkeld dat TRAIL selectief kan afleveren aan het oppervlak van melanomacellen. 
Dit geneesmiddel, “anti-MCSP:TRAIL”, bindt selectief aan het eiwit MCSP en wordt op 
dat moment actief. MCSP is een eiwit dat in meer dan 95% van alle melanomen tot 
over-expressie komt. Helaas kunnen melanoom cellen ook resistent worden voor TRAIL. 
Omdat sigma liganden de werking van chemotherapie kunnen versterken (zie hoofdstuk 
2) hebben we getest of het sigma ligand rimcazol de therapeutische werking van anti-
MCSP:TRAIL in melanomen kan versterken (hoofdstuk 7). Dit bleek inderdaad het geval 
te zijn en uit de gegevens die in hoofdstuk 7 worden gepresenteerd blijkt dat er een 
aanzienlijke versterking optreedt. In het volgende hoofdstuk (hoofdstuk 8) is nagegaan 
welke veranderingen er optraden in de stofwisseling van melanomacellen (A375M) na 
behandeling met anti-MCSP:TRAIL en rimcazol. Hiertoe werd de opname van de PET 
tracers 18F-FDG en 18F-FLT in de tumorcellen gemeten. De opname van 18F-FDG is een maat 
voor het suikerverbruik en die van 18F-FLT voor de DNA synthese en daarmee de snelheid 
van celdeling. Na behandeling met anti-MCSP:TRAIL en rimcazole was er een verhoging 
in  de  opname  van  18F-FDG  zichtbaar,  in  overeenstemming  met  de  eerder  genoemde 
“metabolic flare”. Daarnaast trad er een sterke vermindering op van de opname van 18F-
FLT wat erop duidt dat rimcazol de celdeling remt. Wanneer melanomacellen behandeld 
werden met zowel rimcazole als anti-MCSP:TRAIL leken met name de cellen die zich niet 233
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meer deelden te worden gedood door anti-MCSP:TRAIL.
  De effectiviteit van deze combinatie van rimcazole en in dit geval oplosbaar TRAIL 
combinatie  hebben  wij  vervolgens  onderzocht  in  kanker  van  de  eierstok  (hoofdstuk 
9). Kankercellen uit biopsiemateriaal van patiënten met eierstokkanker werden daartoe 
behandeld met rimcazol en TRAIL. Bij de ene helft van de patiënten konden de kankercellen 
al worden gedood door ze alleen maar met rimcazol te behandelen. Bij de andere helft 
van de patienten reageerden de cellen slechts matig op de behandeling met rimcazol, 
maar in deze gevallen kon de werking van rimcazol aanzienlijk worden versterkt door 
gelijktijdige  toediening  van  TRAIL.  Op  basis  van  deze  (zeer  voorlopige)  bevindingen 
concluderen wij dat sigma liganden mogelijk gebruikt kunnen worden als geneesmiddel 
bij de behandeling van eierstok kanker.
Conclusies
  Sigma liganden zijn interessante moleculen die kunnen worden gebruikt bij het 
ontwikkelen van technieken om tumoren op te sporen en te behandelen. 234 Streszczenie po polsku
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Wstęp
  Rak  zabija  corocznie  około  ośmiu  milionów  ludzi  na  całym  świecie.   
Pomimo  znacznego  postępu  w  diagnozowaniu  i  leczeniu  raka,  w  następnych  latach 
przewiduje się wzrost liczby osób cierpiących na nowotwory złośliwe. Aby zmniejszyć liczbę 
ofiar, intensywnie poszukiwane są nowe metody pozwalające na szybsze wykrycie raka   
i  bardziej  efektywną  terapię  przeciwnowotworową.  Dlatego  zgromadzenie  wiedzy   
na temat powstawania i wzrostu komórek nowotworowych ma istotne znaczenie.
  Rak  jest  grupą  chorób  nowotworowych  o  charakterze  złośliwym  i  powstaje, 
gdy  normalne  komórki  ciała  zwyradniają  się.  Podczas  tego  procesu,  komórka  ciała   
zaczyna się izolować i ogranicza swój normalny kontakt z resztą organizmu. W zasadzie 
każda  komórka  może  przekształcić  się  w  komórkę  nowotworową.  W  związku  z  tym, 
komórki nowotworowe często różnią się znacznie u poszczególnych pacjentów, a nawet 
komórki nowotworowe u tego samego pacjenta mogą bardzo odbiegać od siebie. Dlatego 
pacjenci,  którzy  zapadli  na  raka, mogą  prezentować  zróżnicowane objawy.  Wszystkie 
typy raka wykazują cztery stadia rozwoju, tzn. inicjację (zapoczątkowanie), promocję 
(wdrażanie), progresję (rozwój, postęp) i konwersję (przekształcanie się) (rys. 1). 
  Podczas  tych  wszystkich  stadiów  komórki  nowotworowe  zmieniają  się   
i coraz mniej przypominają komórki, od których się wywodzą. Te zmiany chronią raka 
przed  systemem  obronnym  organizmu  i  umożliwiają  niekontrolowany  wzrost  komórki 
rakowej. Znanymi przykładami zmian są: 1. stymulacja przez komórki rakowe własnego 
wzrostu, 2. niewrażliwość na programowaną śmierć komórki (naturalny proces śmierci 
uszkodzonych  i/lub  bezużytecznych  komórek,  profesjonalnie  nazywany  apoptozą),   
3. zdolność do wielokrotnego i nieograniczonego podziału komórki nowotworowej na dwie 
identyczne  komórki  siostrzane.  Dzięki  tym  przeobrażeniom  komórka  rakowa  nabywa 
istotną przewagę nad normalnymi komórkami, ale może być przez to również łatwiej 
odróżniona od normalnych komórek.
  Na przykład, przy normalnym wzroście komórek, czynnik wzrostu wiąże się z 
białkiem receptorowym i stymuluje wzrost komórkowy. W celu zmaksymalizowania użytku 
czynnika  wzrostu,  komórki  rakowe  często  zwiększają  liczbę  posiadanych  receptorów 
dla  określonego  czynnika  wzrostu  (następuje  tzw.  nadekspresja  tego  receptora). 
Ta  nadekspresja  aktywuje  wzrost  komórek  nowotworowych,  ale  również  pozwala   
na odróżnienie ich od normalnych komórek organizmu. Jednym z receptorów, który ulega 
nadekspresji w nowotworach, jest receptor sigma.
  Receptory  sigma  są  rodzajem  białek  występujących  w  błonach  różnych 
przedziałów komórkowych tj. retikulum endoplazmatycznego, mitochondriów, lizosomów 
i  plazmolemmy  (zewnętrznej  błony  otaczającej  komórkę).  Ponieważ  receptory  sigma 
są liczniejsze w komórkach nowotworowych niż w normalnych komórkach, mogą być 235
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Fig. 1. Stadia rozwoju nowotworu. Genezę nowotworu rozpoczynają wieloczynnikowe mutacje   
w komórce. Proces chorobowy jest ponaglony, gdy obciążona mutacjami komórka umyka mechanizmom 
obronnym ciała, rozpoczyna nietypowe namnażanie i posiada łatwość genomicznego przystosowania 
się,  umożliwiającą  dalsze  mutacje  i/lub  zmiany  epigenetyczne.  Progresji  guza  towarzyszy  kilka 
cykli adaptacji, namnażania i selekcji. Te procesy, w których komórki nowotworowe nabywają  cech 
bardziej inwazyjnych i lekoopornych, zwiększają przeżycie komórek raka. Ostatecznie, tylko komórki 
nowotworowe o wysokiej ruchliwości przeniosą się z guza pierwotnego do odległych rejonów ciała   
i rozpoczną zaawansowane stadium choroby.
Adapted from Pearson Education, Inc 2009
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one użyte do wykrywania nowotworów. W celu obrazowania receptorów sigma można 
wykorzystać związki chemiczne (ligandy) o wysokim powinowactwie do tych receptorów. 
Ponadto,  badania  naukowe  wykazały,  że  ligandy  receptorów  sigma  mają  właściwości 
przeciwnowotworowe (rozdział 2). 
  W tej pracy doktoranckiej opisane zostały zastosowania ligandów receptorów 
sigma zarówno w diagnozowaniu jak i w leczeniu raka.
Wykrywanie raka
  Niestety,  często  terapia  przeciwnowotworowa  nie  gwarantuje  całkowitego 
wyleczenia.  Jest  to  spowodowane  m.in.  tym,  że  wynik  leczenia  zależny  jest   
od  różnorodnych  czynników  takich  jak:  1.  szybka  diagnoza,  2.  określenie  dokładnej 
lokalizacji guzów pierwotnych i wszystkich przerzutów (metastaz), 3. dobór odpowiedniej 
terapii  przeciwnowotworowej.  Dlatego  natychmiastowa  diagnoza  jest  niezbędna,  aby 
polepszyć obecne terapie do walki z rakiem.
  Diagnoza  raka  może  być  przeprowadzona  przy  użyciu  inwazyjnych   
lub nieinwazyjnych technik. Do inwazyjnych metod diagnostycznych zalicza się np. biopsje 
oraz  badanie  podczas  zabiegu  chirurgicznego.  Te  metody  ograniczają  się  do  badania 
nowotworów o znanej lokalizacji, ale są mniej użyteczne w stwierdzeniu rozległości procesu 
nowotworowego. Ponadto, określenie rozmiaru nowotworu i jego charakteru przy użyciu 
tych metod jest trudne i niedokładne. Do nieinwazyjnych metod diagnostycznych zalicza 
się: 1. pobranie próbki krwi w celu stwierdzenia, czy w krwiobiegu obecny jest podwyższony 
poziom  czynników  związanych  z  chorobą  nowotworową,  2.  anatomiczne  obrazowanie 
guzów  nowotworowych  metodą  ultrasonografii  (USG),  tomografii  komputerowej  (TK), 
obrazowania magnetyczno-rezonansowego (MR), 3. molekularne obrazowanie za pomocą   
tomografii emisyjnej pojedynczych fotonów (SPECT) lub pozytonowej tomografii emisyjnej 
(PET). PET jest atrakcyjną metodą ponieważ, w przeciwieństwie do próbek krwi, TK i MR, 
dostarcza informacji o lokalizacji i funkcjonowaniu nowotworu.
  PET jest bardzo czułą techniką medycyny nuklearnej, która wykorzystuje izotopy 
radioaktywne ulegające pozytonowemu rozpadowi (rys. 2). Pozytony są subatomowymi 
cząstkami  elementarnymi,  o  tej  samej  masie  jak  elektron,  ale  w  przeciwieństwie   
do  elektronów  o  negatywnym  ładunku,  pozytony  są  pozytywnie  naładowane.  Po 
kontakcie  pozytonu  i  elektronu  następuje  proces  anihilacji  (zamiany  materii  na 
promieniowanie elektromagnetyczne). W tym procesie następuje emisja dwóch fotonów 
(kwantów światła, promieniowania gamma, γ), które zarejestrowane są przez kamerę 
PET.  Ponieważ  te  dwa  fotony  ulegają  emisji  zawsze  pod  kątem  180°  w  stosunku  do 
siebie, ta właściwość może być użyta w celu zlokalizowania rozpadającego się izotopu 
w  ludzkim  ciele.  Przyłączanie  izotopu  np.  fluoru-18  (18F)  do  związków  biologicznych 
takich  jak  cukry,  może  być  użyte  do  zobrazowania  zużycia  cukru  przez  organizm 237
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(metabolizm  cukrów)  za  pomocą  PET.  Ponieważ  komórki  nowotworowe  potrzebują 
generalnie więcej energii (np. z cukrów) niż zdrowe komórki,  18F-fluorodeoksyglukoza 
(18F-FDG)  gromadzi  się  w  nich  w  większej  ilości  niż  w  zdrowych  komórkach.  W  ten 
sposób  można  dokładnie  zlokalizować  pierwotny  guz  i  wszystkie  przerzuty.  Związki 
takie  jak  18F-FDG  mogą  być  użyte  do  monitorowania  zachowania  normalnego  cukru   
w organizmie, dlatego nazywa się je znacznikami. 
  Wszystkie komórki ciała przyswajają cukry, dlatego  18F-FDG nie jest specyficznym 
znacznikiem do odróżnienia komórek nowotworowych od normalnych komórek. Dlatego 
nauka  skupia  się  na  rozwijaniu  nowych  związków,  które  wybiórczo  gromadzą  się   
w nowotworach. Przegląd takich znaczników przedstawiony jest w tabeli 1. Receptory 
sigma często  ulegają nadekspresji w  nowotworach, dlatego ta praca poświęcona jest 
Fig. 2. Pozytonowa tomografia emisyjna: A) powszechnie używane izotopy emitujące pozytony 
w PET; B) schemat pokazujący zasady działania techniki  PET: lewy panel ilustruje zasady fizyczne   
a prawy panel pokazuje metodologię praktyczną.
anihilacja β+ e-
kwant γ
kwant γ
ν
emissja pozytonu
emisja neutrino
proton rozpada się 
do neutronu 
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B)
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Izotopy emitujące pozytony   
18F  109.8 min.  
11C  20.4 min.  
13N  9.97 min.  
15O  2.04 min.  
Okres półtrwania
68Ga   68.3 min.  
89Zr   78.4 godz.  
   
   
 
   
   
   
 
   
   
 
   
   
   
 
Produkt rozpadu
89Y
18O
11B
13C
15N
68Zn
Max. energia (MeV)
0.63
0.96
1.20
1.74
1.83
0.90
0.3
0.4
0.7
1.1
1.2
1.1
Średni zasięg (mm) β+ fraction
0.97
0.99
1.00
1.00
0.88
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badaniom  wykorzystującym  ligandy  receptorów  sigma  w  diagnozowaniu  guzów.   
Do naszej dyspozycji mieliśmy ligand receptorów sigma: 1-(3,4-dimetoksyfenetyl)-4-(3-
fenylopropylo)piperazynę  oznakowaną  izotopem  węgla-11  (11C-SA4503)  o  aktywności 
promieniotwórczej. 
  W  pierwszej  części  pracy  doktoranckiej  opisana  jest  weryfikacja  11C-SA4503   
w wykrywaniu i obrazowaniu guzów u zwierząt eksperymentalnych za pomocą mikroPET 
(skanera PET przystosowanego do małych zwierząt). Możliwym problemem 11C-SA4503 
w diagnozowaniu nowotworów może być współzawodnictwo naturalnego fizjologicznego 
liganda  ze  związkiem  promieniotwórczym  o  miejsce  wiążące  w  receptorach  sigma.   
Z literatury wiadomo, że hormony steroidowe mają powinowactwo do receptorów sigma 
i wiążą się z nimi. Aby wykazać możliwe wiązanie się tychże hormonów do receptorów 
sigma w komórkach nowotworowych hodowanych in vitro (w probówce) oraz w guzach 
nowotworowych  in  vivo  (u  zwierząt  eksperymentalnych),  przeprowadziliśmy  badania 
nad  współzawodnictwem  pomiędzy  hormonami  steroidowymi  a  11C-SA4503  (rozdział 
3). Zauważyliśmy, że zarówno podwyższenie poziomu hormonów steroidowych, jak i ich 
obniżenie, miało znaczny wpływ na swoiste gromadzenie się 11C-SA4503 w komórkach 
nowotworowych.  Współzawodnictwo  progesteronu  z  11C-SA4503  o  miejsce  wiążące   
w  receptorach  sigma  może  wyjaśnić,  dlaczego  badania  PET  przy  użyciu  ligandów 
receptorów sigma dają czasami różniące się rezultaty. Eksperymenty in vitro wykazały, 
że nie tylko progesteron miał wpływ na swoiste wiązanie  11C-SA4503, ale także męski 
hormon płciowy testosteron oraz produkty przemiany tych hormonów steroidowych.
Tabela 1. Przykłady znaczników PET wykorzystywanych w onkologii
   
   
   
   
   
   
   
   
   
 
   
   
 
 
   
   
   
 
   
   
   
 
   
   
   
   
   
   
   
       
       
Białka docelowe
transportery glukozy (GLUTs) i heksokinazy (HKs)       
kinaza tymidyny typu 1 (TK-1)                                       
transportery aminokwasów                                          
kinaza choliny      
eksponowanie fosfatydyloseryny na powierzchni błony komórkowej                         
receptory estrogenowe (ERs)                              
receptory somatostatynowe typu 2 (SST2Rs) 
reduktazy wewnątrzkomórkowe
receptory androgenowe (ARs) 
receptor nabłonkowego czynnika wzrostu typu 2 (Her2/neu) 
czynnik wzrostu śródbłonka naczyniowego A (VEGF-A)                                         
receptor nabłonkowego czynnika wzrostu typu 1 (EGFR, Her1)
Znaczniki PET w onkologii
18
18
18F-fluoroetylotyrozyna (FET)
11C-metionina (MET)
11C/   F-analogi choliny
18F-aneksyna A5
18F-fluoroestradiol (FES)
18F-L-dihydroksyfenyloalanina (DOPA)
18F-5-fluorouracyl (5-FU)
18F/   Ga-analogi oktreotydu
18
18
89Zr-trastuzumab
F-fluoromisonidazol (FMISO)
F-fluoryzowane analogi androgenu
89
89
Zr-bewacizumab
Zr-cetuksymab
F-fluorodeoksyglukoza (FDG)
F-fluoro-L-tymidyna (FLT)
syntaza tymidylanowa          
transportery aminokwasów                            
wielki transporter aminokwasów (LAT), dekarboksylaza aromatycz- 
 energetyka komórkowa
 namnażanie komórek
 transport aminokwasów
 metabolizm fosfolipidów
 transport aminokwasów
 apoptoza
 funkcja endokrynna
 namnażanie komórek
 neowaskularyzacja
 funkcja endokrynna
 funkcja endokrynna
 hipoksja (niedotlenienie)
 funkcja endokrynna
 namnażanie, przeżywanie, różnicowanie
 naciek nowotworowy i przerzuty
Proces biochemiczny
18
64
~ 90% skanów
nych L-aminokwasów (AADC), oksydaza monoaminowa (MAO)239
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  Wysoka  ekspresja  receptorów  sigma  obecna  jest  również  w  ośrodkowym 
układzie nerwowym. Dlatego w przypadku mózgu mówi się o wysokim sygnale tła, który 
może utrudnić obrazowanie nowotworów mózgu za pomocą radioaktywnie oznakowanych 
ligandów  receptorów  sigma.  W  dalszej  części  niniejszej  pracy  doktoranckiej  opisane 
są  badania  nad  obrazowaniem  gruczolaków  przysadki  mózgowej  (guzów  o  czynności 
hormonalnej) za pomocą 11C-SA4503. Albinotyczny szczep szczurów Wistar (powszechnie 
stosowany model do badań naukowych nad anatomią i fizjologią ssaka) predysponowany 
jest w późniejszej fazie życia do spontanicznego rozwoju gruczorlaków przysadki. Warto 
nadmienić, że ten typ nowotworu występuje także w ludzkiej przysadce. Niniejsza praca 
opisuje  pierwsze  badania  nad  ekspresją  receptorów  sigma  w  gruczolaku  przysadki. 
Rodzdzial 4 zawiera skany przeprowadzone za pomocą metody mikroPET na podstarzalych 
szczurach  (w  przedziale  wiekowym  od  28  do  36  miesięcy).  Porównany  jest  tu  pobór 
11C-SA4503 przez zdrową przysadkę z poborem 11C-SA4503 przez gruczolaka przysadki. 
Ponadto testowaliśmy, czy gruczolaki przysadki mają wpływ na wchłanianie 11C-SA4503 
w mózgu, w tarczycy i w innych organach. Zastosowanie ligandów receptorów sigma 
i techniki PET z wysoką dokładnością rozpoznało wszystkie gruczolaki przysadki, gdyż 
11C-SA4503 gromadził się w większej ilości w guzach przysadki niż w zdrowej przysadce. 
Analiza farmakokinetyczna wykazała, że przyczyną podwyższonego wchłaniania znacznika 
przez guzy był zwiększony poziom receptorów sigma w komórkach guza. Zauważone 
zostało również, że mózg szczurów posiadających guzy wykazywał umiarkowany wzrost 
wchłaniania  11C-SA4503.  Ten  wzrost  w  mózgu  nie  był  spowodowany  wzrostem  ilości 
receptorów sigma, lecz prawdopodobnie rezultatem zmian w przepływie krwi.
Leczenie raka
  Leczenie różnych typów raka ligandami receptorów sigma wstrzymuje namnażanie 
się komórek nowotworowych i prowadzi następnie do ich śmierci. Dlatego doszukuje się   
zastosowania ligandów receptorów sigma jako nowych terapeutyków do walki z rakiem 
w medycynie klinicznej. W drugiej części pracy doktoranckiej opisane są przedkliniczne 
badania nad aktywnością przeciwnowotworową tychże ligandów, stosowanych zarówno   
w monoterapii (przy użyciu jednego preparatu) jak i politerapii (przy łączeniu kilku leków) 
z ligandem wywołującym apoptozę i spokrewnionym z czynnikiem martwicy nowotworu 
TNF, nazywanym TRAIL (od skórtu angielskiej nazwy Tumor necrosis factor (TNF)-Related 
Apoptosis Inducing Ligand). 
  Ligandy  receptorów  sigma  są  toksyczne  dla  komórek  nowotworowych,  ale   
nie  dla  większości  normalnych  komórek.  Jednakże  stosunkowo  wysokie  stężenie   
(20-100 μM) ligandów receptorów sigma jest niezbędne aby zabić komórki nowotworowe. 
Może być to spowodowane przez fakt, że ligandy receptorów sigma muszą przekroczyć 
bariery (błony komórkowe), zanim będą one mogły związać się z receptorami sigma. Innym 240 Streszczenie po polsku
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wytłumaczeniem może być, że relatywnie wysoki ułamek receptorów sigma powinien być 
związany z ligandem, aby wywołać pożądany efekt terapeutyczny. Rozdział 5 wyjaśnia, 
który z tych spekulowanych powodów zgadza się z prawdą. Zapełnienie miejsc wiążących 
receptorów sigma w komórkach nowotworowych przez terapeutyki zostało wyznaczone 
techniką  wykorzystującą  związki  promieniotwórcze,  a  następnie  zostało  porównane   
z poziomem śmierci komórkowej. Eksperymenty wykazały, że związanie prawie wszystkich 
receptorów sigma przez ligand jest konieczne w celu wywołania efektu terapeutycznego. 
Przypuszczamy, że wykorzystanie 11C-SA4503 i techniki PET umożliwi określenie poziomu 
ekspresji i stopnia zapełnienia receptorów sigma u pacjentów z chorobą nowotworową. 
W ten sposób pacjenci kwalifikujący się do terapii z ligandami receptorów sigma mogliby 
być wyselekcjonowani i optymalna dawka terapeutyczna takiego liganda mogłaby być 
wyznaczona. Przyszłe badania są konieczne aby określić, który znacznik jest najbardziej 
stosowny  do  zobrazowania  zmian  metabolizmu  komórek  nowotworowych  po  podaniu 
ligandów receptorów sigma.
  Podczas eksperymentów in vitro zaobserwowaliśmy, że komórki nowotworowe 
prezentowały wzmożony metabolizm glukozy, który poprzedzał śmierć komórkową. Ten 
efekt, opisany jako „wybuch metaboliczny” („metabolic flare”), ma tymczasową naturę   
i pojawia się także, gdy komórki noworowe leczone są hormonalnie. Niestety, badania   
in vitro nie zawsze odzwierciedlają te przeprowadzone in vivo. Dlatego użyliśmy zwierząt 
doświadczalnych do sprawdzenia, czy podawanie ligandów receptorów sigma poprzedzone 
jest również „wybuchem metabolicznym” (rozdział 6). Najpierw komórki nowotworowe 
czerniaka złośliwego (linii komórkowej A375M) wstrzyknięte zostały podskórnie myszom 
laboratoryjnym,  a  po  uformowaniu  się  guzów  nowotworowych,  myszom  podawany 
był  ligand  receptorów  sigma  o  nazwie  rimcazol.  Reakcja  komórek  nowotworowych 
na  leczenie  rimcazolem  była  monitorowana  przy  użyciu  18F-FDG  i  skanera  mikroPET. 
Rimcazol spowodował silne zahamowanie (czterokrotne) wzrostu czerniaka i początkowe 
wzmożenie poboru 18F-FDG przez guza. Ligandy receptorów sigma mają przez to wpływ 
na metabolizm glukozy i  wywołują  efekt „wybuchu metabolicznego” także u zwierząt 
doświadczalnych. 
  Większość  pacjentów  z  czerniakiem  złośliwym  posiada  przerzuty  oddalone 
(rozsiane po całym ciele). Przerzuty czerniaka są często oporne na standardowe metody 
leczenia  nowotworów.  Badania  przedkliniczne  wykazały,  że  dobre  rezultaty  terapii 
przeciwnowotworowej  osiągane  są  za  sprawą  tzw.  cytokin  (np.  interferonu-gamma   
i białka TRAIL). W Uniwersyteckim Centrum Medycznym w Groningen (UMCG) opracowany 
został  nowy  terapeutyk,  który  wybiórczo  dostarcza  TRAIL  na  powierzchnię  komórek 
czerniaka złośliwego. Ten eksperymentalny terapeutyk, „anty-MCSP:TRAIL”, wybiórczo 
wiąże się z białkiem MCSP (proteoglikanem siarczanu chondroityny czerniaka złośliwego) 
i zostaje zaktywowany. MCSP to białko, które jest nadekspresjonowane w przynajmniej 241
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95-ciu procentach czerniaków złośliwych. Niestety, po pewnym czasie komórki czerniaka 
złośliwego  stają  się  oporne  na  działanie  cytokiny  TRAIL.  Natomiast  ligandy  receptorów  sigma 
potrafią wzmocnić działanie chemoterapii (rozdział 2). Dlatego przeprowadziliśmy badania 
nad rimcazolem i jego możliwością zwiększenia efektu terapeutycznego białka fuzyjnego 
anty-MCSP:TRAIL w czerniaku złośliwym hodowanym in vitro (rozdział 7). Rezultaty 
tych  eksperymentów  wykazały  znaczne  wzmocnienie  efektu  przeciwnowotworowego. 
W następnym rozdziale (rozdział 8) podajemy, jakie zmiany metaboliczne występują 
w  czerniaku  złośliwym  (A375M)  po  jednoczesnym  podaniu  rimcazolu  i  białka   
anty-MCSP:TRAIL.  Następnie  przeprowadziliśmy  pomiary  wchłaniania  znaczników  PET, 
18F-FDG i  18F-FLT, przez komórki nowotworowe, które zostały lub nie zostały poddane 
opisanej  powyżej  terapii.  Wchłanianie  18F-FDG  odzwierciedla  konsumpcję  glukozy,   
a wchłanianie 18F-FLT odzwierciedla syntezę DNA i intensywność podziałów komórkowych. 
Komórki  leczone  rimcazolem  i  białkiem  anty-MCSP:TRAIL  zwiększyły  pobór  18F-FDG,  zgodnie   
z wcześniej opisanym efektem „wybuchu metabolicznego”. Ponadto, zauważony został 
znaczny  spadek  poboru  18F-FLT  sugerujący  hamowanie  podziału  komórkowego  przez 
rimcazol. Podawanie komórkom czerniaka zarówno rimcazolu jak i białka anty-MCSP:TRAIL 
spotęgowało śmierć tych komórek, których podział został zahamowany przez rimcazol. 
  Kombinacja rimcazolu i białka TRAIL była następnie testowana na komórkach 
guza jajnika (rozdział 9). Komórki nowotworowe wyizolowane z pacjenta metodą biopsji 
inkubowane  były  z  rimcazolem  i  białkiem  TRAIL.  Komórki  nowotworowe  pochodzące 
od  połowy  pacjentów  mogły  być  zabite  przez  sam  rimcazol.  Komórki  nowotworowe   
od drugiej połowy pacjentów były jedynie umiarkowanie wrażliwe na rimcazol. W tym 
jednak  przypadku  działanie  przeciwnowotworowe  było  znacznie  wzmocnione  przez 
równoczesne  podanie  rimcazolu  i  białka  TRAIL.  Na  podstawie  tych  wstępnych  badań 
wywnioskowaliśmy, że ligandy receptorów sigma mogą być obiecującymi terapeutykami 
w leczeniu raka jajnika.
Podsumowanie
  Ligandy receptorów sigma są obiecującymi związkami, które mogą dać początek 
nowym metodom rozpoznawania i leczenia nowotworów.Acknowledgements244 Acknowledgements
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2TCM     two-tissue compartment model
Akt    a serine-threonine protein kinase, also called protein kinase B
ATCC     American Type Culture Collection
ATP     adenosine 5’-triphosphate
BBB    blood-brain barrier
Bcl-2    B-cell lymphoma-2 family of proteins
BPND     nondisplaceable binding potential
CI     cooperativity index
CT    computed tomography
DHEA-S    dehydroepiandrosterone-3-sulphate
DMEM     Dulbecco’s minimum essential medium
DMT     N,N-dimethyltryptamine
DNA     deoxyribonucleic acid
DTG     1,3 di-ortho-tolylguanidine
EC50     half maximal effective concentration
FCS     fetal calf serum
FDA     Food and Drug Administration
FDG     2-deoxy-2-fluoro-D-glucose
FLT     3’-fluoro-3’-deoxy-L-thymidine
GLUT     glucose transporter
HIF1α     hypoxia-inducible factor
HK     hexokinase
H&E     hematoxylin and eosin staining
HPLC     high-performance liquid chromatography
IHC     immunohistochemistry
IC50     half maximal inhibitory concentration
i.p.     intraperitoneal administration
IVC     individually ventilated cage
K1/k2     partition coefficient
Kd     dissociation constant
Bq    Becquerel (MBq: megabecquerel; TBq: terabecquerel)
MCSP    melanoma chondroitin sulfate proteoglycan
MDR    multi-drug resistance
MRI    magnetic resonance imaging
OC     ovarian carcinoma
PET     positron emission tomography
PBS     phosphate-buffered saline249
P-gp     P-glycoprotein
PGRMC1   progesterone receptor membrane component 1
PI    propidium iodide
PI3K    phosphoinositide 3-kinase
RBC     red blood cells
ROI     region of interest
SA4503    1-[2-(3,4-dimethoxyphenyl)ethyl]-4-(3-phenylpropyl)piperazine
s.c.    subcutaneous administration
SD    standard deviation
SEM    standard error of the mean
SPECT     single-photon emission computed tomography
SUV     standardized uptake value
TAC     time-activity curve
TRAIL     tumor necrosis factor (TNF)-related apoptosis-inducing ligand
    (rhTRAIL: recombinant human TRAIL; sTRAIL: soluble TRAIL)
TK1     thymidine kinase 1
VT     total distribution volume
zVAD-fmk  N-benzyloxycarbonyl-valyl-alanyl-aspartyl-(O-methyl)-fluoromethyl-
    ketone